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Thesis Summary 
The work presented herein applies advanced techniques in an ultrahigh 
resolution Fourier transform ion cyclotron resonance mass spectrometry (FTICR 
MS) to study one of the most amyloidogenic amyloid proteins – human islet 
amyloid polypeptide (hIAPP) and we also demonstrate alternative analytical 
techniques for proteomics. 
Exploring the aggregation and inhibition pathways of amyloid proteins is 
critical for future therapeutic development.  Previous studies demonstrated the 
early, soluble oligomers of amyloid proteins are more toxic to neuro cells than 
mature amyloid fibrils due to their ability to penetrate and destroy neuro cell 
membranes.  Current analytical techniques for amyloid protein studies, including 
nuclear magnetic resonance (NMR) spectroscopy, fluorescence spectrometry, 
transmission electron microscopy (TEM), and atomic force microscopy (AFM), 
are difficult to perform as they require molecular isolation and focus on studying 
individual target early oligomers from a mixtures of oligomers.  Previous 
literature, however, has demonstrated the ability of MS in observing as well as 
isolating a specific oligomer from an in vitro amyloid protein sample.  Thus, MS 
has been applied together with electron-based dissociation technique in this thesis 
to determine the aggregation as well as inhibition pathways of hIAPP.  
The results herein demonstrate the region around Gly-33 and Ser-34 of hIAPP 
is critical for hIAPP aggregation since it is the minimum interaction region 
between the two hIAPP units which was shown by the electron-based dissociation 
spectra of the dimer as well as the trimer of hIAPP.  hIAPP has also shown to be 
deamidated rapidly within a month at Asn-21, Asn-22, and Asn-35 residues, 
regarding there are seven potential deamidation sites within the sequence.  The 
deamidated hIAPP species with iso-aspartic acid residue products at the 
Thesis Summary 
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deamidation sites shows a significant change in the amyloid fibril morphology 
which may help to explain the previously observed acceleration of aggregation 
rate by inducing 5% of deamidated hIAPP into non-deamidated hIAPP solution.   
 The methodologies applied in studying the aggregation pathway of hIAPP are 
further used to explore the inhibition pathways between hIAPP and potential 
inhibitors.  From the results, two different inhibition pathways are proposed to 
effectively prevent the formation of hIAPP fibrils.  Inhibitors interacting 
specifically at the critical aggregation region around Gly-33 and Ser-34, are shown 
to prevent the formation of hIAPP fibrils by forming hetero-complexes (a complex 
composes of hIAPP and inhibitor).  The alternative inhibition pathway requires 
an inhibitor which interacts non-specifically with hIAPP and triggers the formation 
of non-toxic amorphous aggregates faster than the generation of normal, toxic 
hIAPP oligomers.  These two proposed inhibition pathways show an effective 
inhibition effect on formation of hIAPP fibrils, however, only the non-specifically 
interaction pathway was effective in preventing the aggregation of the deamidated 
from hIAPP since the protein sequence as well as structure are distorted in the 
deamidated hIAPP which significantly affects the specific interaction between the 
deamidated hIAPP and inhibitors.  
 The in vitro studies propose the potential aggregation and inhibition pathways 
for hIAPP; it is critical, but unfortunately very challenging, to study these 
molecular interactions in vivo due to the solvents and column chemistry required 
by the current liquid chromatography (LC) approach which is necessary for 
complex mixture studies.  In order to study the in vivo molecular interactions, an 
alternative analytical technique, therefore, is required.  
 Herein, two dimensional mass spectrometry (2DMS) is applied to study 
proteomic samples ranging from standard protein digests to whole cell lysate 
Thesis Summary 
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digest without online LC separation.  Various sample preparation and 2DMS 
acquisition methods have been applied to optimise the proteomic outputs from 
2DMS.  From the results, 2DMS shows a similar capability in studying 
proteomics compared to the standard LC tandem MS (MS/MS) techniques.  The 
peptides assigned in 2DMS experiments are more hydrophilic, basic, and short, 
which are complementary to those assigned in the LC MS/MS technique, thus 
more proteins can be covered by combining the results obtained from 2DMS and 
LC MS/MS, in which a deeper proteome coverage is achieved.  2DMS is shown 
to be a viable alternative analytical tool for proteomics, in which is also potential 
for the in vivo study of molecular interactions in the coming future.  
 The final section of this thesis provides a conclusion on all the works that 
have been demonstrated herein and discusses the future research which we needed 
to improve/enhance the current knowledge on amyloid protein studies using MS 
as well as 2DMS for proteomics.   
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Chapter 1 Introduction 
 Mass spectrometry (MS) is an important technique to study biological 
molecules because of its accuracy, sensitivity, speed, and the capability of 
simultaneous analysis.1, 2  MS is commonly applied to provide sequence and 
modification information,3, 4 as well as structure and quantification analysis of 
biological molecules.5, 6   
This thesis focuses on the applications of advanced technologies in mass 
spectrometry for protein analysis, which includes the application of tandem MS to 
explore the aggregation and inhibition mechanisms of amyloid proteins, as well as 
development of a new analytical technique which is suitable for the study of fragile 
amyloid aggregates in a complex mixture.   
This chapter contains three sections, including introduction of mass 
spectrometry (section 1.1), applications of MS of amyloid proteins, deamidation, 
as well as proteomics studies (section 1.2), and an overview of the thesis (section 
1.3).  
 
1.1 Introduction of Mass Spectrometry  
 MS is a powerful analytical instrument which provides molecular mass 
information of gas state molecules by measuring the mass-to-charge (m/z) ratios 
of ions.  The first MS, which was also named a “parabola spectrograph”, was 
invented in 1912 by J.J. Thomson and the mass spectra of O2, N2, CO, CO2, and 
COCl2 were obtained.
7  MS has been rapidly developed in the last century.8  MS 
is currently one of the most common analytical instruments in an array of studies, 
including metabolic,9 proteomics,3 genomics,10 and petrolomics.11  In general, 
MS contains three major components which are the ionisation source, the mass 
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analyser, and a detector.  The key ionisation techniques, mass analysers, and 
fragmentation methods for these studies will be discussed in this section.   
 
1.1.1 Key Ionisation Techniques in Mass Spectrometry  
 In a mass spectrometer, only charged gas state molecules can be detected, 
thus it is important to ionise analytes prior to MS detection.  In general, ionisation 
techniques can be classified into two categories which are hard and soft ionisation.  
Hard ionisation indicates the ionisation process is energetic, fragments and 
molecular ions from the analytes are obtained simultaneously.8  Fragments 
generated from hard ionisation are useful for elucidating the structures of analytes; 
these ionisation methods; however, are not suitable for a mixture of analytes as 
complex spectra with multiple fragments from each analyte are generated which 
is challenging for data analysis.  On the other hand, molecular ions are almost 
exclusively generated in soft ionisation which leads to less complicated spectra.  
This method is more suitable for the studies of mixtures of analytes, particularly 
when it couples with isolation and fragmentation (section 1.1.3) techniques in MS. 
 
1.1.1.1 Electron Ionisation 
 Electron ionisation (EI) is one of the classic ionisation techniques for MS and 
was first introduced by Dempster in 1918.12  In general, an EI source contains a 
heated filament, an anode, an inlet for gaseous samples, and an ionisation chamber 
(see Figure 1.1).  In EI, electrons are generated from a heated filament, 
accelerated to ~ 70 eV, and moved towards the anode in an ionisation chamber.8  
Vaporised molecules are introduced from the inlet which is orthogonal to the 
heated filament, then collided with the electron beam to remove an electron, and 
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result in the formation of radical cations (M+•).  The overall EI process can be 
represented by the following equation: 
M + e- → M+• + 2e-            [Eq.1]  
M represents the vaporised molecule, e- represents the electron, and ․represents 
the radical.  
 
Figure 1.1.  Schematic representation of an EI source (Reproduced from De 
Hoffmann et al. 2007).8 
  
The energetic radical cations generated from EI are often not stable which 
result in further dissociation and generate fragment ions, thus, EI is a hard 
ionisation technique.  The extensive fragment ions generated during ionisation 
provide extra information for structure elucidation of the analytes (see Figure 1.2).  
EI is commonly applied to separated, volatile, small molecules;13 the complex 
spectra generated from EI, however, limited application to small molecules (~ 600 
Da).  Gas chromatography (GC) is the most common separation techniques 
coupled with EI for clinical, environmental, food/drug analysis, and other 
applications.14 
Chapter 1 Introduction 
4 
 
 
Figure 1.2.  EI-MS spectrum of pentadecane (C15H32) (Reproduced from the 
tutorial material provided by SCION Instruments, West Lothian, United Kingdom). 
 
1.1.1.2 Chemical Ionisation 
 Chemical ionisation (CI) was first introduced by Talrose in 1952 and the 
ionisation method was further developed by Munson and Field in 1966.15, 16  
Proton transfer is the most common ionisation reaction applied in CI.  Reagent 
gas molecules, i.e. methane, isobutane, and ammonia etc., are first ionised using 
EI.8  The protons generated in the EI process are then transferred to the analyte 
molecules if the molecules contain a higher proton affinity than the applied regent 
gas.  Taking methane (CH4) as an example, the overall CI process can be 
represented by the following equations: 
Step 1: EI of reagent gas – methane (CH4) 
CH4 + e
- → CH4+• +2e-           [Eq.2] 
CH4
+• + CH4 → CH5+ + CH3•          [Eq.3] 
Step 2: Proton transfer 
M + CH5
+ → MH+ + CH4          [Eq.4] 
M represents the vaporised analyte molecule, e- represents the electron, and ․
represents the radical.  
 Compared to EI, CI is a milder ionisation technique which results in less 
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extensive fragmentation during ionisation.8  The molecular ions (MH+) generated 
by CI are even-electron molecules which are usually more stable than the odd-
electron radical cations (M+•) produced by EI.  Thus, the extent of fragmentation 
generated in CI is less than with the EI process, which results in a relative higher 
intensity of molecular ion in the CI spectrum.  CI also requires volatile and less 
complex samples, just like EI.15  
 
1.1.1.3 Matrix Assisted Laser Desorption  
 Matrix assisted laser desorption (MALDI) was first introduced by Karas and 
Hillenkamp in 1985.17-18  It was then applied to a broad range of non-volatile and 
thermally labile samples, including polymers, glycoproteins, and large inorganic 
molecules. 17, 19  In 1988, Tanaka et al. showed that protein and polymer with m/z 
over 100,000 could be analysed by MALDI MS,20 who was then awarded with the 
Nobel prize of Chemistry.  Since then, MALDI was further applied in large 
molecule analysis, such as DNA and proteins.21, 22 
 Currently, the mechanism of MALDI, especially the origin of ions generated 
in MALDI, is still under debate.23-25  In general, desorption and ionisation are the 
two important steps to generate a MALDI spectrum.  Analytes are first mixed 
with matrix solution which contains small organic molecules.  2,5-
dihydroxybenzoic acid (DHB), 3,5-dimethoxy-4-hydroxycinnamic acid (SA), and 
α-cyano-4-hydroxycinnamic acid (CHCA) are the examples of common matrices 
for MALDI for protein and peptide analysis (see Figure 1.3).26, 27  The common 
features of these matrices are composed of an aromatic ring for absorbing laser 
energy and a functional group for providing a proton for analytes.  When samples 
(mixed of analytes and matrix) are irradiated with laser, matrix molecules absorb 
a large amount of energy which result in an ablation of a portion of matrix 
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crystals.28, 29  Neutral analyte molecules are vaporised together with the 
expanding matrix plume, protons are then transferred from the matrix to the 
analyte molecules, and result in the formation of ionized molecules (see Figure 
1.4).   
 
Figure 1.3.  Common matrices (A) 2,5-dihydroxybenzoic acid (DHB), (B) 3,5-
dimethoxy-4-hydroxycinnamic acid (SA), and (C) α-cyano-4-hydroxycinnamic 
acid (CHCA) to use in protein and peptide analysis with MALDI source.  
 
 
Figure 1.4.  The principle of MALDI (Reproduced from EI-Aneed et al. 2009).29 
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 MALDI is a soft ionisation technique which does not induce fragmentation 
during ionisation, but excess irradiation from laser energy can still lead to 
fragmentation of molecular ions.  In general, only singly-charged ions are formed 
during MALDI which provides an advantage in spectrum analysis due to less 
complexity.  Low shot-to-shot reproducibility is one of the major disadvantages 
of MALDI, which is contributed mostly by the non-uniform distribution of matrix 
and analyte within the layers.   
 
1.1.1.4 Electrospray Ionisation 
 Electrospray ionisation (ESI) was first introduced by John Fenn in 1984 who 
was then rewarded with a Nobel Prize in Chemistry in 2002 for this invention and 
its development.30  ESI is generated at atmospheric pressure by applying a strong 
electric field to a liquid that flows out slowly from a capillary tube (see Figure 
1.5).31-33  The electric field is formed by applying several kilovolts (kV) potential 
difference between the capillary tube and the counter electrode, which are 
normally separated a few centimetre.  Charges are then continuously generated 
and accumulated at the liquid surface that located at the tip end of the capillary 
(Taylor cone) under the electric field, which leads to the formation of highly 
charged droplets.  The radial dispersion of the droplets is reduced by using a low 
flowrate, coaxial gas (sheath gas) and the solvent on the droplets is continuously 
evaporated by a heated inert gas, i.e. nitrogen, or a heated capillary.  When the 
solvent has evaporated, the sizes of the droplets decrease while the number of 
charges retained on the droplets remains the same, which leads to an increase of 
the charge per droplet volume, resulting eventually in a “Coulombic repulsion”.  
When the “Coulombic repulsion”, which is generated by the charges on the droplet, 
is greater than the surface tension (Rayleigh limit), the droplets explode into 
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multiple smaller sized droplets.34  The daughter droplets generated continue to 
undergo further Coulombic explosions and then travel along the electric field and 
eventually form desolvated ions, which can be detected by the mass analyser.  
The detailed mechanism of generating ions from the charged droplets is still under 
debate, the ion ejection model (IEM), the charge residue model (CRM), and the 
chain ejection model (CEM), however, are the most commonly accepted models 
to explain the ions generation of small molecules, large folded proteins, and 
unfolded proteins respectively (Figure 1.6).   
 
Figure 1.5.  The principle of ESI source (Reproduced from Banergee et al. 
2012).33 
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Figure 1.6.  ESI models, including ion ejection method (IEM), charge residue 
method (CRM), and chain ejection method (CEM), that are proposed to explain 
the formation of gas phase ions from charged droplets (Reproduced from 
Konermann et al. 2012).35  
 
 ESI allows the ionisation of very fragile analytes without disrupting the non-
covalent interactions between molecules.36, 37  Compared to MALDI, ESI 
generates multiply charged ions through protonation or deprotonation, which 
allows large biomolecules to be analysed at a low m/z range and can improve 
sensitivity.  Furthermore, ESI can easily couple with high performance liquid 
chromatography (HPLC) and capillary electrophoresis (CE), which are the two 
common methods for the separation of biomolecules.38, 39  ESI, therefore, has a 
wide range of applications including proteins,40 DNA,41 polymers,42 and small 
polar molecules.43  The major disadvantages of ESI include sensitivity to salt 
contaminants and inability to effectively ionise many non-polar compounds. 
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1.1.1.5 Nano Electrospray Ionisation 
 Nano electrospray ionisation (nESI) is a nano flow analogue of ESI (section 
1.1.1.4) to increase sensitivity of ESI.  The orifice of the nESI emitter (~ 0.5 –5 
µm) is much smaller than ESI, the droplets formed in the ionisation process, 
therefore, are initially much smaller.44  The smaller droplets formed during the 
nESI process are believed to allow a more efficiency desolvation which results in 
higher efficiency of converting charged droplets to gas phase ions, leading to 
improvement in ionisation efficiency compared to the ESI source.  A schematic 
of nESI is shown in Figure 1.7.  
 
Figure 1.7.  The schematic diagram of nESI (Reproduced from Mandal et al. 
2012).45 
 
 In addition to the difference in sample consumption, lower voltages (0.5 – 1.5 
kV) can be used in the nESI process.  Furthermore, the source temperature 
applied in the nESI can be lower than the ESI as the droplets formed are smaller 
which requires less desolvation.  This feature is of particular importance for the 
studies of native proteins using MS as high source temperature can unfold/denature 
the proteins.46 
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1.1.2 Mass Analysers 
 Once ions are generated from the ionisation source, they are transmitted down 
to the mass analyser by electric potentials, separated according to their m/z, then 
detected and measured by the mass analyser.  In this section, three major mass 
analysers, quadrupole, time-of-flight (TOF), and Fourier transform ion cyclotron 
resonance (FTICR) MS, will be discussed. 
Different mass analysers have different principles to separate ions, for 
example, quadrupole separates ions according to their m/z trajectory stabilities, 
TOF separates ions according to their flight velocities (flight time), and FTICR 
separates ions according to their resonance frequencies.  Mass analysers can be 
further classified into two groups according to the ion transmission properties.  
Some analysers, i.e. quadrupole, allow only ions with a particular m/z to pass 
through at a particular time, and some analysers, i.e. TOF and FTICR, allow the 
concurrent detection of all ions. 
Mass range, speed of analysis, mass accuracy, and resolving power are the 
four main characteristics for evaluating the performance of a mass analyser.  
Mass range is the limitation of m/z range that a mass analyser can measure in a 
single scan.  Speed of analysis is the rate required to measure over a particular 
mass range in a mass analyser.   
Mass accuracy is the accuracy of the m/z measured by a mass analyser which 
is calculated by the difference between theoretical (exact) and measured m/z.  
Parts-per-million (ppm) is the common unit for the expression of mass accuracy 
(see Eq. 5).  Mass accuracy is also affected by the stability and the resolving 
power of a mass analyser (if other species interfere with the measurement).  Mass 
analysers with high mass accuracies help to improve elemental composition 
determination.47  
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Error (ppm) =
(𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑚/𝑧−𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚/𝑧)
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚/𝑧
 𝑥 106   [Eq. 5] 
Resolving power is the ability of a mass analyser to distinguish two signals 
from two ion packets with a small difference in their m/z ratios.  The resolving 
power can be calculated by m/Δm50% (see Figure 1.8), where m is the m/z value 
of the peak andΔm50% is the peak width measured at half maximum (FWHM).  
A greater resolving power indicates the mass analyser has a higher ability to 
distinguish ions with small m/z differences, therefore, a high resolving power mass 
analyser is useful in complicated sample measurement.48, 49 
 
Figure 1.8.  Resolving power calculated by Full Width Half Maximum (FWHM).   
 
1.1.2.1 Quadrupole Mass Analyser 
 The principle of the quadrupole analyser was first introduced by Paul and 
Steinwegen in 1953.50  The quadrupole was further developed into a commercial 
instrument by Shoulders, Finnigan, and Story.51 
 A quadrupole consists of four circular rods which are parallel to each other 
and the rods are connected oppositely in pairs (see Figure 1.9).  Ions are injected 
and travel along the z axis, and oscillate in the x and y plane.  The oscillation of 
ions is influenced by the electric field generated by direct current (DC), voltage 
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(U), and radio frequency (RF) amplitude (V) on the rods.  The potentials on the 
different pairs of rods are set to be out of phase by 180o and rapidly oscillate 
between the pairs of rod, which results in the formation of low field regions (saddle 
points) to transmit particular m/z ions (see Figure 1.10).8, 52, 53  Only particular 
ions with the stability of the trajectories at the particular U and V values can be 
transmitted and detected, while other unstable ions are discharged onto the rods, 
neutralised and cannot be detected.  
 
Figure 1.9.  The layout of a quadrupole which contains four parallel rods, 
connecting diagonally in pairs of positive and negative terminals (Reproduced 
from EI-Aneed et al. 2009).29 
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Figure 1.10.  The formation of saddle points by rapidly oscillating the electric 
potential on the opposite pair of rods in order to retain the positive charged ion in 
the centre of the quadrupole (See https://aquadrupauliontrap.wordpress.com/the-
mechanical-analogue for information, accessed 02nd Oct, 2018).   
 
 Ions are accelerated before entering the quadrupole, then remain at the same 
velocity in the z axis during the transmission through quadrupole.  The trajectory 
stability of ions in the xz and yz planes can be represented by the following 
equations:54 
a = 
8𝑞𝑈
𝑚𝑟0
2𝜔2
             [Eq.6] 
q = 
4𝑞𝑉
𝑚𝑟0
2𝜔2
             [Eq.7] 
where a and u are directly proportional to the U and V values respectively, q is the 
ion charge, m is the ion mass, r0 is the field radius, and ω is the angular frequency.  
For different m/z ions, the a and q values obtained from equation 6 and 7 are 
different which results in generating various stability areas.  Since the U and V 
values are the two variables for different m/z ions, a stability area as a function of 
U and V values containing various m/z ions can be plotted (see Figure 1.11).  As 
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shown in Figure 1.11, each m/z ion is stable under its stability area and is 
discharged outside the area.  During data acquisition, the quadrupole varies the 
U and V values.   
 
Figure 1.11.  Representation of the stability diagram of ions in a quadrupole.  
Ions are represented by m1, m2, and m3 with increasing the mass respectively.  
Each ion is stabilised under its area, i.e. m1 ion is only stabilised in the green area, 
and being transmitted down the quadrupole to the detector.  The quadrupole scans 
according to the scan line and only a particular ion can be transmitted to the 
detector each time.  
 
 The quadrupole is commonly used as an ion guide, collision cell, and mass 
analyser by varying the U/V value.  When a quadruple is an ion guide or collision 
cell, the U value is set to zero and the quadrupole is RF-only, which allows all ions 
to pass through the quadrupole down to the low mass cut off (LMCO).  When a 
quadrupole is a mass analyser, the U/V value is adjusted to a particular ratio that 
only specific m/z ion can pass through the quadrupole, the resolving power of 
quadrupole, therefore, can be adjusted by varying the U/V value.   
 In general, the mass range of a quadrupole is approximately one decade , the 
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FWHM resolution is usually around 2000 (at m/z 1000), the mass accuracy is 
around 100 ppm, and the operating pressure is around 10-5 Torr.8  The quadrupole 
is widely applied in different research studies because of its robustness, reliability, 
small footprint, and lower-cost production.55, 56  Quadrupoles are also commonly 
used as an ion guide and collision cell in order to couple with other mass analysers, 
e.g. TOF and FTICR, to achieve tandem MS (section 1.1.3).57, 58  The major 
disadvantages of a quadrupole are low resolving power and limited mass range. 
 
1.1.2.2 Time-of-flight Mass Analyser 
 The principle of the time-of-flight (TOF) mass analyser was first introduced 
by Stephens in 1946 and was further designed into the first commercial instrument 
(linear TOF mass analyser) in 1955 by Wiley and McLaren.59, 60   
 In TOF-MS, ions generated from an ion source are accelerated through the 
flight tube by an electric field which is caused by the potential difference between 
the electrode and extraction grid.  To a first-order approximation, all ions obtain 
same kinetic energy in the acceleration region, and drift in a flight tube which is a 
free-field region according to their m/z, and reach the detector at different times, 
allowing separation of ions by m/z ratios (see Figure 1.12).  The process of ion 
drifting in TOF mass analyser can be represented by the following equations: 
Kinetic energy obtained by the ion: 
E = 
1
2
𝑚𝜐2 = qV             [Eq. 8] 
Velocity of the ion (rearranged from Eq. 8): 
υ = √
2𝑞𝑉
𝑚
              [Eq. 9] 
where E is the kinetic energy obtained by the ion, m is the ion mass, υ is the ion 
velocity, q is the ion charge, and V is the electric potential generated from the 
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potential difference between electrode and extraction grid.   
 
Figure 1.12.  The outline of a linear TOF (Reproduced from Opsal et al. 1985).61  
Ions (black dot) are accelerated in the yellow region by the electric potential, drift 
through the green region (flight tube), and reach the detector (right). 
 
Eq. 9, it shows the velocity of ion is inversely proportional to the mass1/2 
which indicates heavier ions have a lower velocity, thus they require a longer time 
to drift through a flight tube and vice versa.  The time for ion to reach a detector 
can be calculated by the following equation: 
t = 
𝐿
𝜐
             [Eq. 10] 
where t is the ion drift time across the flight tube and L is the length of flight tube.  
The time for ions to reach a detector can be presented in terms of ion mass by 
combining Eq. 9 and Eq. 10 as follows: 
t = √
𝑚𝐿2
2𝑞𝑉
 = √
𝑚
𝑧
√
𝐿2
2𝑒𝑉
          [Eq. 11] 
where z is the number of charge on the ion and e is the charge constant.  
 Previous results showed that a linear TOF mass analyser could detect protein 
samples in 100 – 200 attomole amounts.62, 63  In a linear TOF mass analyser, there 
is, in theory, no upper mass limit which makes it suitable for the detection of large 
biomolecules and polymers.64, 65  Furthermore, the analysis speed of TOF is very 
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fast, in which a spectrum can be obtained in ~100 micro-seconds.8   
In reality, the kinetic energies obtained by each ion are slightly different, 
which results in the spreading of ions (with same m/z) drift times and causes peak 
broadening and decreases mass resolution.  In order to minimise the spreading of 
ion’s (same m/z) drift time, delayed pulsed extraction and reflectron are the two 
common techniques that applied to correct the kinetic energy differentiation 
between ions (see Figure 1.13).  In delayed pulsed extraction, a delayed pulse is 
applied to all ions and ions with lower kinetic energy stay in the acceleration region 
longer than higher kinetic energy ions which results in lower kinetic energy ions 
obtain more energy before entering the flight tube.  Since the initial lower kinetic 
energy ions receive more energy in the acceleration region, the velocities of these 
ions increase and catch up with the initial higher kinetic energy ions in the flight 
tube, both ions reach the detector at the same time. 
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Figure 1.13.  The implication of a delayed pulsed extraction in a TOF mass 
analyser which improves the mass resolution (Reproduced from De Hoffmann et 
al. 2007).8  The black dot represents an ion with higher kinetic energy, while the 
white dot represent an ion with lower kinetic energy.  The white dot (low kinetic 
energy ion) stays longer in the acceleration region which gains more energy before 
entering the flight tube, as a result the velocity of white dot is higher than the black 
dot and both dots reach the detector at the same time.  
 
The reflectron is also used to correct the kinetic energy spreading between 
ions.  This idea was first introduced by Mamyrin in 1973.66  The reflectron, 
placed opposite to the source and detector, acts like a mirror which reflects the ions 
coming from the source to the detector which is placed next to the ion source (see 
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Figure 1.14).  The ions with higher kinetic energy penetrate the reflectron more 
deeply than the ions with lower kinetic energy, the higher kinetic energy ions, 
therefore, stay in the reflectron longer than the lower kinetic energy ions which 
results in both ions reach the detector at the same time.  With the applications of 
delayed pulse extraction and reflectron, the accuracy of the TOF mass analyser can 
be improved from 200 ppm to 10 ppm and the FWHM resolution is enhanced from 
5,000 to 20,000 (at m/z 1,000).8 
 
Figure 1.14.  The application of a reflectron in a TOF mass analyser which helps 
to improve the mass resolution (Reproduced from De Hoffmann et al. 2007).8  
The black dot represents an ion with higher kinetic energy, while the white dot 
represents an ion with lower kinetic energy.  Since the black dot contains higher 
kinetic energy, it penetrates the reflectron deeper than the white dot, which results 
in arriving the detector at the same time. 
 
1.1.2.3 Fourier Transform Ion Cyclotron Resonance Mass Analyser 
 The Fourier transform ion cyclotron resonance (FTICR) mass analyser was 
first introduced by Marshall and Comisarow in 1974.67  FTICR has been widely 
applied in scientific research due to its high resolving power and mass accuracy.68-
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71  Herein, the major principles of FTICR and its applications will be discussed.  
Cyclotron motion.  In a FTICR mass analyser, an FTICR cell is placed in 
superconducting magnet which generates a homogenous magnetic field across 
the cell.  When ions in the FTICR cell move perpendicular to the magnetic 
field, the ions will experience the “Lorentz force” which is perpendicular to the 
ion motion as well as the magnetic field (see Figure 1.15).  The Lorentz force 
can be calculated by the following equation: 
F = qv x B            [Eq.12] 
where F is the Lorentz force experienced by the ion, q is the ion charge , v is the 
ion velocity, and B is the magnetic field strength of the magnet.  
 Under the influence of magnetic field, ions move around the centre of the 
magnetic field axis which results in an orbital movement, and this motion is 
called “cyclotron motion”.  The theoretical cyclotron frequency of an ion can be 
represented by the following equations:  
ωc = 
𝑞𝐵
𝑚
             [Eq.13] 
fc = 
𝜔𝑐 
2𝜋
 = 
𝑞𝐵
2𝜋𝑚
 = 
1.535611 ×107𝐵
𝑚/𝑧
       [Eq.14] 
where ωc is the ion cyclotron frequency, m is the ion mass, fc is the cyclotron 
frequency expressed in Hertz.  Eq. 14 shows the cyclotron frequency of an ion 
is inversely proportional to its m/z ratio which indicates the heavier ion rotates 
with a lower cyclotron frequency and vice versa.  Because of this relationship, 
the cyclotron motion can be used to distinguish different m/z ratios and thus be 
used as a mass analyser.  
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Figure 1.15.  The cyclotron motion of a positively charged ion (left) and a 
negatively charged ion (right) in the presence of magnetic field (B) (Reproduced 
from Marshall et al. 2002).69 
 
 In general, the ICR frequencies of ions range from a few kHz to a few MHz.  
Eq. 14 clearly shows that the cyclotron frequency of an ion is independent of its 
velocity and kinetic energy, which is a key feature for FTICR to achieve a high 
resolving power.  In other mass analysers, i.e. TOF, delayed pulsed extraction 
and reflectron are required to correct the energy spreading issue which causes 
poor resolution (section 1.1.2.2).8   
 
Trapping motion.  If the magnetic field defines the z axis of Cartesian 
coordinates, ions orbit in the x and y plane inside an FTICR cell because of the 
influence of the magnetic field mentioned above, in order to prevent the ions 
“escaping” via the z axis dimension, two trapping plates with low electric potential 
are applied to create a potential well.  When the energies of the ions are lower 
than the trapping voltage, the ions are trapped in the ICR cell and oscillate back 
and forth between the plates.  The trapping motion frequencies of ions are around 
several kHz which can be represented by the following equation:  
ωz = √
2𝑞𝑉𝑡𝑟𝑎𝑝𝛼
𝑚𝑎2
           [Eq.15] 
where ωz is the ion oscillating frequency in z axis induced by the trapping motion, 
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q is the ion charge, Vtrap is the trapping potential applied in the trapping plates, and 
α is the value determined by the trapping geometry (type of ICR cells), and a is 
the plate-to-plate distance in the cell.   
 Magnetron motion.  The trapping motion induced by the two trapping 
plates is an effective method to prevent ions to escape from the z axis inside an 
FTICR cell.  However, it also induces the magnetron motion, which is an 
undesirable side effect generated from the trapping motion.  In between the two 
trapping plates, an electrostatic field is generated, ions in the FTICR cell 
experience the magnetic force as well as the electric force, which results in a 
second motion in the x and y plane which is named the magnetron motion.  The 
magnetron motion induced by the trapping plates can be represented by the 
following equation:  
ωm = 
𝑉𝑡𝑟𝑎𝑝𝛼
2𝜋𝐵𝑎2
            [Eq.16] 
where ωm is the magnetron frequency of the ion, Vtrap is the trapping potential 
applied in the trapping plates, α is the value determined on the trapping geometry 
(types of ICR cells), B is the strength of magnet, and a is the plate-to-plate distance 
in the cell.   
 Compared to the cyclotron motion, the magnetron motion acting on an ion is 
much slower (with the frequency <100 Hz).  Since the cyclotron motion and 
magnetron motion are acting in the x and y plane, the frequency measured by an 
FTICR cell is a “reduced” cyclotron frequency which can be represented by the 
following equation: 
ωmeasured =ωc – ωm           [Eq.17] 
where ωc is the cyclotron frequency and ωm is the magnetron frequency.  
 A high trapping potential is preferred to effectively trap the ions in an FTICR 
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cell, however, Eq. 16 and Eq.17 show that a high trapping potential increases the 
magnetron motion which results in a larger offset of the ideal cyclotron frequencies 
of the ions.  Thus, a balance between high ion trapping efficiency and interrupting 
the ideal cyclotron frequency is required.  The summarised ion motions, 
cyclotron motion, trapping motion, and magnetron motion, in a penning trap are 
shown in Figure 1.16.   
 
Figure 1.16.  The cyclotron motion (υc), trapping motion (υm), and magnetron 
motion (υm) in a penning trap (Reproduced from Marshall et al. 1998).70 
 
Excitation and detection in FTICR cell.  When ions enter an FTICR cell, 
the cyclotron radii of the ions are too small to generate a detectable signal.  
Furthermore, because the initial phase of the ions is random, the cyclotron 
frequencies of the ions in the cell are incoherent, the current generated on one 
detector is balanced out by the other detector plate, which results in zero net current 
generated on the detector plates.  Thus, an excitation pulse which is ideally 
generated by using a spatially uniform electric field with an amplitude (E0) that is 
perpendicular to the magnetic field is applied to the ions.  The electric field used 
for excitation has the same frequency as the cyclotron frequency of an ion 
(resonant).  During excitation, the size of the ion cloud remains the same while 
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the ion cloud accelerates with a spiral trajectory,72 which results in a larger, 
detectable cyclotron radius (see Figure 1.17).  The radius of the post-excited ion 
cloud can be represented by the following equation: 
r =  
𝐸0𝑇𝑒𝑥𝑐𝑖𝑡𝑒
2𝐵
            [Eq. 18] 
where r is the radius of the post-excited ion packet, E0 is the electric field applied 
to excite the ions, Texcite is the excitation duration, and B is the magnetic field.   
 
Figure 1.17.  Representation of an ion cloud in an FTICR cell when excited (left) 
showing acceleration with a spiral trajectory into a large, detectable orbit (right) 
(Reproduced from Marshall et al. 2002).69  
 
 According to Eq. 18, the radii of the post-excited ion clouds are independent 
of m/z; therefore, all ions can be excited to the same cyclotron orbits in the FTICR 
cell.  Frequency-sweep excitation (chirp) and stored waveform inverse Fourier 
transform (SWIFT) are the two common excitation methods applied in the FTICR 
cell to increase the cyclotron radius of the ion cloud for detection.  The chirp, 
which was first proposed by Marshall in 1974,73 excites the ions over a broad 
frequency range by slowly sweeping through the relevant frequencies with a low 
excitation voltage (see Figure 1.18A).74  However, the excitation amplitude of 
chirp is non-uniform particularly towards the ends of the frequency range, which 
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results in influencing the observed relative abundances of the ions, as well as, the 
poor mass selectivity at the beginning and the end of the sweep frequencies which 
limits the performances of chirp in an FTICR cell.  The SWIFT was then 
proposed by Marshall which reversed the excitation process.75  The desired 
excitation mass is first defined and converted back into a frequency domain 
spectrum, and then stored in memory to generate the time domain waveform to 
excite the desired m/z ion; as a result, SWIFT provides the flattest broadband 
excitation (see Figure 1.18B).  SWIFT is further applied to isolate the desired m/z 
ions in an FTICR cell by over exciting the undesired m/z ions to an orbit larger 
than the FTICR cell, thus only desired m/z ions are retained in the cell (see Figure 
1.18C).  
 
Figure 1.18.  The excitation methods applied in FTICR cell using (A) frequency-
sweep excitation (chirp) and (B) stored waveform inverse Fourier transform 
(SWIFT).  (C) Ions ejection from the FTICR cell by applying the SWIFT 
excitation (Reproduced from Marshall et al. 1998).70 
 
 The excited ion cloud circulates between the two detection plates which 
generates a differential current.  The detected ICR signal is proportional to the 
differential current which can be represented by the following equation:76  
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∆𝑄
𝑑𝑡
=  − 
2𝑞(
𝑑𝑦
𝑑𝑡
)
𝑑
           [Eq. 19] 
where q is the charge of the ion, y is the position of ion in the y-axis, and d is the 
distance between the ion and the detection plate.  
 According to Eq. 19, the ICR signal increases proportionally with the post-
excitation radius as dy/dt is increased with a larger radius.  Ions with different 
m/z are excited into the same orbit in the FTICR cell (Eq. 18) and the detection in 
the ICR cell is non-destructive which allows the simultaneous detection of a wide 
m/z range in the cell.  Furthermore, the FTICR signal is also increased according 
to the number of charges on the ion, thus, the sensitivity is enhanced for multiply-
charge ions.69, 70 
 
FTICR cells.  Cubic and cylindrical cells are two common geometries in 
FTICR cell design.70  The cubic cell contains three sets of plates which are placed 
opposite to one another and arranged like a cubic box.  The three sets of opposed 
plates are used for excitation, detection, and ion trapping (see Figure 1.19A).   
 There are two common types of cylindrical cells which are the open 
cylindrical cell and the cylindrical cell with end-caps, one of which has segmented 
end-caps which is known as the infinity cell.77  For the open cylindrical cell, the 
middle part of the cell contains two sets of opposed, cylindrical plates which are 
used for excitation and detection, and there are two extra sets of cylindrical plates 
placing to the left and the right of the middle part of the open cylindrical cell which 
are used for ion trapping (see Figure 1.19B & 1.19C).78  The open cylinder cell 
design allows effective ion trapping in the z axis with the minimum influence of 
the ion cyclotron frequencies.  For the infinity cell, the middle part of the cell also 
contains two sets of opposed, cylindrical plates which are used for excitation and 
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detection, two end plates are placing to the left and right of the cylindrical 
excitation and detection plates (see Figure 1.19B).77  The trapping voltages are 
carefully divided across the trapping plates in order to trap the ions in the z axis, 
but minimise z-axis ejection during excitation and drastically increase sensitivity.   
 
Figure 1.19.  The configurations of (A) cubic, (B) infinity, and (C) open-ended 
cylindrical cells (Reproduced from Marshall et al. 2002).69  E is the plate for 
excitation, D is the plate for detection, and T is the plate for trapping.   
 
Resolving power.  As mentioned above (Section 1.1.2), resolving power is 
useful to determine the capability of a mass analyser to separate the ions with a 
close m/z differences.  The resolving power of FTICR can also be represented as 
follows:79, 80 
𝑚
∆𝑚
=
1.274 𝑥 107𝑧𝐵𝑇𝑎𝑞𝑛
𝑚
         [Eq. 20] 
where m is the mass of ion, z is the charge of ion, B is the magnetic field strength, 
and Taqn is the transient length.  
 According to Eq. 20, the resolving power of FTICR is determined by the 
length of transient and the strength of magnetic field.  Ideally, the transient length 
of an ion can last forever in a FTICR cell; however, the coalescence as well as the 
ion cloud radius (and detectable signal) decays with acquisition time as there are 
collisions between the ions and the residual background gas molecules, and the ion 
cyclotron frequency is interrupted which results in the decay of the transient signal.  
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Thus, the pressure of a FTICR cell is always required to be maintained at < 10-10 
torr in order to reduce the number of background gas molecules in the cell.   
Furthermore, the resolving power increases proportionally to the strength of 
magnetic field according to Eq. 20.  The strengths of magnets used in FTICR 
experiments range from 1.5 to 21 Tesla (T), and a recent study of a complex crude 
oil sample showed that a 21 T FTICR MS contains 2.2-fold higher mass-resolving 
power than a 9.4 T FTICR MS.81   
 
Dynamic range.  To generate a detectable image current in FTICR, 
currently the lowest required amount of ions required is ~ 187.69, 70  The peak 
intensity in FTICR MS spectra is directly proportional to the number of ions in a 
FTICR cell, thus more ions are always preferred in order to generate a more intense 
peak with a significant signal-to-noise (S/N) ratio for peak assignment.  However, 
when more than ~ 10,000 ions are trapped in the FTICR cell, Coulombic repulsions 
between ions become significant which results in shifting and broadening the 
peaks in FTICR mass spectrum depending on the strength of the magnetic field.70  
This phenomenon is also known as the space charge effect.  Furthermore, peak 
coalescence can occur when two ions contain similar m/z ratio and both of the ion 
clouds are significant large enough to coalesce.76  The space charge and peak 
coalescence effects in FTICR are inversely proportional to the magnetic field 
strength, indicating a higher magnet field strength is always desired to achieve a 
greater dynamic range in FTICR cell.   
 
1.1.3 Tandem Mass Spectrometry 
 Tandem mass spectrometry (MS/MS) involves at least two stages of MS 
detection, precursor ions are either dissociated into fragment ions or involved in a 
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reaction which leads to the change of mass or charge of the ions.8  Fragment ions 
generated in MS/MS provide extra information for molecular assignment and 
structural elucidation, thus MS/MS is applied to proteomics studies.82-84   
 Many fragmentation techniques have been developed and are widely applied 
in proteomics studies to sequence biomolecules.  Different fragmentation 
techniques show advantages in certain application areas.  Common 
fragmentation techniques include collisionally activated dissociation (CAD),82 
infrared multiple photon dissociation (IRMPD),85 sustained off-resonance 
irradiation collision-induced dissociation (SORI-CID),82 ultraviolet 
photodissociation (UVPD),86 electron capture dissociation (ECD),87 electron 
transfer dissociation (ETD),83 electron induced dissociation (EID),88 and electron 
detachment dissociation (EDD).89  The possible fragment ions of a biomolecule 
can be summarised by the Roesptorff nomenclature (see Figure 1.20).90  In this 
section, the three major fragmentation techniques, including CAD, IRMPD, and 
ECD, are discussed. 
 
Figure 1.20.  The possible fragment ions of a biomolecule. 
 
1.1.3.1 Collisionally Activated Dissociation 
 Collisionally activated dissociation tandem MS (CAD MS/MS) is the most 
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common fragmentation technique applied in proteomics studies as CAD is 
compatible with most of the mass analysers, e.g. quadrupole, TOF, and FTICR MS.  
CAD MS/MS was first introduced by Jennings in 1968.91  
In CAD MS/MS, precursor ions are accelerated by the electric fields in the 
ion optics and then collided with a non-reactive gas molecule, usually helium, 
argon, or nitrogen.  The kinetic energy from the precursor ion is converted into 
internal energy and results in fragmentation.  The internal energy is rapidly 
distributed across the precursor ion, and causes the “slow heating” effect in ions, 
usually breaking the weaker bonds available, thus is known as an ergodic process.  
In a protein/peptide, therefore, the fragmentation occurs at the weakest amide bond 
of the ion.  The fragmentation at amide bonds results in generating b and y ions 
which contain the N-terminus and C-terminus of the protein/peptide respectively 
(see Figure 1.21).92  CAD MS/MS does not only generate b and y ions, but also 
produces the loss of neutral molecules, i.e. H2O and NH3, which increase the 
complexity of a MS spectrum.   
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Figure 1.21.  Diagram to show the formation of the b and y ions in CAD MS/MS 
fragmentation.92 
 
CAD MS/MS is commonly applied in determining sequence information 
about biomolecules.  Since CAD MS/MS is an ergodic fragmentation process, in 
which the weakest bonds are dissociated first, it is not suitable to apply CAD 
MS/MS to study of non-covalent interactions between biomolecules, as well as 
fragile post translation modifications (PTMs), i.e. glycopeptide and 
phosphopeptide. 
 
1.1.3.2 Infrared Multiple Photon Dissociation 
 Infrared multiple photon dissociation tandem MS (IRMPD MS/MS) is 
another fragmentation technique that is commonly used to study biomolecules.85, 
93  Compared to CAD MS/MS, IRMPD MS/MS is usually applied on ion trapping 
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based instruments, i.e. ion trap, linear ion trap, and FTICR MS, only.80, 94 
 In IRMPD MS/MS, photons generated from an IR laser are absorbed by the 
precursor ion, which excites the ion to a higher energy state (vibrational state) and 
leads to a dissociation.  Just like CAD MS/MS, IRMPD MS/MS is an ergodic 
process, the energies from the photons are re-distributed among the ion molecules 
which results in fragmentation of the weaker bonds (amide bonds in biomolecules).  
Thus, b- and y- ions are generated during IRMPD MS/MS (see Figure 1.21).   
 The carbon dioxide (CO2) laser is the most common laser used in IRMPD 
MS/MS as it is widely available, relatively cheap, as well as providing a 
wavelength at 10.6 μm which is suitable to be absorbed by a broad range of 
biomolecules.  Since each photon generated by a CO2 (~25 W) laser only 
provides ~ 0.1 eV of energy, a high laser power or a long irradiation time (0.1 – 1 
second) is required to produce effective IRMPD fragmentation.  A prerequisite 
of IRMPD is that the ions of interest must be able to absorb the photons, i.e. they 
must have a chromophore. 
 
1.1.3.3 Electron Capture Dissociation 
 Electron capture dissociation tandem MS (ECD MS/MS) was first introduced 
in 1998 by Zubarev et al. to fragment multiply charged proteins.95  ECD 
fragmentation is not as common as CAD and IRMPD fragmentations because ECD 
MS/MS is usually implemented in FTICR MS,83 even though recently ECD has 
also applied in the other types of mass analysers.96, 97 
Compared to CAD and IRMPD MS/MS, ECD MS/MS is believed to be a 
non-ergodic process in that the precursor ion is dissociated before the energy is 
randomised in the ions.98  In ECD MS/MS, low energy electrons, ~1-3 eV, are 
generated and captured by a multiply charged precursor ion and the N-Cα bond of 
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the ion is cleaved, even-electron c ions (with N-terminus) and odd-electron z• ions 
(with C-terminus) are formed (see Figure 1.22A).  At least one electron is 
captured by the precursor ion during the ECD fragmentation process and results in 
a charge neutralisation effect (see Eq. 21), thus only multiply-charged precursor 
ions are suitable for ECD fragmentation to avoid generation of neutral species 
which cannot be detected by MS.  The electron capture process can be 
represented by the following equation: 
[M + 𝑧H]𝑧+ + 𝑒− (1 − 10 eV) → [M + 𝑧H](𝑧−1)+•     [Eq. 21] 
where M is the precursor ion, z is the charge of the ion, and e is the electron.  
Apart from c and z ions, a and y ions may also be generated from the ECD MS/MS 
as minor products (see Figure 1.22B). 
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Figure 1.22.  Diagram to show the generation of the (A) c and z ions and (B) a 
and y ions in ECD MS/MS fragmentation.92 
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Implementation of ECD.  A hollow cathode behind the FTICR cell is used 
to generate electrons for ECD fragmentation.  The kinetic energy difference 
between the electrons and precursor ion cloud is required to be as minimum as 
possible in order to maximise the electron capture process.84  
 
ECD fragmentation mechanisms.  Several fragmentation mechanisms 
were proposed to explain the generation of c and z
․
 ions during ECD MS/MS.  
Herein, the two major proposed ECD MS/MS fragmentation mechanisms are 
discussed.  
 Cornell mechanism.  The Cornell mechanism was first proposed by the 
research group of McLafferty in Cornell University in 1998.95  The Cornell 
mechanism suggests electrons are captured by protonated sites, including the 
amino group at N-terminus and the side chain of basic amino acids (histidine, 
arginine, and lysine), and form a hydrogen atom.  The hydrogen atom is then 
attracted to the amide oxygen (at the protein/peptide backbone) and forms a 
carbon-centered aminoketyl radical precursor ion.  The N-Cα bond that is 
adjacent to the carbonyl group is cleaved and forms c and z ions (see Figure 1.23)
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Figure 1.23.  The Cornell mechanisms of ECD MS/MS with electron captured at the (A) C-terminus and (B) N-terminus to generate the c and z 
ions.83 
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Utah-Washington mechanism.  The Utah-Washington mechanism was first 
proposed by the research group of Simons from University of Utah in 2003.99  
The mechanism was then further explained by the research group of Turecek from 
University of Washington in 2005.100  In the Utah-Washington mechanism, 
electrons are directly captured at the amide group (the protein/peptide backbone) 
and formed a carbon-centered aminoketyl radical precursor ion.  The N-Cα bond 
which is adjacent to the carbonyl group is cleaved and generates c and z ions (see 
Figure 1.24).  The carbonyl anion generated during the electron capture process 
is then neutralised by a proton that is transferred from a charged site.    
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Figure 1.24.  The Utah-Washington mechanism of ECD MS/MS to generate the c and z ions.83
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Fragmentation efficiency of ECD MS/MS.  The fragmentation efficiency 
can be measured by comparing the total abundance of fragment ions against the 
total abundance of the precursor ion.  When well-tuned, the fragmentation 
efficiency of an ECD MS/MS efficient is ~ 20% for a doubly charged peptide ion, 
however, > 80 % fragmentation efficiency can be achieved with some highly 
charged protein ions.84  The fragmentation efficiency of ECD in a highly ordered 
structural protein can also be enhanced by combining the fragmentation techniques 
of IRMPD and ECD MS/MS as the energy contributed by IRMPD can destabilise 
the internal non-covalent bonds which results in obtaining more c and z ion 
fragments.101, 102 
 Applications of ECD MS/MS.  Being radical-based rather than slow-
heating based, ECD MS/MS has a very different fragmentation mechanism 
compared to CAD and IMRPD MS/MS, thus it has several advantages in the 
following applications.  
 De Novo Sequencing.  In the studies of ECD MS/MS, a high sequence 
coverage was achieved in the top-down spectra of ubiquitin (~ 8.6 kDa) and 
cytochrome c (~ 12.4 kDa),84, 95 which indicated ECD has extensive cleavage and 
is useful for de novo sequencing analysis.  Previous studies also showed that 
complementary fragments were also observed when both CAD and ECD MS/MS 
were applied in studying biomolecules, so that a larger sequence coverage was 
obtained which contributed to a higher successful rate in de novo sequencing of 
the biomolecules.103 
 Preservation of fragile PTMs and non-covalent interaction.  
Phosphorylation and glycosylation are two important protein modifications which 
relate to protein functionality.104  The covalent linkages between the protein 
backbone and phospho-/glycan group are weaker than amide bonds, which results 
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in the PTM being lost rapidly with CAD and IRMPD MS/MS.  Thus, it is 
challenging to locate the site of phosphorylation and glycosylation in the protein 
backbone using CAD and IRMPD MS/MS.  ECD MS/MS, on the other hand, 
preserves these fragile linkages; while still fragmenting the protein backbone 
through radical mechanisms and results in providing sufficient information to 
localise the fragile PTMs on the biomolecules.4, 105 
 Non-covalent interactions between proteins and protein-ligands are 
commonly observed; however, it is challenging to localise the interaction sites 
between these molecules as the non-covalent bonds are weaker than the covalent 
bonds in the protein backbone, which results in fragmentation at the non-covalent 
interaction site when using CAD and IRMPD MS/MS, losing structural 
information.  However, ECD MS/MS can localise the interaction site of proteins 
and protein-ligand complexes by fragmenting the protein backbone while 
preserving the non-covalent bonding.  Using ECD MS/MS, the non-covalent 
interaction sites between proteins and protein-ligands can be located quite 
accurately, often to several amino acid residues.37, 106, 107 
 Disulfide Bond Cleavage.  In CAD and IRMPD MS/MS, the presence of a 
disulfide bond significantly hinders protein fragmentation.108  Thus, reduction 
and alkylation are usually required prior to CAD and IRMPD MS/MS in order to 
yield a good sequence coverage of the protein.  In ECD MS/MS, the electron is 
preferentially captured at the disulfide bond site which results in a reduction of the 
S-S bond, and allows fragmentation on the protein backbone (see Figure 1.25).92, 
109 
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Figure 1.25.  Diagram to show the electron is captured by the disulfide bond and 
results in the S-S bond cleavage.92  
 
 Differentiation of isomeric products from deamidation.  Iso-aspartic acid/ 
aspartic acid and γ-glutamic acid/ glutamic acid are the common products obtained 
during deamidation of proteins (detail discussion in section 1.2.2).110, 111  The 
mass of iso-aspartic acid and γ-glutamic acid are exactly the same as aspartic acid 
and glutamic acid respectively, the only difference is the methylene group (-CH2-) 
from the side chain of aspartic acid and glutamic acid is added into the backbone 
of iso-aspartic acid and γ-glutamic acid (see Figure 1.26).  It is challenging to 
differentiate these isomeric products using CAD and IRMPD MS/MS.  ECD 
MS/MS, however, can differentiate the iso-aspartic acid and γ-glutamic acid from 
aspartic acid and glutamic acid respectively.112, 113  In iso-aspartic acid and γ-
glutamic acid, there is a possibility that the bond cleavage takes place at the Cα-C 
bond rather than the N-Cα bond at the iso-aspartic acid and γ-glutamic acid 
deamidation site, which results in a formation of a c ion with an addition of 58 Da 
(C2H2O2) at the deamidation site and a complementary z ion with a loss of 57 Da 
(a hydrogen ion is used to convert z
˙
 to z, thus a loss of 57 Da instead of 58 Da) 
(see Figure 1.27).112, 114, 115 
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Figure 1.26.  Deamidation mechanisms of (A) asparagine and (B) glutamine.  
The protein backbone is coloured in red; while the amino acid side chain groups 
are coloured in black.  
 
Figure 1.27.  Diagram to show the ECD fragmentation mechanism at the iso-
aspartic acid deamidation site to generate a (c+58 Da) ion and a (z-57 Da) ion.114 
 
 Other electron-based fragmentation techniques.  Since ECD MS/MS is 
usually applied on FTICR MS, electron transfer dissociation (ETD) was then 
invented in 2004 by Syka et al.38  Reactive radical anions are generated by 
ionising the reagent molecules, i.e. azulene and fluoranthene, through a negative 
chemical ionisation process.  The precursor ions and radical anions are then 
transferred to the ion trap MS where ion-ion interaction takes place.  During the 
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ion-ion interaction, electrons from the radical anions are transferred onto the 
precursor ions, which results in the formation of radical cations and leads to further 
fragmentation.  
 Hot ECD MS/MS is an interaction between precursor ions and more energetic 
electrons (~ 6-10 eV).  In hot ECD, the chance of secondary fragmentation 
increases which results in extensive fragmentation, indicating the generation of w-
ions.92  Electrons with higher energy (~ 20 – 100 eV) are used in in electron 
induced dissociation (EID) which results in the most extensive protein/peptide 
fragmentation as all bonds in the backbone are possible to be cleaved.116   
 For negative precursor ions, electron detachment dissociation (EDD) with 
energetic electrons (~ 10-25 eV) is used and results in Cα-C backbone cleavage 
and generates a-, x-, c-, and z-ions.  
 
1.1.4 Bruker 12 Tesla Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometer 
 In a Bruker 12 T FTICR-MS (see Figure 1.28), ions can be generated by a 
nESI, ESI, or MALDI source.  Ions generated by ESI or nESI are then passed 
through the glass capillary with temperature ranged from 40oC to 220oC which 
helps to evaporate the solvent surrounding the analytes.  The orthogonal design 
of the ion source and ion funnels allows the separation of neutral molecules from 
the ionised analytes because the electric field from ion funnels only affects the path 
of charged molecules, as a result only ions are transmitted to the later parts of the 
instrument.  The dual ion funnels with a source octopole are used to focus the 
ions before passing through to the Qh front end which contains a quadrupole and 
a hexapole collision cell.  The quadrupole in the Qh front end is used for m/z 
filtering if mass isolation is required.  Ions are then passed to the hexapole for 
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accumulation and CAD/ETD fragmentation can be performed if necessary.  The 
radical anions are generated in the nCI source for ETD fragmentation.  Ions are 
then transferred through a hexapole (ion guide) and reach the infinity cell which is 
placed within a superconducting magnet (12 T). 
 
Figure 1.28.  Diagram to show the instrument design of the Bruker 12 T solariX 
FTICR MS used in this work (Reproduced from the tutorial material provided by 
Bruker Daltonics, Bremen, Germany).  
 
 Ions in the infinity cell can be fragmented by IRMPD or ECD if necessary.  
The electron cathode is placed at the opposite side of the ion entrance in the ICR 
cell with lenses placed between the cathode and ICR cell to extract electrons for 
ECD MS/MS.  IR laser is placed at the same side of the cathode.  The on-axis 
laser beam (generated from a CO2 laser) passes through the hollow cathode and 
reaches the ICR cell for IRMPD MS/MS.   
 The resolving power of the Bruker 12 T FTICR MS is around 600,000 at m/z 
400 acquiring in broadband mode with the low mass detection at m/z 147 and four 
mega-word data points (32 bits).  Mass accuracy is usually less than 0.5 ppm with 
internal mass calibration and less than three ppm with external mass calibration.  
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1.2 Applications of Mass Spectrometry 
 There are a wide range of applications that are based on MS analysis.9, 21, 47, 
81, 114, 117, 118  In this thesis, the applications of MS are mainly focused on amyloid 
proteins studies, including the underlying aggregation and inhibition mechanisms 
of amyloid proteins, the effects of deamidation on amyloid proteins aggregation 
and inhibition, as well as amyloid-related proteomics studies.   
 
1.2.1 Introduction of Amyloid Proteins 
Abnormal aggregation of proteins and peptides into mature amyloid fibrils is 
a hallmark in approximately 50 human disorder diseases, including Alzheimer’s 
disease (AD), Parkinson’s disease (PD), type II diabetes (T2D), and Huntington’s 
diseases (HD) (see Table 1.1).119, 120  The disorder diseases can be further 
classified into three different groups: 1) neurodegenerative conditions, in which 
aggregation happens in brain; 2) non-neuropathic localised amyloidosis, in which 
aggregation happens in a single organ/tissue rather than brain; and 3) 
nonneuropathic systemic amyloidosis, in which aggregations happens in several 
organs/tissues simultaneously. 
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(Table 1.1 continue) 
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(Table 1.1 continue) 
 
Table 1.1.  Table to summarise the most common human amyloid diseases.120
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The overall structures of amyloid fibrils are often determined by transmission 
electron microscopy (TEM) and atomic force microscopy (AFM).121, 122  An 
amyloid fibril is composed of insoluble mature peptide fibrils originating from 
smaller, soluble monomer peptides, which are believed to refold into crossed β-
strands perpendicular to the fibril axis.123, 124  In order to determine the molecular 
level details of amyloid fibrils, high-resolution structural studies using solid-state 
nuclear magnetic resonance (SSNMR) spectrometry have been used and the 
molecular level interactions between the aggregates of amyloid beta 1-40 (Aβ1-40) 
were observed.125, 126  
 The formation of amyloid fibrils can be explained by a “nucleated growth” 
mechanism, which includes a lag phase, followed by an exponential growth phase, 
and eventually reach a final plateau (see Figure 1.29A).120, 127  In the lag phase, 
nuclei with the smallest amount of aggregates that are stable for the further growth 
rather than dissociation back into the monomer units are formed.127  Thus, the 
nuclei of the aggregates contain the highest Gibbs free energy in the aggregation 
process (see Figure 1.29B).  Once the nuclei are formed, the aggregation process 
changes to the growth phase, in which the association of monomer/ early oligomer 
units onto the nuclei is rapid.  When most of the monomer/ early oligomers units 
are associated with the nuclei, the aggregation process then reaches the final 
plateau stage.   
 
Figure 1.29.  Diagram to show (A) the various aggregation phases of amyloid 
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proteins and (B) the free energy of aggregates in various states during aggregation 
process (Reproduce from Arosio et al. 2015).127 
 
  The nucleated growth mechanism of amyloid fibril has been demonstrated by 
thioflavin T (ThT) fluorescence spectrometry experiments.  When ThT 
molecules bind to the mature β-sheet formed by the amyloid fibrils, a significant 
fluorescence emission is given at wavelength of 490 nm when the mixture is 
excited with a wavelength at 450 nm (see Figure 1.30B).127, 128  ThT molecule has 
been proposed to be stabilised at the surface side chain of the mature β-sheet fibril 
axis in order to generate fluorescence emission (see Figure 1.30C).128 
 
Figure 1.30.  Diagram showing (A) the molecular structure of ThT, (B) the 
emission wavelength (nm) of the mixture solution when ThT is bound onto 
amyloid fibrils, and (C) the proposed interaction mechanism between ThT 
molecule and mature amyloid fibrils (Reproduced from Biancalana et al. 2010).128  
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1.2.1.1 Amyloid Proteins Studies using Mass Spectrometry 
 The formation of amyloid fibrils is a hallmark in the human amyloid diseases; 
however, the early oligomers generated from amyloid proteins have been shown 
to be more toxic than the fibrils in vitro as the early oligomers can diffuse through 
cell membranes and lead to cell dysfunction.129, 130  Experiments using TEM, 
AFM, SSNMR, and ThT fluorescence spectrometry have provided critical and 
valuable information on the structure and the time required for the formation of 
amyloid fibril, but the molecular level interactions between the early oligomers are 
difficult to observe by these methods as it is challenging to separate and detect a 
particular oligomer, i.e. dimer, from the monomer units and the orders of oligomers.  
Recently, MS has been demonstrated as an appropriate method to study the 
aggregation and inhibition mechanisms of amyloid proteins by observing the 
interaction between the early oligomers.117, 131-137  
 Aggregation mechanisms of amyloid proteins studied by MS.  Previous 
studies have shown that early oligomers were able to be detected in micro-molar 
(μM) concentration in MS experiments; while different orders of oligomers were 
detected as each of the oligomer contains different m/z ratio.117  CAD MS/MS 
was used to demonstrate the type of interaction between the early oligomers; in 
general, the bonding between the early oligomers is non-covalent.135  Thus, CAD 
MS/MS cannot further demonstrate the interaction site between the early 
oligomers.  
Recently, ion mobility-mass spectrometry (IM-MS) was developed to study 
the aggregation mechanism of amyloid proteins.  A gradient of electric field is 
applied to further separate the early oligomers based on their secondary and 
tertiary structures, in which the compact oligomers are travelling faster than the 
open-structured oligomers.138  The collision-cross section (CCS) of the oligomers 
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is obtained through the experiment, and computational modeling can simulate the 
interaction between the oligomers in order to match with the CCS provided in the 
experiment.138, 139  Thus, IM-MS is widely applied in the study of the amyloid 
proteins aggregation mechanisms.117, 131, 139   
Inhibition mechanisms of amyloid proteins studied by MS.  Understanding 
the underlying inhibition mechanisms of the early oligomers of amyloid proteins 
is critical for drug development, thus MS has also been applied in determining the 
inhibition mechanisms of amyloid proteins.  
Similar to the studies of aggregation mechanisms, MS, CAD MS/MS, and 
IM-MS experiments are used to observe the presence, the type, and the prediction 
of the interaction between the early oligomers and potential inhibitors 
respectively.134, 136, 137  MS was also promoted as a rapid screening method to 
predict the potential usage of the inhibitors by observing the change in the binding 
ratio between the early oligomers and the potential inhibitors.137 
ECD MS/MS has also been applied in the previous studies to localise the 
interaction site between amyloid protein (α-synuclein) and potential inhibitor 
(spermine) down to the molecular level which is useful for further drug 
development.37  
 
1.2.2. Introduction of Deamidation 
 Deamidation is a non-enzymatic PTM which has been proposed as an 
important step in many of time-related biological processes, including homeostatic 
control, protein turnover, as well as cell development and aging.140-142  
Deamidation occurs spontaneously in solution at asparagine (Asn) and glutamine 
(Gln) residues, and results in iso-aspartic acid/ aspartic acid and γ-glutamic acid/ 
glutamic acid formation respectively (see Figure 1.26), in which a negative charge 
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is induced at the deamidation site in a neutral pH solution (physiological buffer). 
111, 112, 143  The deamidation rate of Asn is faster than Gln due to the shorter 
distance between the main chain amido group (-NH-) and the side chain amide 
group (-NH2-).
110, 144  Upon deamidation of Asn, an additional methylene group 
(-CH2-) is added into the backbone of iso-aspartic acid and γ-glutamic acid, which 
can result in a dramatic change in the tertiary structure, stability, folding, and 
function of proteins.145, 146   
 The deamidation rate of protein depends on the primary sequence, secondary 
and tertiary structure, temperature, pH, ionic strength, and buffer ions.143, 147-150  
Previous studies showed that the time frames for human proteins to be completely 
deamidated are ranged from 2 to >2000 days.111, 140  Recently, the deamidation 
rates of proteins at pH 7 with temperature at 37oC can be predicted by the 
computational simulation based on the deamidation rate library generated by the 
pentapeptide models of Asn and Gln residues, and the reliable 3D structures of the 
proteins.111, 140, 149, 150  The deamidation prediction accuracy is believed to be ~ 
95% for exposed, flexible peptides.150 
 Deamidation has been shown to have significant effects in enhancing the 
aggregation rate of amyloid proteins.  Previous studies have shown that 
deamidation can accelerate certain amyloid fibril formation including mutated Aβ 
(D7N and D23N) observed in Alzheimer’s disease.113, 151, 152  Aggregation of 
amylin associated with T2D,153, 154 β2-microglobulin from dialysis-associated 
amyloidosis disease, 5, 155 and αβ-crystallin from human eye lens have also been 
shown to be affected by deamidation.156   
 
1.2.2.1 Deamidation Studies using Mass Spectrometry 
 Liquid chromatography, 157 NMR,158 Raman spectroscopy,159 and infrared 
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spectrometry153 have been applied in studying protein modifications, but 
deamidation remains a challenge as a subtle change in the modification.  MS is a 
powerful tool for examining deamidation in proteins as the deamidation reaction 
produces products with a mass shift of +0.984 Da (-NH2 to -OH) at the deamidated 
residue (see Figure 1.26), which is readily detected by MS.114, 160-162  Previous 
studies also suggested that deamidation can be directly quantified by measuring 
the peak area of the non-deamidated and deamidated peaks, thus the percentage of 
deamidation in the sample can be estimated.163, 164 
 MS is useful in detecting deamidation and provides deamidation percentage 
in the sample, tandem MS/MS can further locate the deamidation site in proteins, 
as well as differentiate the isomeric deamidation products.112, 115, 160-164  CAD 
MS/MS helps to indicate the deamidation site with a mass shift (+0.984 Da) 
appears in the b and y ion fragments containing the deamidated residue, while 
normal fragments are obtained in the region that does not contain deamidated 
residue.164  ECD MS/MS not only localises the deamidation site in protein, but 
also uses to differentiate the isomeric products of deamidation by the mass shift of 
+58 and -57 Da at the c and z ion fragments of iso-/γ- deamidation products 
respectively (see section 1.1.3.3).  The peak intensity of iso-/γ- deamidation 
products can also compare with the peak intensity of aspartic acid/glutamic acid 
in order to determine the ratio of the isomeric products.163 
 
1.2.3. Introduction to Proteomics 
 The terminology of “Proteomics” was first introduced in 1997 and proteome 
was introduced by Mark Wilkins in 1994, which is a combination of the words 
“protein” and “genome”.165  Proteomics is a proteome study that includes the 
large-scale of proteins generated by a living organism.  In proteomics studies, the 
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structures and functions of proteins are analysed in detail.   
 In proteomics, MS is used to measure the mass of proteins and peptides which 
provides information on the identity, the chemical modifications, as well as the 
structures of the proteins.  Proteomics research is involved significantly in 
searching for biomarkers for diseases,166 quantifying the critical proteins and their 
relative PTMs changes,167, 168 observing the structural changes of proteins,58, 102 
and monitoring the interactions of potential drugs with proteins in the living 
organism.3, 169  These studies contribute to the prevention and treatment of 
diseases, such as cancer,170 neurodegenerative diseases,118 and bacteria diseases, 
etc.171 
 
1.2.3.1. Proteomics Studies using Liquid Chromatography-Mass 
Spectrometry 
 Many thousands of proteins are involved in a single proteomics study.  As a 
result there is no suitable analytical instrument to handle such a huge number of 
analytes in a single run other than MS.   
 Types of proteomics studies.  In general, there are three different types of 
MS proteomics studies, including top-down proteomics, middle-down proteomics, 
and bottom-up proteomics.   
 Top-down proteomics.  Top-down proteomics is the study of the whole size 
proteins without cutting the proteins into pieces.  Top-down proteomics preserves 
the highest sequential and chemical modification information of the proteins as 
less treatments and chemicals are required for the samples, which helps to preserve 
the structure, PTMs, and full sequence of the proteins.172, 173  Top-down 
proteomics, therefore, is suitable for the structural, as well as de novo sequencing 
studies of proteins.58, 102, 105  However, MS requirements for top-down proteomics 
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are the highest due to the presence of a huge number of fragments in a single MS 
spectrum.  Thus, ultra-high resolving power MS, i.e. FTICR MS or at least 
orbitrap MS, is required for top-down proteomics; as a result, top-down proteomics 
is not as common as bottom-up proteomics.  
 Bottom-up proteomics.  Bottom-up proteomics is the study of peptides 
which are digested from proteins.  Enzymatic digestion (i.e. chymotrypsin, 
pepsin, and trypsin digestion) and chemical digestion (i.e. cyanogen bromide) are 
the two common methods to cut proteins into peptides.174, 175  In protein digestion, 
chemicals, like reducing and alkylating reagents, are commonly mixed with the 
samples in order to achieve a better result of digestion;175, 176 however, artificial 
modifications are also introduced to the samples.  Furthermore, incubation is 
normally required for the enzymatic digestion,175 thus modifications that are 
highly correlated with temperature, i.e. oxidation and deamidation, are also 
induced into the sample.177  At the same time, fragile chemical modifications on 
the proteins are easily removed during the digestion process due to the high 
temperature and long period of incubation.  
 Middle-down proteomics.  Middle-down proteomics is the study of peptides 
that has not been fully digested from proteins, forming a middle ground between 
top-down and bottom-up proteomics.  Middle-down proteomics minimises the 
digestion time of proteins from ~ 12-16 hours to ~ 2-4 hours which helps to reduce 
the loss of the fragile modifications, as well as decrease the artificial modifications 
induced in the samples.178  Furthermore, proteins generated by middle-down 
proteomics contain more protonated sites which favours the fragmentation using 
MS/MS.179  The proteins are that generated from middle-down proteomics are 
not fully digested, thus it is difficult to predict the number of missed cleavages in 
a single peptide/protein which results in challenging data analysis.  
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 Separation methods applied in proteomics studies.  Even though MS is 
capable of detecting various analytes simultaneously, it is still challenging to detect 
hundreds, or even thousands of proteins/peptides in a single scan.  Gel and liquid 
chromatography (LC) separation are the two common methods applied in 
proteomics separation.  Sodium dodcyl sulfate polyacrylamide (SDS-PAGE) gel 
electrophoresis is commonly applied in gel separation, however, it is only suitable 
for large biomolecules, i.e. proteins.  LC, on the other hand, is suitable to apply 
to both protein and peptide separation.  Herein, the various types of LC generally 
applied in proteomics separation are going to be discussed.  
 Stationary and mobile phase are the two keys requirements in LC.  
Stationary phase is a material (solid/liquid) that retained in the LC column which 
is used to adsorb the analyte molecules based on their 
hydrophobicity/charge/structure.  Mobile phase is a material (liquid/gas) that 
passes through the stationary phase of LC and reduces the interaction between 
adsorbed analytes and stationary, which results in elution of the analyte.  
 Separation based on hydrophobicity.  Different amino acids have different 
hydrophobicity value which was defined by Fauchere in 1983, and the 
hydrophobicity values of amino acid are ranged from -1 (most hydrophilic) to +2 
(most hydrophobic). 180  Proteins and peptides are made up with different amino 
acids, which results in containing various hydrophobicity values.  
 Reversed-phase (RP) chromatography is the most common LC method to 
separate proteins and peptides in a mixture based on their hydrophobicity.  The 
stationary phase of RP is made up of alkyl chains (C4/ C8/ C18), different length of 
alkyl chains are attached onto the silica gel based on the separation purpose.181  
The short alkyl chain (i.e. C4) is more suitable for the large analytes, i.e. proteins, 
separation; while the long alkyl chain (C18) is more suitable for the small analytes, 
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i.e. peptide, separation.181  The alkyl chains in RP column provide a hydrophobic 
environment which adsorbs the hydrophobic analytes strongly to the stationary 
phase, thus the hydrophobic analytes are retained on the RP column longer than 
the hydrophilic analytes.  The stronger the interaction between the analytes and 
the stationary phase, the higher concentration of organic solvent (non-polar mobile 
phase) is required in order to elute the analytes out from the column.  Water is a 
polar solvent which can minimise the elution of analytes during loading and 
cleaning process.  The common non-polar organic solvent used for proteomics 
elution is acetonitrile as it contains a lower polarity than water; at the same time, 
it is miscible with water and does not damage the stationary phase.  RP is the 
most suitable LC column to co-operate directly with MS as the buffers used in RP 
are salt-free and do not aggregate or adhere to the biomolecule analytes, thus it is 
generally applied in MS proteomics studies.   
 Hydrophilic interaction liquid chromatography (HILIC) is an alternative LC 
method to separate proteins and peptides based on their hydrophobicity.  The 
stationary phases of HILIC is commonly made up of amino bonded phase, 
alkylamide, or zwitterionic sulfobetaine ligands attaching onto the silica gel.182  
In contrast to RP column, the stationary phase of HILIC provides a hydrophilic 
environment, thus hydrophilic analytes are adsorbed strongly onto the stationary 
phase, in which hydrophilic analytes are retained on the column longer than the 
hydrophobic analytes.  Acetonitrile is the most common loading buffer for HILIC 
column; while water/methanol is applied as the elution buffer due to its high 
polarity.182  Ammonium formate is commonly added into the buffer solutions in 
order to maintain the analytes at a single ionic form .183  HILIC has been 
demonstrated as a better separation on protein/peptide containing PTMs, i.e. 
phosphopeptide and glycopeptide.182, 184 
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 Separation based on charge.  Proteins and peptides contain different charge 
state in a particular pH solution, which can be used to enable separation by LC.  
Strong cation exchange chromatography (SCX) and strong anion exchange 
chromatography (SAX) are two common ion-exchange chromatography applied 
in LC for the separation of positive and negative charged proteins/peptides 
respectively.  The stationary phases of SCX and SAX normally contains a 
negatively charged functional group (sulfonate, -SO3
-) or a positively charged 
functional group (quaternary amine, -N(CH3)3
+) respectively.  The interactions 
between the ion-exchange chromatography columns and analytes are mainly based 
on electrostatic attraction as opposite charges are attracted to each other.  The 
elution buffers of ion exchange columns are always contains high salt content, e.g. 
350 mM NaCl,185 to replace the interactions between the stationary phase 
functional groups and the charged analytes.  Ion exchange columns have been 
demonstrated as an effective tools to enrich lots of modifications,185, 186 however, 
extra clean-up of the samples is required prior to MS analysis.  
 
1.2.3.2 Proteomics Studies using Two Dimensional Mass Spectrometry 
 LC-MS is a powerful technique for separating proteins and peptides prior to 
MS analysis, however, this method limits the study of fragile interaction between 
proteins or protein-ligand as the solvents applied in LC-MS may not preserve the 
weak bonding/structure of biomolecules.  Thus, two dimensional mass 
spectrometry (2DMS) is an alternative method to proteomics study while 
preserving the weak interaction between proteins, and removes the requirement of 
LC prior to MS and MS/MS .  
 Principles of 2DMS.  2DMS is an MS based technique which modulates 
ions in-and-out of a fragmentation zone in an ion trapping device, such as an 
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FTICR cell.  The fragmentation technique (e.g. IRMPD) fragments the precursor 
ions in the FTICR cell, and 2DMS correlates the fragments with the corresponding 
precursor ion according to their modulated frequency.  In traditional MS/MS, 
precursor ion is first isolated by a mass analyser, i.e. quadrupole, according to its 
m/z ratio; in 2DMS, however, mass isolation is not required.   
 2DMS was first introduced by Pfandler et al. in 1987 and further developed 
and applied by Ross et al. in 1993 using an FTICR mass analyser.187, 188  In 2DMS, 
a modulating excitation or de-excitation pulse is used to alter the positions of ions 
inside the FTICR cell, ions that are modulated to overlap with the position of the 
fragmentation zone are dissociated with the applied radius-dependent in-cell 
MS/MS technique, i.e. IRMPD or ECD.  Bensimon et al. showed that by 
increasing the delay period (t1) between the two excitation pulses (P1 and P2) one 
can modulate the ions inside a FTICR cell.189  In 2DMS, an excitation pulse (P1) 
is first applied to all precursor ions so that the ions no longer stay in the centre of 
the FTICR cell.  Then, a delayed period (t1) is applied.  Ions with a cyclotron 
frequency that is a multiple of t1 with an extra half period are de-excited by the 
second pulse (P2), the ions then move back to the centre of the cell; while ions with 
a cyclotron frequency that is an integer multiple of t1 are further excited to a higher 
radius position in the FTICR cell (see Figure 1.31).  In IRMPD MS/MS, the 
fragmentation zone is at the centre of the cell, thus only ions which are de-excited 
back to the centre are fragmented, and no fragmentation is obtained for the ions 
that are outside the fragmentation zone.  In 2DMS, t1 is increased proportional 
with the number of scans, and the phases of the ions that are excited by P1 will 
change according, which results in modulating the radius of precursor ion as a 
function of t1.  Since the fragment ions are modulated in the same way as the 
precursor ion, which can be used as an information to correlate back to the 
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precursor ion.  
 
Figure 1.31.  (A) A summarised diagram to show the pulse sequence applied in 
a 2DMS experiment.  (B) The modulation of ions in 2DMS experiment 
(Reproduced from Van Agthoven et al).190  
 
 Applications of 2DMS.  2DMS is newly applied to proteomics studies, 
including both top-down and bottom-up proteomics.  Previous studies showed 
that similar top-down and bottom-up fragments were obtained from both 
quadrupole precursor isolated MS/MS and 2DMS.191  Peptides from digested 
collagen showed that 2DMS can differentiate and fragment the two precursor ions 
with a similar m/z, which, in general, cannot be isolated and fragmented 
individually by quadrupole mass isolation.192  Peptide assignment from the 
2DMS spectra of digested proteins, such as cytochrome C, calmodulin, and 
collagen, also showed that 2DMS has the potential for the complex proteomics 
studies without LC separation.191-194  
 
1.3 Overview of the thesis 
 This thesis focuses on the studies of one of a highly amyloidogenic protein – 
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human islet amyloid polypeptide (hIAPP, also known as amylin).  In Chapter 2, 
MS is used to determine the aggregation pathway and deamidation sites of hIAPP; 
the rate of aggregation and the structures of amyloid fibrils formation are also 
determined by ThT fluorescence spectroscopy and TEM experiments.  In Chapter 
3, MS is further used to determine the inhibition pathways of wild-type and 
deamidated hIAPP fibrillisation with several potential inhibitors; the inhibition 
effects of the potential inhibitors are measured by MS quantification, ThT 
fluorescence, and TEM experiments.  In Chapter 4, a newly developed analytical 
method – two dimensional mass spectrometry (2DMS) is evaluated for its potential 
to be applied in studying the fragile non-covalent interaction in a proteomics 
sample.  Conclusions of this thesis and future works are summarised in Chapter 
5. 
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Chapter 2 Exploring the Aggregation and Deamidation Mechanisms of 
Human Islet Amyloid Polypeptide Using Fourier Transform Ion Cyclotron 
Resonance Mass Spectrometry 
 
This chapter demonstrates the applications of Fourier transform ion cyclotron 
resonance mass spectrometry (FTICR MS) together with fluorescence 
spectroscopy and transmission electron microscopy (TEM) to study the 
aggregation and deamidation mechanisms of a highly amyloidogenic protein – 
human islet amyloid protein (hIAPP).   
The results presented in this chapter were predominantly carried out by the 
thesis Author, aside from acquisition of transmission electron microscopy (TEM) 
for which data were obtained by Mr. Ian-Hands Portman from the Department of 
Life Science, University of Warwick.   
Two manuscripts entitled “Exploring the Aggregation Mechanisms of Human 
Islet Amyloid Polypeptide Using Fourier Transform Ion Cyclotron Resonance 
Mass Spectrometry” and “Human Islet Amyloid Polypeptide as a Molecular Clock: 
Does Deamidation cause Dimerization?” by Yuko P. Y. Lam, Christopher A. 
Wootton, Ian Hands-Portman; Juan Wei, Cookson K. C. Chiu, I. Romero-Canelon, 
Frederik Lermyte, Mark P. Barrow, and Peter B. O’Connor, have been prepared 
for submission to Analytical Chemistry based on the results presented in this 
chapter. 
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2.1 Abstract 
Human islet amyloid polypeptide (hIAPP) aggregation is a hallmark in type 
II diabetes (T2D) which results in the death of pancreatic beta-cells and the failure 
of islet cell transplants.  The aggregation mechanism of hIAPP has been studied 
for more than ten years, but the aggregation sites have not yet been conclusively 
determined.  Herein, ultrahigh resolution mass spectrometry (MS) has been 
applied in monitoring the formation of early oligomers, especially the dimers and 
trimers of hIAPP.  Tandem MS using electron-based dissociation reveals the most 
important aggregation sites of hIAPP to be the region near Gly-33 and Ser-34 
residues, which contributes to the understanding of the aggregation mechanism.  
Furthermore, the results from MS, fluorescence spectroscopy, and transmission 
electron microscopy (TEM) clearly show that deamidation is not essential for the 
early oligomer aggregation of hIAPP in an aqueous solution since the rate of 
deamidation is much slower than the rate of aggregation.  However, the rate of 
aggregation is accelerated by seeding deamidated hIAPP into solutions before 
incubation.  The Asn-21, Asn-22, and Asn-35 amino acid residues in the 
incubated hIAPP solutions were found to be deamidated within seven days.  
Residues Asn-21, Asn-22, and Asn-35 all showed similar degrees of deamidation 
in the incubated solutions, while the degree of deamidation found in the fibril pellet 
is higher than in the incubated solution.  Additionally, aggregation of mutant 
hIAPP with iso-Asp residue mutations at possible deamidation sites showed very 
different fibril formation behaviour compared to the wild-type hIAPP, which may 
help to explain the deamidation-induced acceleration of hIAPP aggregation. 
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2.2 Introduction 
Amyloid fibril formation is a hallmark in a range of human diseases, 
including Alzheimer’s disease,1 Parkinson’s disease,2 and type II diabetes (T2D).3  
An amyloid fibril is composed of insoluble, mature peptide fibrils originating from 
smaller, soluble monomer peptides, which are believed to refold into crossed β-
strands perpendicular to the fibril axis.4, 5  The overall structures of amyloid 
fibrils have been studied in detail for more than a half-century;6-8 the molecular 
details of aggregation, however, are still limited by the difficulties in solubilising, 
separating, and identifying the aggregated biomolecules.  
Human islet amyloid polypeptide (hIAPP; also referred to as amylin) is a 37-
residue hormone peptide co-secreted with insulin and involved in regulating blood 
glucose levels.9, 10  The concentration of hIAPP is around 1% - 2% relative to the 
level of insulin in secretory granules.11  hIAPP contains an intramolecular 
disulfide bond between Cys-2 and Cys-7, as well as, an amidated C-terminus (see 
Figure 2.1A and 2.1B),12 and is an intrinsically disordered protein with a low level 
of persistent helical structure between residues Asn-3 and Leu-27 in solution.13  
Early oligomers of hIAPP have been shown to be a key factor in causing the 
decline of pancreatic β-cell mass and the failure of islet cell transplants used for 
the treatment of T2D.14, 15  In the past decade, electron microscopy, circular 
dichroism (CD), and computational modelling simulations have been the common 
techniques for studying hIAPP aggregates, and a solid β-sheet structure was 
observed in the mature hIAPP fibrils.16-19  However, the aggregation mechanism 
remains poorly understood.20   
Computational docking simulations with residue replacement techniques 
have been applied to explain the aggregation mechanism of hIAPP based on its 
molecular structure.17  Computational models suggested Phe-15, in the α-helix 
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region of hIAPP, was a critical residue for the aggregation since the rate of fibril 
formation was significantly reduced in the mutants where the Phe-15 residue was 
replaced in silico (F15D and F15K mutant hIAPP).  Nuclear magnetic resonance 
(NMR) spectroscopy experiments led to the interpretation that the N-terminal 
segment of hIAPP (residues 1 – 17) was essential for the formation of amyloid 
fibrils.21  These models contrast with the hypothesis that the region of hIAPP 
between residues 20-29 contains amyloidogenic tendency, which was 
demonstrated by comparing the rate of fibril formation between the rat IAPP 
(rIAPP) and hIAPP.16  Rat and human IAPP sequences differ by six amino acid 
residues (of the 37 present), five of which are located within residues 20-29; 
however, experimental data have shown rIAPP did not aggregate over a 5-day 
incubation period while hIAPP was shown to aggregate readily within 20 hours.16, 
22  This hypothesis has been further studied on multiple occasions using short 
sections of hIAPP to identify the active aggregation region, where several studies 
using peptides containing residues 20-29 were shown to aggregate effectively,22-29 
indicating the active aggregation region could be within this range.  Following 
this, solid state NMR also revealed that hIAPP units stack to form β-strands and 
then further aggregate into layers of β-sheets (see Figure 2.1C).12  Ion mobility 
mass spectrometry (IM-MS) was recently used for the study of hIAPP 
aggregation.4, 30-34  The structures of monomer and oligomers were predicted by 
molecular dynamics modeling based on the collision cross-sectional area obtained 
from IM-MS.33, 35, 36  β-strand interaction was determined as the most stable and 
favourable binding motif in the hIAPP dimer.32  A fragment of hIAPP (residues 
28-33) was proposed by Bleiholder et al. as an amyloidogenic region via a ‘steric 
zipper’ assembly pathway using IM-MS.4  Early oligomers of hIAPP are toxic to 
the β-cells;37 however, the conflicting reports on the binding motif hinder drug 
Chapter 2 – Aggregation and Deamidation Mechanisms of hIAPP 
84 
 
development.  Improved understanding of the binding motif of hIAPP is 
therefore required. 
 
Figure 2.1.  (A) The amino acid sequence of hIAPP.  An intramolecular 
disulfide bond is located between Cys-2 and Cys-7, and hIAPP has an amidated 
C-terminus.  (B) The structure of hIAPP monomer (PDB 2KB8) as reported by 
Patil et al.38 using 1H NMR, which contains an α-helical structure from residues 5-
28.  (C) The oligomer structure of hIAPP as demonstrated by Luca et al.12 
indicates each monomer of hIAPP interacts at the β-strand and forms β-sheet layers.  
The potential deamidation sites are coloured in red. 
 
Deamidation is a non-enzymatic post-translational modification (PTM) 
which contributes to protein ageing.39, 40  Deamidation occurs spontaneously in 
solution at asparagine (Asn) and glutamine (Gln) residues, and results in iso-
aspartic acid/aspartic acid and γ-glutamic acid/ glutamic acid formation 
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respectively.41-43  The deamidation rate of Asn is faster than Gln due to the shorter 
distance between the main chain amido group (-NH-) and the side chain amide 
group (-NH2-).
44, 45  With an additional methylene group (-CH2-) into the 
backbone of iso-aspartic acid and γ-glutamic acid; the tertiary structure, stability, 
folding, and function of proteins can be dramatically altered by deamidation.46, 47  
Previous studies showed that deamidation can accelerate certain amyloid fibril 
formation, including mutated amyloid-β (D7N and D23N) observed in 
Alzheimer’s disease.48-50  Aggregation of β2-microglobulin from dialysis-
associated amyloidosis disease,51, 52 and αB-crystallin from human eye lens have 
also been shown to be affected by deamidation.53   
hIAPP is an amyloid protein which contains six Asn and one Gln potential 
deamidation sites (see Figure 2.1).  A previous study from Nilsson et al. used a 
variant of hIAPP segment, residues 20-29 (SNNFPAILSS) which is non-
amyloidogenic and showed that addition of less than 5% of deamidated monomer 
was required to accelerate the fibril formation.54  Results from Dunkelberger et 
al. also showed that deamidation of hIAPP disrupted the β-sheet structure around 
Leu-27, resulting in a morphology change of hIAPP fibrils, along with accelerated 
fibrils formation.55  Even though deamidation shows a significant impact on fibril 
formation, the effects on the deamidation rate, the deamidation site(s), and the 
effects of isomeric deamidation products of hIAPP have not yet been fully 
addressed.  
Herein, Fourier transform ion cyclotron resonance mass spectrometry 
(FTICR MS) is applied in monitoring the aggregation and deamidation of hIAPP.  
Electron capture dissociation tandem MS (ECD MS/MS) is used for determining 
the aggregation sites between the monomer subunits within the dimer and the 
trimer of hIAPP and localising the binding area to the amino acid residue level 
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without disrupting remaining non-covalent bonds.56-59  The concentration of 
soluble hIAPP and the deamidation rate are recorded periodically for 28 days in 
order to study the correlation between aggregation and deamidation in an aqueous 
solution.  The deamidation sites and the extent of deamidation of hIAPP are 
further determined by collisionally activated dissociation (CAD) MS/MS.  
Transmission electron microscopy (TEM) and Thioflavin T (ThT) fluorescence 
spectroscopy are also employed to monitor the rate of fibril formation.  The 
experimental results reveal the aggregation motif of hIAPP, the effects of 
deamidation on hIAPP aggregation, and the rate of deamidation of hIAPP in 
aqueous solution.   
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2.3 Experimental Section 
Sample preparation for early oligomers in wild-type hIAPP, the synthetic 
mutant hIAPPs, the synthetic 30TNVGSNTY37-NH2 peptide, and the mixture 
of hIAPP & 30TNVGSNTY37-NH2.  Wild-type hIAPP lyophilised powder 
(D2162 with purity >97%; Sigma Aldrich Company Ltd, Dorset, England; see 
Supplementary Information, Figure S2.1 – S2.2), the synthetic mutant hIAPPs 
with purity >95% (Pepscan Company Ltd, The Netherlands; see Supplementary 
Information, Figure S2.3), and the synthetic 30TNVGSNTY37-NH2 peptide with 
purity >95% (Eurogentec, England) were initially dissolved in 100% dimethyl 
sulfoxide (DMSO) at a concentration of 500 µM for storage (at -80oC) in order to 
minimise the aggregation rate, as used by Abedini et al..60  The 500 µM stock 
solutions were further diluted with Milli-Q (Direct-Q® 3 UV System, Millipore 
Corporation, US) H2O (~pH 7.5) to 10 µM solutions, and the final concentrations 
of DMSO in each solution were 2% (v/v). 
Wild-type hIAPP lyophilised powder was also dissolved in Milli-Q H2O at a 
concentration of 500 µM and further diluted into 10 µM solution.  The mixture 
of hIAPP & 30TNVGSNTY37-NH2 was prepared by mixing 10 µM hIAPP (in H2O) 
with 10 µM 30TNVGSNTY37-NH2 (in 100% DMSO) in 1:1 ratio in aqueous 
solution, and the final concentration of DMSO in hIAPP aqueous solutions was 
2% (v/v).   
Sample preparation for deamidated hIAPP and fibrils.  The 10 µM 
hIAPP aqueous solution (2000 µL) was incubated at 37oC for 28 days; 50 µL 
solution was collected each day.  Each collected aliquot solution was then 
centrifuged at 14,000 rpm for one hour to separate the soluble hIAPP (supernatant) 
from the insoluble hIAPP fibril (pellet).  The supernatant solution containing 
soluble hIAPP was then diluted 20-fold with 49.5:49.5:1 water/acetonitrile/formic 
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acid prior to MS analysis.  hIAPP fibrillary pellets from 7-, 14-, 21-, and 28-day 
solutions were rinsed with Milli-Q H2O three times and then re-dissolved with 20 
µL of 47.5:47.5:5 water/acetonitrile/formic acid, and sonicated in water bath at 37 
oC for one hour.  Re-dissolved samples were further diluted with 80 µL of 50:50 
water/acetonitrile.  The final concentration of formic acid in solutions was 1% 
(v/v). 
Sample preparation for seeding mutant peptides.  Wild-type hIAPP 
lyophilised powder and synthetic mutant hIAPPs were dissolved in Milli-Q H2O 
to a concentration of 500 µM.  The seeding experiments were performed by 
mixing unmodified hIAPP stock solution with 5%, 10%, 25%, or 50% mutant 
((D)3hIAPP) or ((isoD)3hIAPP) solutions.  Samples were then diluted to a final 
concentration of 10 µM wild-type hIAPP plus mutant ((D)3hIAPP) or 
((isoD)3hIAPP), which were incubated for one week at 37
oC.  The supernatants 
and fibrillary pellets were separated and prepared as mentioned above. 
FTICR MS analysis.  Mass spectra were acquired on a 12 tesla solariX 
FTICR MS (Bruker Daltonik GmbH, Bremen, Germany).  All samples were 
analysed in positive ionisation mode.  For the early oligomers study, nano-
electrospray ionisation (nESI) with a capillary voltage of 0.6 – 1 kV was applied 
and the source temperature was set to 80 oC.  The nESI glass capillaries were 
purchased from World Precision Instruments and pulled on a Sutter P-97 capillary 
puller instrument (One Digital Drive Novato, California, USA).  For the 
detection of deamidated hIAPP and dissociated fibrils, an Apollo II electrospray 
ionisation (ESI) source (Bruker Daltonik GmbH, Bremen, Germany) was used 
with a capillary voltage of 4-4.5 kV.  The ESI flow rate was optimised to 100-150 
µL/h and the source temperature was set to 200oC.  Ions were externally 
accumulated in a hexapole collision cell before transferred to an infinity cell (ICR 
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cell) for excitation and detection.61  Data obtained from FTICR-MS were 
analysed using Bruker DataAnalysis 4.2 software (Bruker Daltonics, Bremen, 
Germany). 
MS/MS fragmentation in the FTICR MS.  For the collisionally activated 
dissociation (CAD) experiments, precursor ions were first isolated using the 
quadrupole mass filter, then collided with argon gas and accumulated in the 
collision cell.  The collision energy was optimised to 2-18 V and the ion 
accumulation time to 1-3 seconds.  Fragments were then transferred to the 
infinity cell for detection.  For the ECD experiments, precursor ions were first 
isolated using the quadrupole with a wide mass-to-charge isolation window (~100 
Da) and accumulated in the collision cell for 1-3 seconds.  Ions were then 
transferred to the infinity cell, further isolated using Multi-CHEF62 isolation with 
an excitation power of 45-55%, and then irradiated with 1.2 eV electrons from a 
1.5 A heated hollow cathode.  For the infrared-ECD (IR-ECD) experiments, a 25 
W continuous-wave CO2 infrared laser (Synrad Inc, US) was used to activate the 
protein during ECD in order to increase the fragmentation efficiency.63  The pulse 
length and laser power were optimised to 20-50 ms and 12.5 W (50% power) 
respectively, which is just below the influence threshold for obtaining IRMPD 
fragment ions.  The most intense isotopic peak from each fragment with signal-
to-noise ratio (S/N) over five was manually matched with the theoretical m/z.  All 
of the fragments were internally calibrated and then assigned with an uncertainty 
less than one part-per-million (ppm) (see Supplementary Information, Table S2.1-
S2.12).  
Studying intermolecular binding strength within oligomers via FTICR 
MS/MS.  The area of the highest isotope peak of each oligomer was measured 
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using Bruker DataAnalysis 4.2 software.  The percentage of dimer ion (%) was 
calculated as follows:  
Dimer (%)=
Peak area of dimer
Total peak area of monomer+ dimer
 ×100% 
A dissociation curve for dimer ions was obtained by plotting the percentage of 
dimer remaining against the CAD energy used.  The same calculation method 
was applied to obtain the dissociation curve of other oligomer ions. 
Transmission electron microscopy (TEM).  The TEM images of the 
incubated solutions, including 10 µM hIAPP solutions, 10 µM synthetic mutant 
hIAPPs solutions, 10 µM synthetic 30TNVGSNTY37-NH2 solution, and mixture of 
hIAPP & 30TNVGSNTY37-NH2 solution, were acquired on a Jeol 2010F TEM 
operated at 200 kV.  10 µL of incubated solution was transferred onto a carbon-
coated grid and settled for one minute, followed by removing the excess solution 
using filter paper.  A 2% (w/v) uranyl acetate solution was used for the negative 
stain.  Multiple images with magnification from x10,000 to x40,000 were 
acquired.  
Thioflavin T (ThT) fluorescence reactivity.  The fluorescence reactivity 
of the 10 µM hIAPP, mutant ((D)3hIAPP), mutant ((isoD)3hIAPP), and hIAPP 
seeding solutions were measured using a GloMax®-Multi Detection System 
(Promega; Wisconsin, USA).  All samples were placed in a black 96 well-plate 
and mixed with 10 µM ThT aqueous solution.  Fluorescence spectra of the 
samples were acquired every 45minutes with excitation at 405 nm and emission 
measurement at 490 nm, in a similar fashion to Chan et al.64, 65. 
Incubated solutions were diluted with water to 10 µM and mixed with 10 µM 
ThT solution.  Fluorescence spectra of incubated hIAPP solutions were acquired 
under same experimental conditions as above.  The intensities obtained from the 
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fluorescence spectrometer were normalised to the signal intensity of the most 
mature fibril.  
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2.4 Results  
Early oligomer formation in hIAPP.  Aggregated hIAPP is composed of 
mature and insoluble polypeptide fibrils, whose overall structure has been reported 
previously.33, 66  The early, soluble oligomers are viable for MS study and can 
provide insights into the fundamental amino acid residue level binding between 
individual hIAPP monomer units and how they link together to form a higher order 
structure.  High resolution MS allowed observation of the early oligomers of 
hIAPP via direct infusion without prior separation.  Oligomers, up to the 
pentamer, were detected in the nESI-MS spectrum of the 10 μM hIAPP in aqueous 
solution with 2% DMSO residual present in the solvent (see Figure 2.2A).  
Similar observations of the oligomers’ distribution pattern were found in the nESI-
MS spectrum of the 10 μM hIAPP in aqueous solution only (see Supplementary 
Information, Figure S2.4).  Despite very closely positioned oligomer peaks and 
overlapping isotopic envelopes with various charge states (5+ dimer/ 10+ tetramer 
and 2+ monomer/ 4+ dimer/ 6+ trimer), the isotopic patterns of each oligomer were 
still well-resolved.  Observed signal intensity of the oligomers decreased with 
increasing size of oligomer species.  
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Figure 2.2.  (A) An nESI-MS spectrum of the early oligomers from the 10 μM hIAPP aqueous solution with 2% (v/v) residual DMSO.  
Oligomers; monomer (circle), dimer (square), trimer (star), tetramer (triangle), and pentamer (pentagon), were detected in the spectrum.  Inset, 
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enlarged regions of spectra are shown for the labelled species.  Coloured shapes represent the calculated isotope distributions for the different 
species overlaid onto the observed patterns.  (B) ECD MS/MS spectrum of the 7+ charge state hIAPP dimer.  Highlighted fragments represent 
the critical dimer c- and z-ion observed.  The assigned ECD MS/MS fragments of the 7+ charge state hIAPP are included in Supplementary 
Information Figure S2.9 and Table S2.4.  Summarised fragments observed in the ECD MS/MS spectrum of the (C) 7+ dimer and (D) 8+ trimer 
of hIAPP.  Examples of the critical assigned dimer/ trimer c- and z-ions from the ECD MS/MS are inserted.  Highlighted sequences represent 
the proposed non-covalent interaction region.  Coloured shapes represent the calculated isotope distributions as in (A)
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In order to gain sequence-specific hIAPP interaction information, the hIAPP 
dimer and trimer ions were also studied via ECD MS/MS.  The ECD MS/MS of 
the 7+ hIAPP dimer ion (see Figure 2.2B-2.2C; Supplementary Information, 
Figure S2.9 & Table S2.4) produced 33 monomer c-ions, four monomer z-ions, 
seven monomer y-ions, seven dimer c-ions, and 30 dimer z-ions (representing the 
mass of a hIAPP unit plus a c-/z-ion fragment).  The most critical dimer 
fragments identified from the spectrum were M+z3 and M+c29.   
ECD MS/MS was further applied to the hIAPP trimer to fragment the 
oligomer while preserving the non-covalent interaction between hIAPP units.  
Compared to the previous hIAPP dimer spectrum, the ECD MS/MS spectrum of 
the 8+ charge state trimer was more complex due to the presence of monomer, 
dimer, and trimer fragments simultaneously, though sequence informative 
fragments were successfully observed (see Figure 2.2D; Supplementary 
Information, Figure S2.10 & Table S2.5).  Aside from the monomer and dimer 
fragments, trimer c- and z-ion (representing the mass of two hIAPP units plus a c-
/z-ion fragment) were also obtained.  21 monomer c-ions, two dimer c-ions, one 
dimer z-ion, three trimer c-ions, and 24 trimer z-ions were identified from the ECD 
MS/MS spectrum.  The most critical trimer fragments found in the spectrum were 
2M+z5 and 2M+c34.  Similar ECD MS/MS fragments were obtained from hIAPP 
dimer and trimer which were dissolved solely in aqueous solution (see 
Supplementary Information, Figure S2.11 & Table S2.6-S2.8).   
In order to test whether the proposed interaction region (around Gly-33 and 
Ser-34) was amyloidogenic, an eight-residue segment of hIAPP (30TNVGSNTY37-
NH2) was synthesised, but the structure of the sequence was unknown.  The 3+ 
charge state trimer of 30TNVGSNTY37-NH2 at m/z 1281 (overlapping with 6+ 
charge state hexamer of the segment) was isolated and fragmented with ECD 
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MS/MS.  The most critical trimer fragments (representing mass of two 
30TNVGSNTY37-NH2 plus c-/z-ion) were 2M+z5 and 2M+c5 (see Supplementary 
Information, Figure S2.13B & Table S2.9).  
 
From soluble oligomers to mature and insoluble fibrils.  hIAPP has been 
shown to oligomerise during incubation,4, 31, 55 where the soluble oligomers can 
combine and orientate into a β-sheet structure forming a mature and insoluble fibril.  
When hIAPP monomers aggregate, the concentration of free hIAPP monomer 
decreases, and as a result can be used to follow the extent and rate of hIAPP 
aggregation into oligomers.  In order to determine the aggregation rate, a 10 μM 
solution of hIAPP was incubated at 37oC; the concentration of soluble hIAPP was 
then determined by comparison of relative MS peak area of the monomer in each 
aliquot of the incubated sample over 28 days.  A reduction in the percentage of 
soluble hIAPP was observed after the first week of incubation (see Figure 2.3A).  
After 12 days incubation, ~ 50% reduction of the percentage of soluble hIAPP was 
observed.  After 28 days incubation, only 25% of remaining soluble hIAPP 
monomer was observed in the 10 μM solution. 
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(Figure 2.3. Continue) 
 
Figure 2.3.  (A) Plot showing the amount of soluble hIAPP in the 10 μM solution changing over time measured using MS.  (B) The relative 
fluorescence activity of the 10 μM ThT solution, incubated 5 μM and 10 μM hIAPP solutions measured at emission 490 nm with excitation at 405 
nm.  The TEM images of the (C) fresh, (D) 1-week, (E) 2-week, and (F) 4-week incubated 10 μM hIAPP solutions.  The TEM images of the (G) 
1-week 10 μM hIAPP segment solution and (H) 1-week 10 μM hIAPP segment solution mixed with 10 μM hIAPP solution.  The scale bars for 
each TEM image are inset. 
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FTICR MS is well suited for the quantification of soluble proteins (such as 
hIAPP) in solution, but ESI is limited to soluble components only, and cannot 
effectively ionise the mature, insoluble fibrils.  Thus, the relative concentration 
of amyloid fibril formed in the incubated solutions was determined by the ThT 
fluorescence reactivity at emission 490 nm (see Figure 2.3B).64, 67  Both solutions 
showed limited detectable aggregation by ThT fluorescence for the first 40 hours 
of incubation (lag phase), followed by a sharp increase to a maximum value at 
around 55 hours.  The end time relative emission of the 10 μM hIAPP solution 
was 2.7 times higher than the emission recorded in the 5 μM solution.  
The formation of amyloid fibrils in the 10 μM solutions was also monitored 
by TEM.  Freshly solubilised hIAPP molecules clump together, which can be 
observed as small black clusters shown in the TEM images (see Figure 2.3C).  
Loosely-packed and elongated fibrils were clearly observed in the TEM images of 
the 1-week incubated sample images (see Figure 2.3D).  The longest fibril 
observed within the 1-week incubated solution was 5.1 μm.  Long fibrils were 
still observed in the incubated 2-week sample (see Figure 2.3E), along with shorter, 
more densely packed fibrils, showing a gradual change in the hIAPP fibril structure 
at longer incubation time.  Very dense fibrils were observed at the 4-week stage 
(see Figure 2.3F), showing little remaining space between the fibril branches.  
Relatively short fibrils were observed in the 10 μM solution of 30TNVGSNTY37-
NH2 which had been incubated for one week.  When the hIAPP and segment 
peptides were mixed together, short fibrils were found in the 1-week incubated 
mixture of hIAPP and 30TNVGSNTY37-NH2 solution; however, it was impossible 
to differentiate the components of the fibrils using TEM.  
 
Deamidation site(s) and rate of hIAPP.  Deamidated hIAPP has been 
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proposed as an accelerating factor for the formation of amyloid fibrils,55 thus 
determining the specific deamidation sites is required in order to study the effect 
of deamidation on the natural hIAPP aggregation mechanism.  Deamidation sites 
were determined using CAD MS/MS on the deamidated hIAPP species.  The 1+ 
charge state of the y5 fragment clearly showed a deamidated peak (+0.984 m/z) in 
the incubated sample (see Figure 2.4A).  For the b fragments, no deamidated 
peaks were observed for the first 20 amino acid residues (see Figure 2.4B); 
however, a deamidated peak was present corresponding to the b21 fragment (see 
Figure 2.4C).  Furthermore, another deamidated peak was detected 
corresponding to the b22 fragment ion in the incubated solution (see Figure 2.4D).   
 
Figure 2.4.  Key CAD MS/MS fragments of hIAPP revealing deamidation at 
amino acid residues after four weeks incubation at 37oC (A) y5, (B) b20, (C) b21, 
and (D) b22 are shown. The blue/red circles indicate the isotopic peaks of 
singly/doubly deamidated fragments, respectively. 
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Subsequently, the deamidation rates of each deamidated site were determined 
by calculating the percentage ratio between the non-deamidated and the 
deamidated fragment ion peak areas for each sample.  In the incubated solution, 
the earliest deamidation instance was observed on day 5, and was identified in the 
y5 fragment ion (see Figure 2.5A).  Deamidation at the b21 and b22 fragment ions 
was observed on day 8.  Though the extent of deamidation increased with the 
incubation time; a similar percentage and rate of deamidation were found in the y5, 
b21, and b22 fragment ions at the various time points for the incubated solutions.  
After 28 days incubation, each deamidated fragment ion (y5, b21, and b22) of the 
soluble hIAPP showed ~18% deamidation.  The fibrillary pellets showed a 
greater extent of deamidation than the soluble hIAPP species.  Deamidation was 
observed in the day-7, day-14, day-21, and day-28 samples (see Figure 2.5B).  On 
day-7, ~7.5% of the y5 fragment ion was deamidated while no deamidation was 
observed for the b21 and b22 fragment ions in the pellet.  On day-14, the extent of 
deamidation for the y5 fragment ion increased sharply to 16% and the b21 and b22 
showed ~7.5% deamidation.  After 28 days incubation, the extent of deamidation 
of the y5, b21, and b22 fragment ions were at 39%, 30%, and 29% respectively, 
distinctly larger than for the soluble hIAPP species above.
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Figure 2.5.  The extent of deamidation observed in CAD MS/MS fragments; the y5 (black), b21 (red), and b22 (blue) for 10 μM aqueous hIAPP 
(A) solutions and (B) dissolved fibril solutions.
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Aggregation of mutant ((D)3hIAPP) and ((isoD)3hIAPP).  In order to 
ascertain the effects of deamidation on the aggregation process, pure mutant hIAPP 
peptides were synthesised with aspartic acid ((D)3hIAPP) or isoaspartic acid 
((isoD)3hIAPP) replacement at the detected deamidation site from above, i.e. 
residues 21, 22, and 35 (see Supplementary Information, Figure S2.3).  The 7+ 
charge state dimers of ((D)3hIAPP) and ((isoD)3hIAPP) observed in the nESI-MS 
spectrum of the 10 μM aqueous solutions were fragmented by ECD MS/MS (see 
Supplementary Information, Figure S2.16, S2.17 & Table S2.11, 2.12), and similar 
fragments were obtained in both spectra as in the ECD spectra of the 7+ charge 
state dimer of wild-type hIAPP.  The relative fluorescence activities of the 10 μM 
solutions of ((D)3hIAPP) and ((isoD)3hIAPP) were measured and the lag phases 
of the formation of mature fibrils were ~ 30 hours (see Supplementary Information; 
Figure S2.18).  TEM images of the ((D)3hIAPP) and ((isoD)3hIAPP) solutions 
incubated at 37oC for one week were also obtained (see Figure 2.6A & 2.6B).  
Branched and elongated fibrils were observed in ((D)3hIAPP) incubated solution; 
while densely packed fibrils were found in ((isoD)3hIAPP) solution.  The fibril 
structures observed in ((isoD)3hIAPP) solution were distinctly different from the 
fibrils found in wild-type hIAPP and ((D)3hIAPP).   
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Figure 2.6.  The TEM images of 10 μM (A) ((D)3hIAPP) and (B) ((isoD)3hIAPP) 
solutions after one week incubation at 37oC.  The scale bar for each TEM image 
is shown accordingly.  (C) A plot showing the normalised percentage of soluble 
hIAPP in the 10 μM solutions with spiking different percentage of mutant 
((D)3hIAPP) or ((isoD)3hIAPP) to wild-type hIAPP (control) measured using MS 
after one week incubation.  * indicates the p-value of the sample percentages are 
less than 0.05 compared to the control percentage in a paired t-test.  (D) The 
relative fluorescence activity of 10 μM hIAPP, 9.5 μM hIAPP plus 0.5 μM (5%) 
((D)3hIAPP), and 9.5 μM hIAPP plus 0.5 μM (5%) ((isoD)3hIAPP) measured at 
emission 490 nm.   
 
((D)3hIAPP) and ((isoD)3hIAPP) solutions were individually spiked into 
wild-type hIAPP solution at 5%, 10%, 25%, and 50% amounts.  After one week 
incubation, the percentage of remaining soluble monomeric hIAPP in the seeded 
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solutions was consistently less in the spiked solutions than the control hIAPP 
incubated solution, and less soluble hIAPP was found in the mutant ((isoD)3hIAPP) 
spiked solutions compared to the ((D)3hIAPP) spiked solutions (Figure 2.6C).  
The p-values of seeding 5% and 10% mutant ((D)3hIAPP) into the solution were 
higher than 0.05, which indicated the differences between the seeded solutions and 
the control sample were not significant.  The p-values of the remaining seeded 
solutions were less than 0.05, which showed significant differences between the 
control and the seeded solutions.  The normalised percentage of soluble hIAPP 
with 5% spiking of ((D)3hIAPP) or ((isoD)3hIAPP) was 4% and 9% less than the 
soluble hIAPP found in the control incubated solutions respectively.  The 
normalised percentage of soluble hIAPP consistently decreased with increased 
amounts of ((D)3hIAPP) or ((isoD)3hIAPP) in the incubated solutions.  For the 
solutions with 50% spiking of ((D)3hIAPP) or ((isoD)3hIAPP), the normalised 
percentage of soluble hIAPP was 28% and 46% less than the soluble hIAPP found 
in the control solutions respectively.   
The measured percentage change of fluorescence reactivity in 5% mutant 
hIAPP seeded solutions further indicated that the amount of amyloid fibrils formed 
in the seeded solutions was consistently higher than the wild-type hIAPP incubated 
solution and the overall percentage of amyloid fibrils formed in ((D)3hIAPP) and 
((isoD)3hIAPP) seeded solutions was 27% and 48% higher than the wild-type 
hIAPP incubated solution respectively (Figure 2.6D).  Both measurements 
showed that the deamidated hIAPP enhanced the amyloid fibril formation, and the 
((isoD)3hIAPP) had a ~2 fold larger effect on enhancing hIAPP fibril formation 
than ((D)3hIAPP).   
In order to examine the effects of mutant ((D)3hIAPP) and ((isoD)3hIAPP) in 
incubated solutions and fibrillary pellets, MS spectra of mixed wild-type hIAPP 
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with various spiking percentage of mutant ((D)3hIAPP) and ((isoD)3hIAPP) were 
acquired (see Supplementary Information, Figure S2.19).  The peak intensity of 
mutant ((D)3hIAPP) and ((isoD)3hIAPP) were consistently higher in the fibrillary 
pellets compared to the incubated and the fresh solutions. 
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2.5 Discussion  
Understanding the aggregation mechanism of hIAPP will help the 
development of appropriate drugs to inhibit the formation of amyloid fibrils.68, 69  
However, the difficulties in handling aggregated hIAPP and the conflicting reports 
of proposed binding sites hinder drug development.  In addition, various reports 
showed that the rate of hIAPP fibril formation was accelerated by seeding the 
solution with deamidated polypeptides,54, 55 but the role of deamidation under 
general hIAPP aggregation is poorly understood.  Thus, high resolution mass 
spectrometry (FTICR MS) and tandem mass spectrometry were applied to 
determine the position of the non-covalent bonding interaction between hIAPPs, 
as well as the role of deamidation in aqueous solution.  TEM and ThT 
fluorescence spectrometry were also utilised for monitoring the insoluble fibrils 
formed during the experiment.   
FTICR MS and MS/MS investigation of hIAPP interaction regions.  A 
series of oligomers (from monomer to pentamer) was found in the mass spectrum 
of the wild-type hIAPP solution (see Figure 2.2A).  The detection of consecutive 
hIAPP oligomers in the mass spectrum (dimer, trimer, tetramer, and pentamer) 
suggests that hIAPP associates in a sequential process, with individual monomers 
attaching to growing oligomers.  The relative signal intensity of each oligomer 
generally decreased with increasing number of monomer units, suggesting 
observed species are early oligomers from sequential aggregation.  Larger hIAPP 
oligomers above pentamer were not observed, which is attributed to oligomer’s 
decreasing solubility and thus viability for ESI-MS.  
The dissociation of dimers and trimer into monomer hIAPP units in CAD 
MS/MS indicates the interactions between hIAPP units are fragile and non-
covalent (see Supplementary Information, Figure S2.5 & S2.6).  Comparatively, 
Chapter 2 – Aggregation and Deamidation Mechanisms of hIAPP 
110 
 
the ECD MS/MS spectra of hIAPP dimer and trimer ions provide details of the 
non-covalent interaction between individual hIAPP units.  Even though limited 
dimer fragments were obtained from the ECD MS/MS (see Supplementary 
Information, Figure S2.7) and the IR-ECD MS/MS (See Supplementary 
Information, Figure S2.8) spectra of the 5+ dimer ion, the 7+ hIAPP dimer ion 
showed extensive fragmentation under ECD MS/MS (see Figure 2.2B & 2.2C).  
With a higher charge state precursor ion, the number of identified dimer z-ions 
increased by 27, and four more dimer c-ions were observed (for a total of 30 dimer 
z ions and seven dimer c ions).  The M+c29 ion (representing mass equal to one 
hIAPP (M) plus a c29 ion from a second hIAPP unit) was the first c-ion dimer 
fragment observed from the 7+ hIAPP dimer, which indicates the hIAPP dimer 
begins to interact at Ser-29 (towards the N-terminus). Subsequent c-ion dimer 
fragments, from M+c29 to M+c36 were also observed, indicating an interaction 
region between Ser-29 and Thr-36.  On the other hand the M+z3 (representing 
mass equal to one hIAPP (M) plus a z3 ion from a second hIAPP unit) was the first 
z-ion dimer fragments observed from the 7+ hIAPP dimer ECD spectrum, which 
suggests the hIAPP dimer interaction begins at Asn-35 (towards the C-terminus), 
and as a result, subsequent z-ion dimer fragments, from M+z5 to M+z36, were also 
detected, indicating an interaction region between Cys-2 and Asn-35.  The 
overlapping regions from dimer c- and z-ions indicates that there are several 
interaction points in between Ser-29 to Asn-35.  The proposed interaction region 
also agrees with the observation from the ECD MS/MS spectra of 5+ and 7+ 
charge states of hIAPP dimer that the hIAPP units are symmetrically interacting 
near the C-terminus.   
In order to extend the knowledge of the hIAPP aggregation mechanism, the 
hIAPP trimer 8+ ion was also interrogated using ECD MS/MS. The only 
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monomeric fragments observed in the ECD spectrum of 8+ hIAPP trimer are c-
ions, which demonstrates the consistency of interaction towards the C-terminus 
region of 5+ hIAPP dimer, 7+ hIAPP dimer, and 8+ hIAPP trimer species (see 
Figure 2.2D).  The observation of 2M+z5 and 2M+c34 ions indicates the 
association region of the third hIAPP unit is located around Gly-33 and Ser-34. 
The non-covalent interactions observed from the ECD spectra of the 7+ hIAPP 
dimer and the 8+ hIAPP trimer are highly correlated showing that the aggregation 
mechanism of trimer is very similar to that of hIAPP dimerization.   
The proposed interaction region of hIAPP oligomers was further investigated 
through studying the aggregation of a synthesised eight-residue segment of hIAPP 
(30TNVGSNTY37-NH2).  The sequential dissociation trend of 
30TNVGSNTY37-
NH2 oligomers under CAD MS/MS (see Supplementary Information, Figure 
S2.13A) showed that a similar association pattern/region is adopted between 
30TNVGSNTY37-NH2 and hIAPP oligomers.  This hypothesis is strongly 
supported by the ECD fragments obtained from the trimer of 30TNVGSNTY37-
NH2 as the same aggregation region (the Gly-33 and Ser-34 residues) was observed 
(see Supplementary Information, Figure S2.13B).   
Rate of hIAPP aggregation.  Soluble hIAPP units were shown to rapidly 
form mature fibrils within just one week of incubation which led to a dramatic 
reduction in the percentage of soluble polypeptide observed (see Figure 2.3A).  
Fluorescence experiments using ThT (see Figure 2.3B) indicated that the lag 
phases of mature hIAPP fibril formation were similar in the 5 µM and 10 µM 
hIAPP solutions; however, the amount of amyloid fibril formed was greater than 
two fold higher in the 10 µM hIAPP solution compared to the 5 µM hIAPP solution.  
The amyloid fibril formation was further revealed by the TEM images recorded at 
different time points (see Figure 2.3C-2.3F).  The synthesised peptide 
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(30TNVGSNTY37-NH2) also formed observable fibrils within one week which 
could indicate its ability to be amyloidogenic (see Figure 2.3G & 2.3H).  
Deamidation site(s) and rate of hIAPP.  The exact deamidation sites 
within monomer hIAPP were investigated using CAD MS/MS.  The first 
deamidation site can be localised at Asn-21 and the second at Asn-22 via the 
observed deamidated peaks for the b21 and b22 fragment ions (see Figure 2.4).  A 
y5 fragment also showed deamidation in the 4-week sample indicating there was a 
third deamidation site at the Asn-35 residue within 4-weeks of incubation at 37oC.  
The deamidation rate of each site was then calculated using the peak area ratio 
between non-deamidated and deamidated peaks, and a similar deamidation rate 
was found for the Asn-21, Asn-22, and Asn-35 sites in the soluble hIAPP (Figure 
2.5).  The extent of deamidation at the Asn-21, Asn-22, and Asn-35 residues in 
fibril pellets was observed to be consistently higher at all time-points.  The 
residue Asn-35 was the earliest deamidation site observed in the incubated 
solutions and contained the highest extent of deamidation in the fibril pellets, 
which agrees with the findings in previous deamidation studies,42, 70 suggesting 
that the primary sequence of Ser-35Asn-Thr in hIAPP had the shortest deamidation 
time among all the other segments studied.  
Aggregation of mutant ((D)3hIAPP) and ((isoD)3hIAPP).  The fluorescence 
activity of ((D)3hIAPP) and ((isoD)3hIAPP) solutions showed mutant hIAPPs 
samples had a shorter lag phase in forming mature fibrils compared to the wild 
type hIAPP (see Supplementary Information, Figure S2.18), which supports the 
hypothesis that deamidated hIAPPs accelerate the aggregation rate of non-
deamidated hIAPP.  The lag phase of amyloid fibril formation did not show a 
distinct increase upon seeding 5% mutant hIAPPs into solutions; the MS 
quantification results and the fluorescence data showed the rate and the amount of 
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amyloid fibril formation were enhanced upon seeding the solution with various 
percentages of mutant hIAPP (see Figure 2.6B & 2.6C).  Additionally, a greater 
amount of mutant hIAPPs was observed in the fibrillary pellet compared to the 
control solutions; which also suggests the important role of ((D)3hIAPP) or 
((isoD)3hIAPP) in enhancing fibril formation (see Supplementary Information, 
Figure S2.19).  The fluorescence measurement and MS quantification showed the 
effect of seeding ((isoD)3hIAPP) is twice that of seeding the same amount of 
((D)3hIAPP) into non-deamidated hIAPP solutions.  The difference between the 
TEM images of incubated ((D)3hIAPP) and ((isoD)3hIAPP) solutions also agrees 
the greater effect of ((isoD)3hIAPP) compared to ((D)3hIAPP) (see Figure 2.6A & 
2.6B).  The observed morphology of fibrils was different in ((isoD)3hIAPP) 
compared to ((D)3hIAPP), indicating differences in the aggregation behavior and 
rate of non-deamidated hIAPP, as observed in the MS and fluorescence.   
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2.6 Conclusion 
The experimental results here demonstrate that the most important aggregation 
regions between individual hIAPP units within oligomers in the gas phase occurs 
toward the C-terminus of the peptides, around residues Gly-33 and Ser-34.  The 
aggregation mechanisms of the dimer and trimer of hIAPP were shown by ECD 
MS/MS to be very similar, with both structures interacting primarily towards the 
C-terminus of the peptides.  Furthermore, the aggregation of individual hIAPP 
units into oligomers was shown to occur much faster than deamidation.  Mature 
fibrils were formed within two days of incubation and deamidated hIAPP was not 
observed until the fifth day, suggesting that, in general, aggregation and 
deamidation are independent processes.  Asn-21, Asn-22, and Asn-35 residues 
are largely deamidated, and no deamidation was observed at the other Asn/Gln 
residues.  The extent of deamidation was higher in the fibrillary pellets than in 
the solutions, which indicates the deamidated hIAPP tends to form fibrils faster 
than the wild-type hIAPP.  This hypothesis is further supported by accelerated 
aggregation rate observed for ((D)3hIAPP) and ((isoD)3hIAPP) and a higher 
percentage of mutant hIAPPs identified in the fibrils of hIAPP solutions spiked 
with mutants ((D)3hIAPP) or ((isoD)3hIAPP) in wild-type hIAPP solutions.  The 
TEM images further showed the different morphology of (isoD)3hIAPP fibrils 
compared to wild-type hIAPP and ((D)3hIAPP) fibrils, which explains the 
acceleration of aggregation caused by the deamidated hIAPP.  Moreover, the 
amount of amyloid fibril formed is directly proportional to the spiking percentage 
of mutant hIAPPs; and the effect of seeding ((isoD)3hIAPP) is twice that of seeding 
the same amount of ((D)3hIAPP) into non-deamidated hIAPP solutions.   
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2.8 Supplementary Information 
 
Figure S2.1.  (A) Summarised b- and y-ion fragments observed in the (B) 18 V 
CAD MS/MS spectrum of the 4+ charge state hIAPP monomer.  The hIAPP 
sequence coverage from the CAD MS/MS was 65% and showed effective 
fragmentation and production of b and y ions from Asn-14 to Try-37; while no 
fragments were obtained from Lys-1 to Ala-13.  Water and ammonia (NH3) loss 
are not labelled in the spectrum, but were common.  The inserts show examples 
of isotopic distribution peaks, i.e. the b25
2+ and y13
1+ ions, which must be resolved 
with high resolution mass spectrometry in order to accurately assign fragment ions.  
The mass difference between the second isotopic peak of y7 ion
 and the third 
isotopic peak of b21 ion was 0.0099 Da, and the resolving power at m/z 753 was 
240,000.  The assigned fragments are listed in the Supplementary Information 
Table S2.1. 
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Table S2.1.  List of the assigned CAD MS/MS fragments of the 4+ charge state 
hIAPP monomer.  
Chapter 2 – Aggregation and Deamidation Mechanisms of hIAPP 
123 
 
 
Figure S2.2.  (A) Summarised a-, c-, y- and z-ion fragments observed in the (B) 
IR-ECD MS/MS spectrum of the 4+ charge state hIAPP monomer.  The hIAPP 
sequence coverage from the IR-ECD MS/MS was 100%.  Amino acid side chain 
losses are not labelled in the spectrum, but were common.  The assigned 
fragments are listed in the Supplementary Information Table S2.2. 
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(Table S2.2. Continue) 
 
Table S2.2.  List of the assigned IR-ECD MS/MS fragments of the 4+ charge 
state hIAPP monomer.  
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Figure S2.3.  Sequences of synthetic mutant hIAPPs.  Asn residues at position 
21, 22, and 35 are replaced with aspartic acid – deamidated ((D)3hIAPP) or 
isoaspartic acid – deamidated ((isoD)3hIAPP) in order to act as deamidation 
mimics.  
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Figure S2.4.  nESI-MS spectrum of the early oligomers from 10 μM hIAPP 
aqueous solution only.  hIAPP monomer (circle), dimer (square), trimer (star), 
tetramer (triangle), and pentamer (pentagon), were detected in the spectrum.  The 
peak intensity decreased gradually with increasing oligomer size.  Inset, enlarge 
regions of spectra are shown for the labelled species.  Coloured shapes represent 
theoretical calculated species overlaid onto observed pattern.  
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Figure S2.5.  (A) The relative peak area of the monomer and the dimer ions 
during the dissociation of the 7+ charge state of hIAPP dimer in aqueous solution 
with 2% residual DMSO (red) and aqueous solution only (green) in the CAD 
MS/MS.  (B) The relative peak area of the monomer and the dimer ions during 
the dissociation of the 5+ charge state of hIAPP dimer in aqueous solution with 
2% residual DMSO (red) and aqueous solution only (green) in the CAD MS/MS.  
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The 7+ charge state of hIAPP dimer was dissociated into 3+/4+ monomer peaks, 
and the 5+ charge state of hIAPP dimer was dissociated into 2+/3+ monomer peaks, 
indicating near-symmetrical charge distribution between monomer units.  The 
dissociation energy required to dissociate 50% of a given complex was used as a 
metric for comparison.  The midpoint dissociation energies for the 5+ and the 7+ 
charge state dimers were 10.5 V and 3.4 V respectively.  Excess CAD energy 
during dimer dissociation resulted in the monomer fragmentation which yielded b 
and y ions, and reduced the monomer relative peak area.  Similar dissociation 
energies were observed from the 5+ and the 7+ charge state dimers in aqueous 
solution only.   
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Figure S2.6.  The relative peak areas of monomer (red), dimer (blue), and trimer 
(green) during the dissociation of the 8+ charge state of hIAPP trimer in aqueous 
solution with 2% residual DMSO in the CAD MS/MS.  The midpoint 
dissociation energies of the 8+ charge state trimer is at 8.4 V.  In the 8+ charge 
state trimer hIAPP, the dissociation of trimer hIAPP results in the increase of 5+ 
charge state hIAPP dimer (blue circle) from 0 V to 9 V; when the dissociation 
energy exceeds 10 V, the amount of dimer hIAPP decreases and results in a 
significant increase in the monomer hIAPP.  The results demonstrate the 
oligomers of hIAPP are dissociating sequentially.  
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Figure S2.7.  (A) Summarised c- and z-ion fragments observed in the (B) ECD 
MS/MS spectrum of the 5+ charge state hIAPP dimer (in aqueous solution with 
2% residual DMSO).  Only one monomer c-ion fragment (c10), three dimer z-
ion fragments (representing the mass of a hIAPP plus a z ion fragment), and three 
dimer c-ion fragments (representing the mass of a hIAPP plus a c ion fragment) 
were detected from the ECD MS/MS spectrum of the 5+ hIAPP dimer ion which 
did not provide sufficient information for interrogating the interaction sites 
between hIAPP units.  Highlighted sequence represents the proposed non-
covalent interaction region.  The amino acid side chain losses are not labelled in 
the spectrum but were common.  The isotopic distribution of the 10+ charge state 
hIAPP tetramer was present and overlapped with the 5+ charge state hIAPP dimer 
during isolation, and higher order oligomers, i.e. tetramer, are observed in the 
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dimer ECD spectrum.  The assigned fragments are listed in the Supplementary 
Information Table S2.3.  
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Table S2.3.  List of the assigned ECD MS/MS fragments of the 5+ hIAPP dimer 
ion (in aqueous solution with 2% residual DMSO). M represents one hIAPP unit.   
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Figure S2.8.  Key IR-ECD fragments of (A) [M+z22]
3+ (red), (B) [M+z23]
3+ 
(blue), and (C) [M+z24]
3+ (green) from the 5+ charge state hIAPP dimer with 
various IR pulse lengths.  When no IR laser was applied, no dimer fragments 
from M+z22 to M+z24 were observed.  When IR pulse length was set to 0.03 s, an 
extra dimer fragment, M+z23, was shown (B).  Dimer fragments from M+z22 to 
M+z24 were identified from the spectrum while IR pulse length was increased to 
0.05 s ((A) and (C) respectively).  The result from IR-ECD fragments of the 5+ 
hIAPP dimer demonstrates the binding region between the dimer hIAPP is 
relatively stronger near the C-terminus of the protein as the binding interaction 
region was first broken towards the center of hIAPP units (Asn-14 to Leu-16), so 
the binding region of individual hIAPPs units is proposed between Leu-16 and 
Ser-34, which contains 19 out of 37 residues
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Figure S2.9.  (A) Summary of  c-, y-, and z-ion fragments observed in the (B) ECD MS/MS spectrum of the 7+ charge state hIAPP dimer (in 
aqueous solution with 2% residual DMSO).  Highlighted sequence represents the proposed non-covalent interaction region.  The side chain 
losses are not labelled for clarity.  An increased number of fragments are observed in the ECD MS/MS spectrum of the 7+ charge state dimer 
than the 5+ charge state dimer spectrum.  Ultrahigh resolution FTICR-MS provides the performance required to resolve the overlapping fragments 
observed, i.e. M+c35 and M+z6 at m/z 1509.3, which are only differentiated by ~ 0.05 Da.  The assigned fragments are listed in the Supplementary 
Information Table S2.4. 
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(Table S2.4. Continue) 
 
Table S2.4.  List of the assigned fragments from the ECD MS/MS spectrum of 
the 7+ charge state hIAPP dimer.  M represents one hIAPP unit.
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Figure S2.10.  (A) Summary of c-, y-, and z-ion fragments observed in the (B) ECD MS/MS spectrum of the 8+ charge state hIAPP trimer (in 
aqueous solution with 2% residual DMSO).  Highlighted sequence represents the proposed non-covalent interaction region.  The side chain 
losses are not labelled for clarity.  The assigned fragments are listed in the Supplementary Information Table S2.5. 
Chapter 2 – Aggregation and Deamidation Mechanisms of hIAPP 
143 
 
 
 
 
 
 
Chapter 2 – Aggregation and Deamidation Mechanisms of hIAPP 
144 
 
(Table S2.5. Continue) 
 
Table S2.5.  List of the assigned fragments from the ECD MS/MS spectrum of 
the 8+ charge state hIAPP trimer ion (in aqueous solution with 2% residual DMSO).  
M represents one hIAPP unit.  
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Figure S2.11.  Summarised fragments observed in the ECD MS/MS spectrum of 
the (A) 5+ charge state dimer, (B) 7+ charge state dimer, and (C) 8+ charge state 
trimer of hIAPP, in aqueous solution.  Examples of the smallest assigned dimer 
c-and z-ions from the ECD MS/MS of the 5+ and the 7+ charge state dimers are 
inserted, respectively.  Examples of the most critical trimer c- and z-ion from the 
ECD MS/MS of the 8+ charge state trimer are also inserted.  Highlighted 
sequence represents the proposed non-covalent interaction region.  Coloured 
shapes represent theoretical calculated species overlaid onto observed pattern.  
The assigned fragments are listed in the Supplementary Information Tables S2.6, 
S2.7, and S2.8. 
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Table S2.6.  List of the assigned ECD MS/MS fragments of the 5+ charge state 
hIAPP dimer (in aqueous solution only).  M represents one hIAPP unit.  
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Table S2.7.  List of the assigned ECD MS/MS fragments of the 7+ charge state 
hIAPP dimer (in aqueous solution only).  M represents one hIAPP unit. 
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Table S2.8.  List of the assigned fragments from the ECD MS/MS spectrum of 
the 8+ charge state hIAPP trimer ion (in aqueous solution only).  M represents 
one hIAPP unit. 
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Figure S2.12.  (A) MS spectrum of the early oligomers of an eight-residue 
segment of hIAPP (30TNVGSNTY37-NH2) in aqueous solution.  Oligomers; 
monomer (circle), dimer (square), trimer (star), tetramer (triangle), pentamer 
(pentagon), and hexamer (diamond), were detected in the MS spectrum.  (B) MS 
spectrum of the mixture of the eight-residue segment of hIAPP (30TNVGSNTY37-
NH2) and hIAPP in 1:1 ratio.  Apart from the expected early oligomers of hIAPP 
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and 30TNVGSNTY37-NH2, mixtures of hIAPP and 
30TNVGSNTY37-NH2 were 
also detected in 1:1, 1:2, 1:3, 2:1, and 2:2 ratio respectively.  Inset, enlarge 
regions of spectra are shown for the labelled species.  Coloured shapes represent 
theoretical calculated species overlaid onto observed pattern.  
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Figure S2.13.  (A) The relative peak areas of monomer (black), dimer (red), 
trimer (blue), and tetramer (green) during the dissociation of the 3+ charge state 
tetramer of the eight-residue segment of hIAPP in the CAD MS/MS.  The 3+ 
charge state tetramer is completely dissociated with CAD energy at 3 V.  The 
relative peak area of the 2+ charge state trimer increases when CAD energy is 
increased from 0 V to 2 V and sharply reduces when the CAD energy exceeds 2 V.  
The relative peak area of the 1+ charge state dimer increases from 0 V to 10 V and 
begins to decrease afterwards.  The relative peak area of the 1+ charge state 
monomer continuously increases with an increase of CAD energy.  (B) Summary 
of the ECD MS/MS fragments of the 3+ charge state hIAPP segment in aqueous 
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solution.  Examples of the most critical assigned trimer c- and z-ion are inserted. 
Highlighted sequence represents the proposed non-covalent interaction region.  
Coloured shapes represent theoretical calculated species overlaid onto observed 
pattern.  The assigned fragments are listed in the Supplementary Information 
Table S2.9. 
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Table S2.9.  List of the assigned fragments from the ECD MS/MS spectrum of 
the 3+ charge state trimer of the hIAPP segment.  M represents one hIAPP unit. 
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Figure S2.14.  The CAD curve of the 4+ charge state hIAPP and 
30TNVGSNTY37-NH2 in 1:1 at m/z 1190.  Only 13% of the mixture was 
successfully isolated and detected by the MS when no CAD energy was applied, 
which indicated the interaction between the biomolecules was very weak.  The 
mixture was completely dissociated when 3 V of additional CAD energy was 
applied.   
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Figure S2.15.  (A) Summary of c- and z-ion fragments observed in the (B) ECD 
MS/MS spectrum of the 4+ charge state mixture of [hIAPP + 30TNVGSNTY37-
NH2] species in aqueous solution.  The most critical identified mixture fragments 
were hIAPP plus z ion of SNTY-NH2, the mass of 
30TNVGSNTY37-NH2 plus c32 
of hIAPP, and the mass of 30TNVGSNTY37-NH2 plus z27 of hIAPP.  The side 
chain losses are not labelled for clarity.  The assigned fragments are listed in the 
Supplementary Information Table S2.10. 
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Table S2.10.  List of the assigned fragments from the ECD MS/MS spectrum of 
the 4+ charge state of [hIAPP + 30TNVGSNTY37-NH2] species.   
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Figure S2.16.  (A) Summary of  a-, c-, y-, and z-ion fragments observed in the 
(B) ECD MS/MS spectrum of the 7+ charge state ((D)3hIAPP) dimer (in aqueous 
solution with 2% residual DMSO).  Highlighted sequence represents the 
proposed non-covalent interaction region.  The side chain losses are not labelled 
for clarity.  The assigned fragments are listed in the Supplementary Information 
Table S2.11.  
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Table S2.11.  List of the assigned fragments from the ECD MS/MS spectrum of 
the 7+ charge state ((D)3hIAPP) dimer ion (in aqueous solution with 2% residual 
DMSO).  M represents one ((D)3hIAPP) unit. 
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Figure S2.17.  (A) Summary of  a-, c-, y-, and z-ion fragments observed in the 
(B) ECD MS/MS spectrum of the 7+ charge state ((isoD)3hIAPP) dimer (in 
aqueous solution with 2% residual DMSO).  Highlighted sequence represents the 
proposed non-covalent interaction region.  The side chain losses are not labelled 
for clarity.  The assigned fragments are listed in the Supplementary Information 
Table S2.12. 
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Table S2.12.  List of the assigned fragments from the ECD MS/MS spectrum of 
the 7+ charge state ((isoD)3hIAPP) dimer ion (in aqueous solution with 2% 
residual DMSO).  M represents one ((isoD)3hIAPP) unit. 
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Figure S2.18.  The relative fluorescence emission intensity of the 
μM and 10 μM mutant hIAPP solutions (A) ((D)3hIAPP) and (B) ((isoD)3hIAPP).  
The relative fluorescence activity of the solutions of ((D)3hIAPP) and 
((isoD)3hIAPP) were measured and the lag phase of the formation of mature fibrils 
were 30 and 32 hours respectively.  Compared to the 10 μM solutions of the 
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synthetic mutant hIAPPs, the 5 μM solutions of ((D)3hIAPP) and ((isoD)3hIAPP) 
had a marginally shorter half-life of mature fibrils formation, which were around 
40 hours.  Even though there was no significant difference between the midpoint 
formations (lag phase) of mature fibrils for the 5 μM and 10 μM solutions, the 
relative fluorescence intensity of the 10 μM solutions of ((D)3hIAPP) and 
((isoD)3hIAPP) were 3.8 and 4.7 times higher than their 5 μM solutions, 
respectively. 
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Figure. S2.19.  The nESI-MS spectra showing the fresh, the incubated solutions, 
and the incubated fibrillary pellets of hIAPP mixed with 5%, 10%, 25%, or 50% 
of mutant ((D)3hIAPP) or ((isoD)3hIAPP). 
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Chapter 3 The Inhibition Pathways of Human Islet Amyloid Polypeptide 
 
 This chapter demonstrates the applications of Fourier transform ion cyclotron 
resonance (FTICR MS) together with fluorescence spectroscopy and transmission 
electron microscopy (TEM) to study the inhibition pathways of various potential 
drugs towards aggregation of an amyloidogenic protein – human islet amyloid 
polypeptides (hIAPP).  
 The results presented in this chapter were predominantly carried out by the 
thesis Author, aside from acquisition of transmission electron microscopy (TEM) 
data were assisted by Mr. Ian-Hands Portman from the Department of Life Science, 
University of Warwick.  
 A manuscript entitled “The Inhibition Pathways of Human Islet Amyloid 
Polypeptide” by Yuko P. Y. Lam, Cookson K.C. Chiu, Christopher A. Wootton, Ji-
Inn Song, Meng Li, Ian Hands-Portman, Mark P. Barrow, and Peter B. O’Connor, 
has been prepared for submission to Nature Chemistry based on the results 
presented in this chapter.  
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3.1 Abstract 
 Human islet amyloid polypeptide (hIAPP) is a highly amyloidogenic protein 
that aggregates rapidly in humans.  Classic structure-based design for 
therapeutics drug development against amyloid proteins is challenging as most 
amyloid proteins are inherently disordered with high conformation flexibility.  
Many compounds are proposed as potential inhibitors of toxic oligomer formation, 
but target regions for inhibiting aggregation and reports on inhibitor performance 
are mixed and often conflict.  Herein, mass spectrometry was used to identify 
binding regions of a range of reported hIAPP aggregation inhibitors and were 
correlated with fluorescence and transmission electron microscopy measurements 
to understand target regions for aggregation inhibition mechanisms of action for 
different classes of inhibitors.  From our results, two mechanisms are shown to 
effectively inhibit the aggregation of wild-type hIAPP either by site-specific 
interaction with the amyloidogenic region on hIAPP (Ser-29 to Asn-35) or 
accelerate the formation of non-toxic amorphous aggregates.  Our data further 
show that the aggregation of deamidated hIAPP could no longer be effectively 
prevented by the site-specific inhibition compounds, instead an amorphous 
aggregate was rapidly formed.  The data herein contribute to understanding the 
inhibition mechanisms on wild-type and deamidated hIAPP using potential 
inhibitors and forms an important basis for future therapeutics development.  
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3.2 Introduction 
Abnormal aggregation of proteins and peptides into mature amyloid fibrils is 
a hallmark in approximately 50 human disorders, including Parkinson’s disease 
(PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and type II diabetes 
(T2D).1-4  Inhibiting amyloid fibrils formation is a critical goal in searching for 
potential therapeutic compounds.  Most amyloid proteins, however, are 
inherently disordered with high conformation flexibility,3, 4 making inhibition sites 
difficult to identify through classic therapeutic development using structure-based 
design.5, 6  Thus, a better understanding of the inhibition mechanisms of current 
amyloid protein aggregation inhibitors would help minimise the time and cost 
spent in searching for therapeutics against amyloid protein aggregation, as well as 
accelerating the development of higher efficiency, less toxic therapeutic 
compounds. 
 Human islet amyloid polypeptide (hIAPP, also named amylin) is a 37 amino 
acid hormone with an intramolecular disulfide bond between Cys-2 and Cys-7.7-11  
hIAPP is stored in the pancreatic β-cell secretory granules and co-secreted with 
insulin to regulate blood glucose levels.12, 13  In general, monomeric hIAPP is 
soluble and inherently disordered, and hIAPP amyloid fibrils are only found in 
T2D patients.7, 8  The formation of hIAPP fibrils does not contribute to T2D, but 
the early oligomers of hIAPP do lead to the decline of pancreatic β-cell mass and 
the failure of islet cell transplantation for T2D treatment.14, 15  Thus, reducing the 
formation of the early oligomers of hIAPP can enhance the graft survival rate.16, 17   
 The early oligomers of hIAPP are more toxic and harmful to the pancreatic 
β-cell than the mature hIAPP fibrils;18 thus potential therapeutic compounds 
should not only inhibit mature fibril formation, but should also interact with the 
early oligomers of hIAPP to prevent the formation of protofibrils.  (-)-
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Epigallocatechin 3-gallate (EGCG), an extract from green tea, is one of the famous 
inhibitors which interacts with the monomeric state of hIAPP and reduces mature 
amyloid fibril formation.19-22  The inhibition mechanism of EGCG on hIAPP 
aggregation is still under debate.  Hudson et al. showed EGCG interacted with 
the monomeric state of amyloid protein and maintained the protein in its pre-
fibrillary state inhibiting further aggregation.23  However, Dagmar et al. showed 
EGCG re-directed amyloid protein into off-pathway oligomers which did not 
induce cell toxicity.24  Not only is the inhibition mechanism not clear, the 
interaction mode between EGCG and hIAPP is also complex because aromatic 
interaction and non-specific hydrophobic interactions with protein sidechains have 
been proposed simultaneously.20, 25, 26 
 Insulin is a hormone peptide with 51 amino acid residues over two chains (A 
chain contains 21 residues and B chain contains 30 residues) and linked by one 
intra-stand and two inter-strand disulfide bonds.27  The concentration of insulin 
is around a hundred times higher than the level of hIAPP in the β-cell secretory 
granules.28  Similar to hIAPP, insulin also aggregates and forms amyloid fibrils, 
but insulin mostly aggregates rapidly at low pH (~pH 2-3) while hIAPP aggregates 
much faster at neutral pH (~pH 7).29-31  Insulin has been shown to be a potential 
inhibitor of hIAPP fibril formation as monomeric insulin can interact with hIAPP 
to form a heterodimer, preventing hIAPP aggregation.32-35  Studies using nuclear 
magnetic resonance spectroscopy (NMR) and ion mobility mass spectrometry 
(IM-MS) with computational prediction suggested the alpha helix region of hIAPP 
(residue 8 – 23) and insulin B chain (residue 9 – 24) interact to form the 
heterodimer complex.32, 34   
 Deamidation is a non-enzymatic post-translational modification which leads 
to protein ageing and has been called a “molecular clock”.36, 37  Deamidation at 
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asparagine (Asn) and glutamine (Gln) residues contributes to the formation of iso-
aspartic acid or aspartic acid, and γ-glutamic acid or glutamic acid respectively, as 
well as stereoisomers.38, 39  Presence of an extra methylene group (-CH2-) in the 
backbone of iso-aspartic acid and γ-glutamic acid contributes to a significant 
alteration in protein structure, stability, folding, and function.40, 41  Deamidation 
in other amyloid proteins, including amyloid-β, β2-microglobulin, and αβ-
crystallin, has been shown to accelerate the amyloid fibril formation.42-47  hIAPP 
contains six Asn and one Gln potential deamidation sites which converted within 
one week of incubation at 37oC.48  A previous study using a non-amyloidogenic 
variant of hIAPP segment, residues 20-29 (SNNFPAILSS) showed that the 
presence of less than 5% of deamidated monomer segment was required to initiate 
the formation of amyloid fibrils.49  Results from Dunkelberger et al. further 
suggested the β-sheet structure of deamidated hIAPP around Leu-27 had been 
disrupted and accelerated the formation of hIAPP fibrils.50  Recent studies have 
further narrowed the deamidation sites of hIAPP to Asn-21, Asn-22, and Asn-35 
residues, and showed mutant hIAPP (with iso-aspartic acid residues replacement 
at the deamidation sites) aggregated into amyloid fibrils faster than the wild-type 
hIAPP.48  Even though deamidated hIAPP has been reported to significantly 
affect the morphology of hIAPP and the aggregation rate, the interactions between 
the deamidated hIAPP and the inhibitors commonly used for preventing the 
aggregation of wild-type hIAPP have not been studied. 
 Fluorescence dye-binding, i.e. thioflavin T (ThT), is one of the most common 
techniques to monitor the kinetics of amyloid fibrils formation,51 as well as the 
effectiveness of potential inhibitors against aggregation by measuring the change 
of onset of fibril formation,52, 53 but the additional dyes and buffers can cause 
misleading results, as well as increase the aggregation rate of amyloid proteins.54, 
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55  Thus, new techniques with high resolution and sensitivity are required to 
monitor the interaction between the early oligomers of hIAPP and potential 
inhibitors. 
 IM-MS has recently been applied to monitor the formation of hIAPP 
oligomers, and the interactions between the early oligomers of hIAPP and various 
potential inhibitors.21, 22, 34, 56-60  These studies demonstrated that mass 
spectrometry (MS) provides high sensitivity and resolution to further study the 
interaction between early oligomers and potential inhibitors.  A high throughput 
screening method has also been proposed to search for the potential inhibitor 
against amyloid proteins aggregation using IM-MS.22  However, understanding 
the underlying inhibition mechanisms between the early oligomers of amyloid 
proteins and the potential inhibitors used can inform further drug development 
directly to inhibit the formation of toxic aggregates.  Electron capture 
dissociation tandem MS (ECD MS/MS) provides the ability to fragment a protein 
backbone while preserving the non-covalent interaction between proteins and 
protein-molecule complexes, 61-63 and thus can be used to determine the interaction 
region between hIAPP and the potential inhibitors.48 
 Herein, Fourier transform ion cyclotron resonance mass spectrometry 
(FTICR MS) is applied in monitoring the interactions between hIAPP and potential 
anti-aggregation drugs.  Both previously reported hIAPP inhibitors (insulin and 
EGCG) and species able to bind to hIAPP, but believed to not inhibit amyloid fibril 
formation are investigated.  MS quantification of soluble amyloid proteins, ThT 
fluorescence emission measurement of the onset of mature fibrils formation, and 
the observation of the overall hIAPP fibrillary structure using transmission 
electron microscopy (TEM) help to evaluate the short- and longer-term inhibition 
performance of the binding molecules.  ECD MS/MS is also applied in order to 
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determine the interaction sites between hIAPP and the potential inhibitors, which 
contributes to the understanding of possible inhibition mechanisms for hIAPP.  
The results herein demonstrate more than one inhibition mechanism can be used 
to prevent the formation of hIAPP fibrils, while also showing that molecules 
capable of binding to hIAPP are not necessarily capable of inhibiting amyloid fibril 
formation.  Analysis of binding locations, correlated with inhibition of fibril 
formation also reveal specific target locations within the protein sequence to 
reduce oligomerization, and provide a basis for higher throughput screening in the 
future. 
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3.3 Experimental Section 
Sample preparation for MS.  Wild-type hIAPP with purity >95% (AS-
60254-1; Eurogentec Ltd., England), the synthetic mutant hIAPP with purity >95% 
and iso-aspartic acid residue replacement at Asn-21, Asn-22, and Asn-35 
((isoD)3hIAPP; Pepscan Company Ltd, The Netherlands), and the synthetic 
30TNVGSNTY37-NH2 peptide with purity >95% (Eurogentect Ltd., England) were 
dissolved in Milli-Q H2O (Direct-Q
® 3 UV System, Millipore Corporation, USA) 
with pH ~7.5 to 500 µM for storage (at -80oC) and samples were consumed within 
two weeks.  3-amino-1-propane sulfonic acid (3-APS), 1H-Benzimidazole-2-
sulfonic acid (BISA), and (-)-epigallocatechin gallate (EGCG) were purchased 
from Sigma Aldrich Company Ltd, England and dissolved in Milli-Q H2O to 500 
µM for storage (at -80oC).  Recombinant human insulin (Sigma Aldrich 
Company Ltd, England) was dissolved in acidified Milli-Q H2O (~pH 5.8) to 500 
µM for storage (at -80oC), as performed by Susa et al.34   
 For the MS spectra of hIAPP with potential inhibitors, 50 µM solutions of 
hIAPP, (isoD)3hIAPP, or 
30TNVGSNTY37-NH2 peptide were initially mixed with 
50 µM solutions of 3-APS, BISA, EGCG, or insulin in Milli-Q H2O separately.  
The mixed solutions were then vortexed for half an hour in room temperature 
before further dilution by 5-fold with Milli-Q H2O into 10 µM solutions.  The pH 
values of all solutions were measured.  The values were between pH 6.8 – pH 7.5.  
The solutions were then centrifuged at 14,000 rpm for five minutes before MS 
analysis. 
 For MS relative quantification, 10 µM solutions of wild-type hIAPP, mutant 
(isoD)3hIAPP, or synthetic 
30TNVGSNTY37-NH2 peptide were mixed with 10 µM 
solutions of 3-APS, BISA, EGCG, or insulin in Milli-Q H2O individually.  A 200 
µL aliquot was extracted from each solution and stored in -80oC while the 
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remaining 300 µL solution was incubated at 37oC for seven days.  After seven 
days, solutions stored at -80oC (regarded as fresh solutions) and solutions 
incubated at 37oC were centrifuged at 14,000 rpm for one hour to separate the 
soluble wild-type hIAPP, mutant (isoD)3hIAPP, or 
30TNVGSNTY37-NH2 peptide 
(supernatant) from the insoluble aggregates (precipitate) in the solutions.  
Supernatant solutions were further diluted 10-fold with 49.5:49.5:1 
H2O/acetonitrile/formic acid and centrifuged at 14,000 rpm for five minutes prior 
to MS analysis. 
 FTICR MS analysis.  MS spectra of the early oligomers of the amyloid 
proteins with or without potential inhibitors were acquired using nano-electrospray 
ionisation (nESI) FTICR MS with a capillary voltage of 0.8 – 1.3 kV and a source 
temperature of 80oC.  The nESI glass capillaries (World Precision Instruments, 
England) were pulled on a Sutter P-97 capillary puller instrument (One Digital 
Drive Novato, USA).  Samples were loaded onto the glass capillaries and inserted 
with nickel chromium wire (Jacobs, USA) to ground the electric potential for 
ionisation.  
For the MS quantification spectra of soluble amyloid proteins, an Apollo II 
electrospray ionisation (ESI) source MS (Bruker Daltonics ,Bremen, Gremany) 
with a capillary voltage of 4 – 5 kV was applied and the source temperature was 
set to 200oC.  The ESI flow rate was optimised to 100 – 150 µL/h.  Five MS 
spectra were acquired for each solutions as technical replicates.   
All mass spectra were acquired on a 12 tesla solariX FTICR MS (Bruker 
Daltonics, Bremen, Germany) in positive ionisation mode.  Sample ions were 
first accumulated from 0.1 – 1 seconds in the hexapole collision cell before being 
directed to an infinity ICR cell for excitation and detection.64  All mass spectra 
were acquired with four mega point (32-bit) transients and were analysed using 
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Bruker DataAnalysis 4.2 software MS (Bruker Daltonics, Bremen, Germany).  
FTICR MS/MS analysis.  For the collisionally activated dissociation 
tandem MS (CAD MS/MS) experiments, precursor ions were isolated using a 
quadrupole mass filter, collided with argon gas and accumulated for 1 – 3 seconds 
in the hexapole collision cell.  The collision energies were varied from 0 – 16 V 
in order to generate the breakdown curves for the precursor ions which were 
composed of the amyloid protein with the bound molecule of interest.  Fragments 
were then directed to the ICR cell for detection.  Five spectra were acquired for 
each collision energy level as technical replicates. 
For ECD MS/MS experiments, precursor ions were first isolated with a wide 
mass-to-charge (m/z) isolation window (100 m/z) in the quadrupole and 
accumulated for 1-5 seconds in the collision cell.  Ions were further transferred 
to the ICR cell and isolated with MULTI-CHEF isolation with an excitation power 
of 50 – 55%.65  The precursor ions were then irradiated with 1.2 eV electrons 
from a 1.5 A heated hollow cathode and the fragments were detected by the ICR 
cell.   
 MS data analysis.  All MS data were analysed using Bruker DataAnalysis 
4.2 software MS (Bruker Daltonics, Bremen, Germany).  The most intense 
isotopic peak from each fragment with signal-to-noise ratio (S/N) over five was 
manually matched with the assigned species.  Five fragments from each spectrum 
were chosen for the internal calibration of the spectrum and all fragments were 
then assigned with an uncertainty of 0.1 – 10 part-per-million (ppm) (see 
Supplementary Information, Table S3.1- S3.15).  
 To study the binding strength between wild-type hIAPP and the potential 
inhibitors, the dissociation curves of each complex precursor ion, which composed 
of hIAPP and the binding molecule, were plotted.  The areas of all the isotopic 
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peaks from each charge state of hIAPP, the complexes, and the potential inhibitors 
(if present) were measured using the Bruker DataAnalysis 4.2 software.  The 
relative percentage of the complex was calculated as follow: 
Complex (%) =  
𝐼𝑠𝑜𝑡𝑜𝑝𝑖𝑐 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑜𝑚𝑝𝑙𝑒𝑥
𝑇𝑜𝑡𝑎𝑙 𝑖𝑠𝑜𝑡𝑜𝑝𝑖𝑐 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎𝑠 𝑜𝑓 ℎ𝐼𝐴𝑃𝑃 + 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 + 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒
 
The dissociation curves for the complexes of hIAPP with different potential 
inhibitors were obtained by plotting the relative percentage of each complex 
calculated above against the applied CAD energies.  The same calculation 
method was used to obtain the dissociation curves of the mutant (isoD)3hIAPP and 
the synthetic 30TNVGSNTY37-NH2 peptide with various potential inhibitors. 
 To study the long-term inhibition performance of each binding molecule 
against hIAPP aggregation, the MS spectra of the incubated wild-type hIAPP 
solutions (with/ without inducing the potential inhibitor) were compared to their 
corresponding fresh MS spectra which were obtained using the solutions stored at 
-80oC.  The absolute peak areas of the fresh and incubated solutions were first 
tested against a two-tailed T-test to differentiate whether the peak areas between 
the fresh and incubated solutions were significant.  The hypothesis applied in the 
two-tailed T-test assumed there was no significant difference between the fresh 
and incubated solutions; thus a p-value that was less than 0.05 (95% confidence) 
meant the two solutions were significantly different and vice versa.  The 
percentage change of soluble hIAPP was then calculated as follows after the two-
tailed T-test: 
% change =  
(𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑒𝑑 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 − 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑓𝑟𝑒𝑠ℎ 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛)
𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑓𝑟𝑒𝑠ℎ 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
 𝑥 100% 
The same calculation method was applied to obtain the percentage change of the 
mutant (isoD)3hIAPP and the synthetic 
30TNVGSNTY37-NH2 peptide experiments. 
 Transmission electron microscopy (TEM).  TEM images of the incubated 
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solutions, including the 10 µM solutions of the wild-type hIAPP, the mutant 
(isoD)3hIAPP, and the synthetic 
30TNVGSNTY37-NH2 peptide individually mixed 
with the 10 µM solutions of 3-APS, BISA, EGCG, and insulin, were acquired on 
a Jeol 2010F TEM which operated at 200 kV.  5 µL of the incubated solution was 
added onto a carbon coated grid (EM Resolutions, England) and settled for one 
minute, followed by using a filter paper to remove the excess aqueous solution.  
A 2% (w/v) uranyl acetate solution was then added onto the carbon grid and settled 
for one minute before removal by a filter paper.  Multiple TEM images were 
acquired with magnification from x10,000 to x50,000.  The contrast of the TEM 
images were auto-corrected by IrfanView 64 software (Irfan, Austria).  
 Thioflavin T (ThT) fluorescence reactivity.  Fluorescence emission 
intensities of the 50 µM solutions of the wild-type hIAPP, the mutant (isoD)3hIAPP, 
the mixtures of wild-type hIAPP with various potential inhibitors were measured 
using a GloMax®-Multi Detection System (Promega, USA) at room temperature.  
All samples were placed in a black 96 well-plate and mixed with a 100 µM ThT 
solution.  Fluorescence emission for the samples in the 96 well-plate was 
measured every 45 minutes for 73 hours (99 sampled points) with excitation at 405 
nm and emission measurement at 490 nm.66, 67  The fluorescence emission 
intensities were normalised to one using the maximum and the minimum readings.  
The lag phase of each sample was then calculated according to the previous 
studies.68, 69 
 The corrected ThT fluorescence emission intensities of the wild-type hIAPP 
and the mutant (isoD)3hIAPP solutions were obtained by using the absolute 
fluorescence emission intensity obtained from the amyloid protein solutions minus 
the absolute fluorescence emission intensity of the 100 µM ThT solution.  The 
corrected ThT fluorescence emission intensities of the mixtures of wild-type 
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hIAPP/ mutant (isoD)3hIAPP with various potential inhibitors were calculated 
using the absolute fluorescence emission intensities obtained from the mixtures 
minus the absolute fluorescence emission intensities of the corresponding potential 
inhibitor.    
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3.4 Results 
The interactions between early oligomers of the wild-type hIAPP and 
potential aggregation inhibitors.  A wide range of molecules has been shown 
to bind to wild-type hIAPP; however, only a small portion of these molecules are 
useful in inhibiting hIAPP aggregation.22, 34  When 10 µM wild-type hIAPP was 
diluted in an aqueous solution, it aggregated rapidly to form early oligomers within 
minutes; as a result, the early oligomers of hIAPP, from monomer up to pentamer, 
were observed in the MS spectrum (see Figure 3.1A).  When hIAPP was mixed 
with an equimolar insulin solution, hIAPP and insulin rapidly formed a 
heterodimer complex (one hIAPP plus one insulin protein) in the solution, together 
with the homodimers of hIAPP and insulin were observed in the MS spectrum (see 
Figure 3.1B).  The hIAPP-insulin heterodimer was the only reaction product 
observed in the MS spectrum.  The homodimer-to-monomer ratio of hIAPP was 
significantly reduced with addition of insulin.   
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Figure 3.1.  The sequences of human insulin and hIAPP.  The MS spectra of the 
10 µM solution of the wild-type hIAPP (A; red circle) only, the 10 µM aqueous 
solutions of the wild-type hIAPP mixed with the 10 µM insulin (B; purple star), 
10 µM 3-APS (C; green square), 10 µM BISA (D; cyan pentagon), and 10 µM 
EGCG (E; yellow triangle). 
 
The MS spectra of equimolar mixture of the wild-type hIAPP and 3-APS/ 
BISA/ EGCG were also acquired individually (see Figure 3.1C – 3.1E) and the 
results obtained from the spectra showed a similar trend.  The early oligomers of 
hIAPP, from monomer to trimer, together with the complexes of the early 
oligomers of hIAPP with 3-APS/ BISA/ EGCG molecule(s) were simultaneously 
observed in the spectrum.  The molecular binding ratios between hIAPP and 3-
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APS/ BISA/ EGCG ranged from 1:1 to 1:3 respectively.   
 
 The performance of potential inhibitors against hIAPP aggregation.  
Fluorescence emission intensity is commonly used to measure the change in lag 
phase and the relative amount of amyloid fibril formation which reflects the 
inhibition effects of the compounds.51, 68, 69  The calculated lag phase of the 50 
µM solution of wild-type hIAPP was around 18 hours (see Figure 3.2A).  The lag 
phase of the 50 µM solution of hIAPP mixed with equimolar of 3-APS was slightly 
reduced to 15 hours, while the lag phase of the 50 µM solution of hIAPP mixed 
with equimolar of BISA was slightly prolonged to 20 hours.  The lag phases were 
significantly extended to 24 and 29 hours respectively, when equimolar insulin and 
EGCG were induced into the hIAPP solutions individually, showing promising 
inhibition of fibril formation.  The amount of mature fibrils formed in the mixture 
solutions of hIAPP and various compounds compared to pure hIAPP were as 
follows, insulin 55%, 3-APS 95%, BISA 114%, and EGCG 33%.  A corrected 
ThT fluorescence emission intensity was also calculated by deducting the emission 
obtained from the potential inhibitor in order to minimise the emission influence 
by the added molecule (see Supplementary Information, Figure S3.1C).  After 
the correction, the amount of hIAPP fibrils that could be detected in the mixture 
solution of hIAPP and insulin was essentially zero, showing potential inhibition of 
hIAPP aggregation.
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Figure 3.2.  (A) The normalised ThT fluorescence emission intensities of the 50 µM wild-type hIAPP only (red circle), the solution mixtures of 
the 50 µM wild-type hIAPP induced with the 50 µM solutions of insulin (purple star), 3-APS (green rectangle), BISA (cyan pentagon), and EGCG 
(yellow triangle).  (B) The percentage of the remaining soluble wild-type hIAPP in the 10 µM solutions, incubated for one week, followed by the 
results of the two-tailed T-test.  TEM images of the 10 µM, one week incubated solutions of (C) the wild-type hIAPP only, the mixtures of the 
wild-type hIAPP and equal molar of (D) insulin, (E) 3-APS, (F) BISA, and (G) EGCG molecules.  Scale bar for each image shown were inset.
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The performances of the potential inhibitors were also measured by 
quantifying the amount of remaining soluble hIAPP between the fresh and one 
week incubated samples (see Figure 3.2B).  Two-tailed t-tests were performed to 
determine whether the differences measured between the fresh and incubated 
solutions were significant.  Pure hIAPP aggregated significantly over 1-week 
incubation period, resulting in 50% remaining soluble hIAPP quantifiable by MS, 
and the t-test p value was less than 0.05.  The remaining soluble hIAPP in the 
hIAPP and insulin solution after one week was ~100% and the t-test p value of the 
fresh and incubated solutions was also greater than 0.05.  The remaining soluble 
insulin quantified in the solution was 88% and the p value was less than 0.05 (see 
Supplementary Information, Figure S3.2).  For other compounds, the quantity of 
the soluble hIAPP was significantly reduced by 21% (3-APS), 33% (BISA) and 
55% (EGCG) in the incubated solutions and the t-test p values were all less than 
0.05.   
 TEM images do not inherently provide quantitation information, but allow 
large-scale fibril structure to be observed in the amyloid aggregates.  Pure hIAPP 
incubated sample produced elongated, crosslinked fibrils observed in the TEM 
images (see Figure 3.2C).  Similar results were observed in the mixtures of 
hIAPP with equimolar solutions of 3-APS or BISA (see Figure 3.2E & 3.2F).  
Fewer fibrils were observed in the TEM image of the incubated solution of hIAPP 
with insulin (see Figure 3.2D).  Numerous circular vesicle-like structures with an 
estimated average diameter of 48 nm were observed in the TEM images of hIAPP 
with EGCG (see Figure 3.2G).  Each circular vesicle seemed to contain several 
dense spots which had an estimated average diameter of 4.2 nm. 
 
The interaction sites between hIAPP and the potential inhibitors.  CAD 
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MS/MS was applied to determine the relative binding energy between the 
monomer unit of hIAPP and the potential inhibitors (see Supplementary 
Information, Figure S3.3), the dissociation curves were then obtained (see 
Supplementary Information, Figure S3.4).  The reaction product ions were 
dissociated completely to the hIAPP monomer ion using low collision energy thus 
strength of interaction can be indirectly compared, but no interaction site 
information was available using CAD MS/MS.   
ECD MS/MS was then applied to the same range of reaction product ions.  
The 7+ molecular ion, which composed of a hIAPP monomer unit with an insulin 
molecule, was fragmented by the electrons in the FTICR cell, 136 fragments were 
identified from the ECD MS/MS spectrum (see Figure 3.3A; Supplementary 
Information, Figure S3.5 and Table S3.1.).  The most critical ECD fragments 
were the z3 and c30 ions (highlighted in Figure 3.3A and 3.3B) indicating the intact 
insulin molecule binds to hIAPP between Ser-29 and Asn-35 residues (see Figure 
3.3C).
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(Figure 3.3. Continue) 
 
Figure 3.3.  (A) The ECD spectrum of the 7+ molecular ion of hIAPP plus insulin.  The highlighted fragments indicate the interaction region 
of hIAPP with insulin.  (B) Summarised ECD MS/MS fragments of the 7+ molecular ion from (A).  The proposed interaction region of the 
monomer unit of hIAPP with an attachment of (C) insulin (purple region), (D) 3-APS (green region), (E) BISA (cyan region), and (F) EGCG 
(yellow region).  Non-interacting regions are shown in red.
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ECD MS/MS was then applied to determine the interaction region between 
hIAPP monomer unit and the other potential inhibitors, i.e. 3-APS, BISA, and 
EGCG.  ECD spectra of each complex were generated (see Supplementary 
Information, Figure S3.6 – S3.8 and Table S3.2 – S3.4) and the detected fragments 
from each spectrum were used to identify the interaction region between hIAPP 
and the potential inhibitors.  For 3-APS and EGCG, the interaction regions were 
similar and located between Arg-11 to Gly-33 (3-APS) and Arg-11 to Ser-34 
(EGCG) (see Figure 3.3D and 3.3F).   
BISA was shown to interact in multiple regions, Lys-1 to Asn-3, Arg-11 to 
Asn-14, and Ser-29 to Tyr-37.  The ECD MS/MS result also indicated the 
sulfonic acid group of BISA bound to the monomer unit of hIAPP between Arg-
11 and Asn-14 residues, while the benzimidazole group of BISA was attached to 
the residues of hIAPP at Lys-1 to Asn-3 and Ser-29 to Try-37 (see Supplementary 
Information, Figure S3.7 and Table S3.3). 
ECD MS/MS of a hIAPP dimer bound to one 3-APS or one BISA molecule 
showed that both 3-APS and BISA effectively bind between Lys-1 and Asn-14 (see 
Figure 3.4B and 3.4C, respectively) which indicates a non-disruptive binding site 
of potential inhibitors. 
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Figure 3.4.  (A) ECD MS/MS spectrum of the 7+ molecular ion of hIAPP dimer bound with one 3-APS molecule.  Critical fragments are 
highlighted.  Binding regions are summarised on the protein structure for (B) 3-APS and (C) BISA. 
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The interactions between the target 30TNVGSNTY37-NH2 peptide and 
the potential inhibitors.  The aggregation region of hIAPP fibrils has previously 
been identified to be between Gly-33 and Ser-34, and the synthetic peptide 
30TNVGSNTY37-NH2 containing this region was shown to be amyloidogenic in 
previous studies.48  Thus, the potential inhibitors were mixed with the target 
peptide in equimolar amount to investigate their inhibition effects against the 
amyloidogenic 30TNVGSNTY37-NH2 peptide. 
 The early oligomers, from monomer to hexamer, of 30TNVGSNTY37-NH2 
peptide were observed in the nESI MS spectrum (see Figure 3.5A).  When the 
peptide was incubated in the presence of insulin, only the low order oligomers, 
monomer and dimer, of the synthetic peptide were observed in the MS spectrum 
(see Figure 3.5B).  The complexes, which composed of 30TNVGSNTY37-NH2 
and insulin, were also observed in the MS spectrum.  The molecular binding 
ratios between 30TNVGSNTY37-NH2 peptide and insulin ranged from 1:1 to 2:1.   
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Figure 3.5.  The MS spectra of 10 µM solution of 30TNVGSNTY37-NH2 (A; red 
semi-circle) peptide only, mixed with equimolar of insulin (B; purple star), 3-APS 
(C; green square), BISA (D; cyan pentagon), and EGCG (E; yellow triangle).   
 
 Similar spectra were observed between 3-APS and EGCG which were mixed 
equimolar with 30TNVGSNTY37-NH2 peptide as the early oligomers, from 
monomer to trimer, of 30TNVGSNTY37-NH2 peptide were observed, along with 
those oligomers bound to 3-APS or EGCG (see Figure 3.5B & 3.5D).  The 
molecular binding ratio between 30TNVGSNTY37-NH2 peptide and 3-APS or 
EGCG ranged from 1:0.25 to 1:2 (for 3-APS) 1:0.2 to 1:1.3 (for EGCG).  Less 
interaction was observed between 30TNVGSNTY37-NH2 peptide and BISA 
molecule as only one reaction product was observed, the tetramer of 
30TNVGSNTY37-NH2 peptide and a BISA molecule (see Figure 3.5C), otherwise 
the MS spectrum was very similar to that of pure peptide (see Figure 3.5A). 
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The inhibition effects of the binding molecules on the mutant 
(isoD)3hIAPP.  hIAPP has been previously shown to be deamidated at Asn-21, 
Asn-22, and Asn-35.48  Furthermore, it was also shown that deamidation mimics 
of hIAPP (mutant (isoD)3hIAPP) could accelerate amyloid fibril formation, thus it 
is of particular interest to investigate whether potential inhibitors are effective not 
just in preventing amyloid protein aggregation, but also deamidated amyloid 
aggregation.  The MS spectra of the mutant (isoD)3hIAPP mixed with equimolar 
amounts of potential inhibitors, i.e. insulin, 3-APS, BISA, and EGCG, were 
acquired (see Supplementary Information, Figure S3.17).  The MS spectrum of 
(isoD)3hIAPP mixed with insulin showed abundant heterodimer peaks consisting 
of (isoD)3hIAPP and insulin in 1:1 ratio.  Other reaction mixtures with 3-APS, 
BISA, or EGCG showed a range of hIAPP monomers and oligomers bound to 
potential inhibitors in ratio of 1:0.5 to 1:5 (hIAPP to potential inhibitor).  
The dissociation curves of (isoD)3hIAPP bound to potential inhibitors are 
shown in Figure 3.6A – 3.6D.  The small molecule species (3-APS, BISA, and 
EGCG) all showed a stronger binding towards the (isoD)3hIAPP than the wild type 
hIAPP.  Whereas the insulin species was dissociated more easily and so was 
bound more weakly to the (isoD)3hIAPP compared to the wildtype.  ECD 
MS/MS of the mutant (isoD)3hIAPP with potential inhibitors showed the 
interaction regions were very similar to those regions observed above for the wild-
type hIAPP (see Supplementary Information, Figure S3.18 – S3.22 and Table 
S3.11 – S3.15).
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(Figure 3.6. Continue) 
 
Figure 3.6.  CAD MS/MS dissociation curves for wild-type hIAPP with potential inhibitors; insulin (A; purple), EGCG (B; orange), 3-APS (C; 
green), and BISA (D; cyan) against the mutant (isoD)3hIAPP (coloured in black) mixed with the same molecules.  (E) The percentage of the 
soluble hIAPP (red bar) and (isoD)3hIAPP (black bar) present in the 10 µM incubated solutions incubated with potential inhibitors for one week, 
including t-test results for changes.  TEM images of the one week incubated 10 µM solutions of (F) (isoD)3hIAPP only, and the mixtures of 
(isoD)3hIAPP with (G) insulin, (H) 3-APS, (I) BISA, and (J) EGCG molecules
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The ThT fluorescence emission of the mutant (isoD)3hIAPP with potential 
inhibitors showed the lag phases of aggregation also to be very similar to those 
observed for the wild-type hIAPP with the EGCG species showing the lowest 
amount of fibril formation (see Supplementary Information, Figure S3.23).   
MS quantification of the (isoD)3hIAPP with potential inhibitors incubated for 
one week were comparable to the trends observed for wild-type hIAPP with 
potential inhibitors above (see Figure 3.6E).  The amount of remaining soluble 
(isoD)3hIAPP only solution was 46% after one week incubation, which was 8% 
less than the wild-type hIAPP.  Similar percentage differences were observed for 
the reaction mixtures containing 3-APS or BISA between wild-type hIAPP and 
(isoD)3hIAPP.  However, EGCG showed a 19% change between hIAPP and 
(isoD)3hIAPP solutions.  In the wild-type hIAPP solution incubated with insulin, 
the recovery of amyloid protein was 99.94% and the two-tailed t-test also showed 
that there was no significant difference between the fresh and incubated solutions, 
indicating essentially no aggregation of wild-type hIAPP occurring.  However, 
for (isoD)3hIAPP incubated with insulin, only 64% of soluble amyloid protein was 
detected after one week incubation and the two-tailed t-test indicated there was a 
significant difference between the fresh and incubated solutions, indicating 
aggregation of (isoD)3hIAPP. 
TEM images of the incubated solutions of the (isoD)3hIAPP with potential 
inhibitors showed the structure of the aggregates.  Short, dense fibrils were 
observed for the (isoD)3hIAPP only (see Figure 3.6F); whereas elongated fibrils 
were observed in the TEM images of (isoD)3hIAPP mixed with 3-APS or BISA 
(see Figure 3.6H and 3.6I).  No significant fibrils were observed in the TEM 
image of the incubated solution of (isoD)3hIAPP mixed with insulin, however, 
several dense black blots were observed (see Figure 3.6G).  A TEM image of the 
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mutant (isoD)3hIAPP mixed with EGCG showed large globular structures with no 
distinct fibrillary structure (see Figure 3.6J).   
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3.5 Discussion 
 Reducing the formation of the early oligomers of hIAPP, as well as inhibiting 
the amyloid fibril formation, helps to enhance the success rate in islet cell 
transplantation for T2D patients. 14, 15  Many studies focus on developing new 
compounds to inhibit the aggregation of hIAPP,3, 10, 11 and recently a high 
throughput screening method was developed to quickly search for potential targets 
out of a hundred of compounds using IM-MS experiments.22  Understanding the 
mechanisms of potential inhibitors not only reduces the trial-and-error searching 
for potential compounds but, more importantly, can also provide guidance to create 
more effective therapeutics with fewer undesirable side reactions to work against 
aggregation-based conditions.  FTICR MS, together with fluorescence 
spectrometry and TEM, have been applied to explore the different inhibition 
mechanisms adopted by potential inhibitors of interest, i.e. insulin, 3-APS, BISA, 
and EGCG, to inhibit the amyloid fibril formation.  
 
 Specific binding to the aggregation region of the wild-type hIAPP and 
inhibition of fibril formation.  Incubated solutions of wild-type hIAPP 
aggregate rapidly to form early oligomers (see Figure 3.1A), followed by mature 
fibrils (see Figure 3.22C), which is consistent with the previous studies.21, 48  
However, when co-incubated with insulin, only monomer and dimer of hIAPP 
were detected, indicating inhibition of normal aggregation behaviour (see Figure 
3.1B).  In addition, a heterodimer was detected indicating clear interactions 
between the two proteins, preventing usual aggregation.   
The lag phase of ThT fluorescence emission and the MS quantification of the 
incubated solution represent the short- and long-term inhibition performance of 
insulin respectively.  The lag phase of the 50 µM solutions of the mixture of 
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hIAPP and insulin was significantly prolonged compared to the 50 µM solution of 
hIAPP alone, which shows insulin can extend the time frame of mature amyloid 
fibril formation (see Figure 3.2A).  Significant amounts of mature fibrils were 
detected by fluorescence experiments, however the bulk emission was also, in part, 
due to insulin aggregation (see Supplementary Information, Figure S3.1).  The 
MS quantification results of the one week hIAPP with insulin incubation solution 
showed a significant decrease in the percentage of soluble insulin (see 
Supplementary Information, Figure S3.2) and no significant change in the 
percentage of soluble hIAPP (see Figure 3.2B).  Less dense fibrils (most likely 
insulin) and small dense regions (presumably hIAPP and insulin heterodimer) were 
simultaneously observed in the TEM image (see Figure 3.2D).  The data acquired 
agree insulin is a promising short- and long-term potential inhibitor for wild-type 
hIAPP aggregation, and agrees with the previous studies using insulin to inhibit 
hIAPP aggregation.32, 34 
Since insulin was shown to be an effective inhibitor in preventing the 
aggregation of wild-type hIAPP, it is important to explore the effective interaction 
sites between hIAPP and insulin molecules which may help for understanding and 
development of new therapeutics.  The interaction between hIAPP and insulin is 
weak and non-covalently bound, which was demonstrated by the CAD MS/MS 
(see Supplementary Information, Figure S3.4).  Using ECD MS/MS, the non-
covalent interaction between hIAPP and insulin was shown to be between residues 
Ser-29 and Asn-35, located within the β-strand region of hIAPP (see Figure 3.3A 
– 3.3C).  Residues of Asn-31 to Ser-34 on hIAPP molecule have previously been 
proposed as the most critical aggregation site for the formation of hIAPP early 
oligomers.48  The result shown herein suggests insulin attaches to the residues of 
Ser-29 to Asn-35, which is the same aggregation region from which hIAPP forms 
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early oligomers, thus the hIAPP involved in the heterodimer complex cannot 
further aggregate to form higher order oligomers, as well as, mature fibrils.   
 The hypothesis that insulin is binding to the critical aggregation region of 
hIAPP and results in decelerating, and even inhibiting the formation of mature 
fibrils is also supported by the experiment that mixed the synthetic 
30TNVGSNTY37-NH2 peptide, which is a segment of proposed aggregation region 
of hIAPP with insulin.  Early oligomers of 30TNVGSNTY37-NH2 peptide were 
significantly reduced when insulin was incubated in the solution (see Figure 3.5B), 
indicating insulin can bind to the critical aggregation region of hIAPP and prevent 
the formation of early oligomers in aqueous solution.   
 Insulin has successfully demonstrated one of the inhibition mechanisms for 
hIAPP aggregation that is non-covalently and specifically bound to the critical 
aggregation region of hIAPP (between Ser-29 and Asn-35), which results in 
preventing the formation of the early oligomers of hIAPP, as well as, mature hIAPP 
fibrils (see Figure 3.7A).  
 
Chapter 3 – The Inhibition Pathways of hIAPP 
205 
 
 
Figure 3.7.  Summarised inhibition mechanisms of various compounds on wild-
type hIAPP aggregation. 
 
Ineffective, non-specific binding of potential inhibitors towards hIAPP.  
Despite effectively binding to hIAPP, 3-APS and BISA molecules bind in a non-
specific way at multiple points across hIAPP (see Figure 3.2C and 3.2D).  Higher 
order oligomers, i.e. trimers, etc., of hIAPP with an attachment of 3-APS/ BISA 
molecules were formed readily demonstrating 3-APS and BISA molecules are not 
effective in inhibiting the formation of hIAPP early oligomers. 
 The lag phases shown by the mixtures of hIAPP and 3-APS/ BISA were 
similar to the lag phase of hIAPP only solution, indicating these molecules do not 
prevent the initial formation of amyloid fibrils either (see Figure 3.2A).  The 
apparent different of the percentage of soluble hIAPP present in between the fresh 
and incubated solution with addition of 3-APS/ BISA molecules also agrees both 
molecules are not effective inhibitors for hIAPP aggregation (see Figure 3.2B).  
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However, the amounts of soluble hIAPP in the incubated solutions with an addition 
of equal molar of 3-ASP/ BISA molecules were 29% and 17% higher than the 
incubated solution of hIAPP only, suggesting 3-APS and BISA molecules do have 
a slight long-term effect in preventing some formation of mature hIAPP fibrils, 
and 3-APS has a higher inhibition effect than BISA.  Normal, elongated fibrils 
were observed in the correlating TEM images which also shows 3-APS and BISA 
do not effectively inhibit the formation of mature hIAPP fibrils (see Figure 3.2E 
and 3.2F), agreeing with the results shown in the previous studies.22 
 CAD MS/MS results clearly demonstrate the interactions between hIAPP and 
3-APS/ BISA are fragile and non-covalent (see Supplementary Information, Figure 
S3.4).  The interaction region between a monomer unit of hIAPP and a 3-APS 
molecule is between Arg-11 and Gly-33 (see Figure 3.3D); while the interaction 
region between a monomer unit of hIAPP and BISA molecule is between Lys-1 to 
Asn-3, Arg-11 to Asn-14, and Ser-29 to Tyr-37 residues (see Figure 3.3E).  ECD 
MS/MS results indicate the sulfonic group of the BISA molecule is interacting 
between Arg-11 and Asn-14, while the benzimidazole group of the BISA molecule 
interacts with Lys-1 to Ans-3 and Ser-29 to tyr-37 regions, demonstrating one 
BISA molecule interacts with two different regions of hIAPP simultaneously.  
These results also show both 3-APS and BISA can interact with the critical 
aggregation region of hIAPP (Asn-31 to ser-34 residues), but do not significantly 
reduce the aggregation rate of wild-type hIAPP.   
 Non-specific binding was observed in the incubated samples of 
30TNVGSNTY37-NH2 peptide and 3-APS (see Figure 3.5C), which shows the 
capability of 3-APS interacted with the critical aggregation of hIAPP.  However, 
BISA showed limited binding to the peptide target (see Figure 3.5D), indicating 
the interaction between BISA and the critical aggregation of hIAPP is weak and 
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possibly easily reversible.  The lower extent of reaction between BISA and 
30TNVGSNTY37-NH2 peptide suggests BISA can interact in a non-specific fashion 
towards hIAPP, but mainly outside of the critical aggregation region (Thr-30 and 
Tyr-37). However 3-APS showed extensive binding to both the critical aggregation 
region peptide and the full hIAPP, indicating a non-specific binding behaviour 
directly including the aggregation region (Thr-30 and Tyr-37), yet still with limited 
inhibition of aggregation.  
 Even though the early oligomers of hIAPP were still formed despite binding 
to 3-APS/ BISA molecules, it is also important to explore the binding regions on 
hIAPP which do not interrupt the formation of hIAPP early oligomers, so called 
non-target regions for compounds.  The ECD MS/MS spectra of the mixtures of 
the hIAPP dimer bound to a 3-APS/ BISA molecule shows the uninterrupted 
binding region is between Lys-1 and Asn-14 on hIAPP molecule (see Figure 3.4), 
which suggests there is no inhibition effect on hIAPP oligomers formation when 
the molecules bind to this region.   
 3-APS and BISA molecules demonstrate non-specific binding mechanisms to 
various sites/regions of hIAPP, which may or may not include the binding towards 
the critical aggregation site of hIAPP.  However, the non-specific binding does 
not seem to decelerate/inhibit the formation of mature hIAPP fibrils effectively in 
short-term and only slightly decrease amyloid fibril formation in long-term (see 
Figure 3.7B). 
 
 Non-specific binding to the wild-type hIAPP to accelerate formation of 
non-toxic aggregates.  Numerous studies have demonstrated that EGCG not 
only effectively inhibits the aggregation of hIAPP, but is also useful in preventing 
other amyloid proteins aggregation.21-24, 26, 70  EGCG was shown to bind non-
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specifically to the wild-type hIAPP molecule with several EGCG molecules 
interacting with even single hIAPP molecules.  Early oligomers of hIAPP bound 
to many EGCG molecules were also observed in the MS spectrum (see Figure 
3.1E), which indicates EGCG is very similar to 3-APS and BISA that they can 
bind to hIAPP in a non-specific way. 
 EGCG showed effective short-term inhibition effects against hIAPP 
aggregation as the lag phase of the mature fibril formation measured by 
fluorescence experiments was significantly prolonged and the amount of fibrils 
formed was the lowest amongst all compounds studied (see Figure 3.2A), which 
indicates EGCG is a potential compound for preventing the formation of mature 
amyloid fibrils.  However, the long-term inhibition effect of EGCG on hIAPP 
aggregation measured by MS quantification shows the opposite conclusion that 
the amount of soluble hIAPP remaining in solution was the least among all the 
incubated solutions, including the incubated solution of purely hIAPP (see Figure 
3.2B).  These data indicate that EGCG may not actually purely inhibit mature 
fibril formation, but instead accelerate formation of globular aggregates which do 
not further aggregate to detectable levels for ThT fluorescence.  TEM images of 
the incubated solution of hIAPP with EGCG helps to explain the results obtained 
from the fluorescence spectrometry and MS quantification results as no mature 
fibril were observed in the TEM images of hIAPP with EGCG, however many 
small circular aggregates were (see Figure 3.2G).  TEM image help to explain the 
minor ThT fluorescence emission in the solution of hIAPP with EGCG as ThT 
only binds to the mature β-sheets of amyloid fibrils,51, 71 when there is no extended 
β-sheet formation, i.e. the small, circular aggregates, ThT molecules cannot attach 
to those aggregates effectively and there is no significant fluorescence emission 
detected.  However, the TEM image clearly showed hIAPP aggregated into 
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amorphous structures and this structure is dense enough to be easily separated by 
centrifugation, thus the MS quantification of the incubated solution of EGCG and 
hIAPP showed a large reduction in available, soluble hIAPP.  These findings are 
very similar to the previous studies stating EGCG could redirect amyloid protein 
aggregation into a non-toxic pathway,24 results herein further show that when 
EGCG is co-incubated with hIAPP, no detectable amyloid fibrils are formed, but 
many amorphous aggregates are observed. 
 Since the EGCG has a very different mechanism in inhibiting the amyloid 
fibril formation, it is interesting to explore the interaction between hIAPP and 
EGCG molecule.  Similar to the other small molecule species, the interaction 
between EGCG and hIAPP is fragile and non-covalent in nature, as reflected by 
CAD MS/MS results (see Supplementary Information, Figure S3.4).  The 
binding region of EGCG to the monomer unit of hIAPP molecule was found to be 
between Arg-11 and Ser-34 (see Figure 3.3F), very similar to the proposed 
interaction region of 3-APS and hIAPP (Arg-11 to Gly-33).  The MS spectrum of 
the target peptide 30TNVGSNTY37-NH2 and EGCG also suggests a non-specific 
interaction, and higher ordered oligomers with the attachment of EGCG were 
observed (see Figure 3.5E).  Data from hIAPP with EGCG samples suggest 
similar interactions to those from hIAPP with 3-APS, but there is drastically 
different aggregation behaviour, possible due to EGCG’s own aggregation 
behaviour.  
 TEM images of purely EGCG solutions showed huge numbers of globular 
aggregates (see Supplementary Information, Figure S3.25A).  TEM image of the 
30TNVGSNTY37-NH2 peptide with EGCG shows the circular aggregates increased 
in size compared to those in the EGCG solution alone (see Supplementary 
Information, Figure S3.25D) and the aggregates further increased in size when 
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hIAPP was incorporated (see Figure 3.2G).  These data suggested the circular 
aggregates observed in the TEM images are composed of the EGCG and available 
protein/ peptide species as the size of the vesicle changed when the length of the 
protein/ peptide varies. 
 The formation of the amorphous aggregates and the inclusion of amyloid 
biomolecules support the MS quantitation and fluorescence data above that hIAPP 
is being consumed into off-fibril aggregation pathways and the rate of EGCG 
aggregation and inclusion of biomolecules seems to be much faster than that of 
amyloid fibril formation as the TEM images are dominated by the amorphous 
aggregates, which do not readily solubilise back into the aqueous solution (see 
Figure 3.7D).  The non-specific binding of EGCG and the creation of globular 
aggregates could also help explain similar effects on results for other amyloid 
proteins observed previously.21-24, 26, 70, 72  
 
 The inhibition performance of the binding molecules towards the mutant 
(isoD)3hIAPP.  Mutant (isoD)3hIAPP is a synthetic deamidation mimic of hIAPP, 
with a replacement of iso-aspartic acid residue at Asn-21, Asn-22, and Asn-35, and 
has been reported as an acceleration factor for hIAPP aggregation and it is 
important to explore the interaction between the (isoD)3hIAPP and the binding 
molecules.48  MS spectra (see Supplementary Information, Figure S3.17) and 
ECD MS/MS data (see Supplementary Information, Figure S3.18 – 3.22) showed 
there was no significant difference between the interaction behaviour (specific/ 
non-specific) or the interaction sites between wild-type hIAPP and the mutant 
(isoD)3hIAPP.  However, there was a significant difference of the interaction 
strength between the molecules and the amyloid proteins (see Figure 3.6A – 3.6D).  
Insulin showed a weaker interaction to the mutant (isoD)3hIAPP, while the 
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interactions between (isoD)3hIAPP and 3-APS/ BISA/ EGCG were stronger than 
normal hIAPP.  The results indicate a change in the structure of (isoD)3hIAPP can 
affect the strength of interaction with large, specific binding insulin molecules 
distinctly, the same behavior did not transfer to small, non-specific binding 
molecules, i.e. 3-APS, BISA, and EGCG.   
The amount of soluble (isoD)3hIAPP remaining when incubated with insulin 
for one week was significantly less compared to the wild-type hIAPP with insulin, 
indicating that the insulin molecule is much less effective at inhibiting the 
aggregation of the mutant (isoD)3hIAPP compared to the wild-type (see Figure 
3.6B).  The amount of the soluble (isoD)3hIAPP incubated with the small 
molecules decreased in similar percentage when compared with the amount of 
soluble hIAPP in the incubated solutions, agreeing with the previous studies 
showing that the mutant (isoD)3hIAPP can aggregate faster than the wild-type.
48  
However, ThT fluorescence measurement showed the lag phase and the amount of 
mature fibrils formed did not dramatically change compared to the wild-type 
hIAPP with insulin incubation (see Supplementary Information, Figure S3.21).  
TEM image of the mutant (isoD)3hIAPP with insulin incubated solution showed 
amorphous aggregates were formed, and as a result it did not produce a detectable 
ThT emission signal, in a similar way to wild-type hIAPP with EGCG above.  
Mature fibrils were still observed in purely (isoD)3hIAPP solution, as well as 
when incubated with 3-APS/ BISA, indicating 3-APS/ BISA does not have any 
significant effect on (isoD)3hIAPP aggregation compared to wild-type hIAPP.  
TEM image of EGCG with (isoD)3hIAPP showed larger, denser black blot 
formation compared to the wild-type, suggesting a more extensive inclusion of 
protein into the circular aggregates.  These were reflected in the MS quantitation 
results, showing a larger decrease in soluble (isoD)3hIAPP compared to the wild-
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type. 
The results here show that 3-APS and BISA molecules do not have significant 
effect on inhibiting the mutant (isoD)3hIAPP.  Previously, insulin was good at 
inhibiting the wild-type hIAPP aggregation and preserving the soluble hIAPP 
monomer in the solution.  The mutant (isoD)3hIAPP incubated with insulin forms 
amorphous structures which are different from the expected amyloid fibrils, and 
this complex is no longer reversibly soluble into aqueous solution.  The EGCG 
molecule still accelerates the aggregation of (isoD)3hIAPP into amorphous 
structures and the rate of this aggregation is also faster than the (isoD)3hIAPP 
solution aggregation.   
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3.6 Conclusion 
 The experimental results here demonstrated two potential inhibition pathways 
are occurring to prevent the formation of toxic hIAPP aggregates.  Inhibitors like 
insulin adopt a direct pathway that interact with hIAPP between Ser-29 and Asn-
35 residues which were proposed to be the most critical aggregation region for the 
formation of hIAPP early oligomers.  These inhibitors are not only effective in 
preventing the formation of toxic hIAPP aggregates, but also able to dissociate the 
hetero-complexes back into the monomer units of hIAPP and inhibitor, which is a 
possible key feature for potential drug development.  These inhibitors, however, 
are only effective towards a limited range of amyloid protein sequences and 
structures, as a result, they are not viable to prevent the aggregation of mutant 
hIAPPs or other amyloid proteins.  On the other hand, other inhibitors, such as 
EGCG, can self-aggregate and trigger the formation of non-toxic, amorphous 
hIAPP aggregates faster than forming the toxic hIAPP aggregates.  These 
inhibitors interact non-specifically to the amyloid proteins, thus they are effective 
to prevent the formation of toxic aggregates regardless of the sequences and 
structures of amyloid proteins.  Despite the inhibition effect, the formation of 
amorphous aggregates seems to indicate the hIAPP units are continuously 
consumed once mixed with these inhibitors, in a long term, very low or even no 
free hIAPP unit is available for the normal physiological function inside the human 
body.  
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(Figure S3.1. Continue) 
 
Figure S3.1.  (A) The absolute ThT fluorescence emission of a 50 µM solution of the wild-type hIAPP (red circles), and the 50 µM solutions of 
the wild-type hIAPP mixed with equal molar of insulin (purple star), 3-APS (green rectangle), BISA (cyan pentagon), and EGCG (yellow triangle).  
(B) The absolute ThT fluorescence emission of the 100 µM ThT solution (black hexagon), and the 50 µM solutions of insulin (purple star), 3-APS 
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(green rectangle), BISA (cyan pentagon), and EGCG (yellow triangle) alone.  (C) The corrected absolute ThT fluorescence emission of the 50 
µM solution of the wild-type hIAPP (red circles), and the 50 µM solutions of the wild-type hIAPP mixed with equal molar of insulin (purple star), 
3-APS (green rectangle), BISA (cyan pentagon), and EGCG (yellow triangle).  The corrected absolute ThT fluorescence emission was calculated 
by using the absolute ThT fluorescence emission of hIAPP mixed with various binding molecules (see Figure S3.1A) minus the absolute ThT 
fluorescence emission of the binding molecules alone (see Figure S3.1B). 
Chapter 3 – The Inhibition Pathways of hIAPP 
223 
 
 
 
Figure S3.2.  The percentage of the soluble wild-type hIAPP (red bar)/ insulin 
(blue bar) which remained in the 10 µM solutions incubated at 37oC for one week.  
The percentage of soluble hIAPP in the fresh solutions and the incubated solutions 
were test against a two-tailed T-test.  The p value that is <0.05 (red font) indicates 
there is a significant different of the soluble hIAPP/ insulin percentage between 
the fresh and incubated solutions, while the p value >0.05 (green font) indicates 
there is no significant difference of the soluble hIAPP/ insulin percentage between 
the fresh and incubated solutions.  
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Figure S3.3.  The representative CAD spectra of (A) the 7+ charge state 
molecular ion of the wild-type hIAPP monomer unit with an intact insulin 
molecule and the 4+ charge state molecular ion of the wild-type hIAPP monomer 
unit with an attachment of (B) an EGCG, (C) a 3-APS, and (D) a BISA molecules.  
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Figure S3.4.  The dissociation curves of the 7+ hIAPP monomer unit with an 
insulin molecule (purple), and the 4+ hIAPP monomer unit with an EGCG 
(orange), a 3-APS (green), and a BISA (cyan) molecules which were generated 
from the Supplementary Information Figure S3.3.  The dissociation curve of the 
7+ charge state of hIAPP with insulin is the lowest among all the other dissociation 
curves, however, this is a bias comparison as the charge state of the molecular ion 
of hIAPP with insulin (7+) is higher than the others molecular ions (4+), and 
previous study has shown variation in the charge state of the peptide leads to 
different fragmentation pattern.73  The dissociation curves of hIAPP monomer 
unit with the binding molecules clearly indicate that the interaction between hIAPP 
and the binding molecules are fragile and non-covalent bind as the dissociations 
resulted in obtaining the hIAPP monomer unit directly and no CAD MS/MS 
fragments were obtained.  
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(Figure S3.5. Continue) 
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Figure S3.5.  (A) The summarised ECD fragments of the 7+ charge state molecular ion of hIAPP monomer unit and an intact insulin molecule.  
The highlighted area (coloured in purple) indicates the proposed interaction region between the monomer unit of hIAPP and an insulin molecule.  
(B) The ECD MS/MS spectrum of the 7+ charge state molecular ion of hIAPP monomer unit and an intact insulin molecule.  The assigned 
fragments are listed in the Supplementary Information Table S3.1. 
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(Table S3.1. Continue) 
 
Table S3.1.  List of the assigned ECD fragments of the 7+ molecular ion of 
hIAPP monomer unit with an intact insulin molecule.  
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Figure S3.6.  (A) The summarised ECD fragments of the 4+ charge state 
molecular ion of hIAPP monomer unit and a 3-APS molecule.  The highlighted 
area (coloured in green) indicates the proposed interaction region between the 
monomer unit of hIAPP and a 3-APS molecule.  (B) The ECD MS/MS spectrum 
of the 4+ charge state molecular ion of hIAPP monomer unit and a 3-APS molecule.  
The assigned fragments are listed in the Supplementary Information Table S3.2.  
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Table S3.2.  List of the assigned ECD fragments of the 4+ molecular ion of 
hIAPP monomer unit with a 3-APS molecule. 
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Figure S3.7.  (A) The summarised ECD fragments of the 4+ charge state 
molecular ion of hIAPP monomer unit and a BISA molecule.  The highlighted 
area (coloured in pink) indicates the proposed interaction region between the 
monomer unit of hIAPP and the benzimidazole group from BISA molecule, the 
highlighted area (coloured in yellow) indicates the proposed interaction region 
between the monomer unit of hIAPP and sulfonic acid group from BISA molecule, 
and the highlighted area (coloured in cyan) indicates the proposed interaction 
region between the monomer unit of hIAPP and a BISA molecule.  (B) The ECD 
MS/MS spectrum of the 4+ charge state molecular ion of the monomer unit of 
hIAPP and a BISA molecule.  The assigned fragments are listed in the 
Supplementary Information Table S3.3. 
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(Table S3.3. Continue)
 
Table S3.3.  List of the assigned ECD fragments of the 4+ molecular ion of 
hIAPP monomer unit with a BISA molecule. 
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Figure S3.8.  (A) The summarised ECD fragments of the 4+ charge state 
molecular ion of hIAPP monomer unit and an EGCG molecule.  The highlighted 
area (coloured in yellow) indicates the proposed interaction region between the 
monomer unit of hIAPP and an EGCG molecule.  (B) The ECD MS/MS spectrum 
of the 4+ charge state molecular ion of hIAPP monomer unit and an EGCG 
molecule.  The assigned fragments are listed in the Supplementary Information 
Table S3.4.  
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Table S3.4.  List of the assigned ECD fragments of the 4+ molecular ion of 
hIAPP monomer unit with an EGCG molecule. 
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Figure S3.9.  The representative CAD spectra of (A) the 5+ charge state 
molecular ion of 30TNVGSNTY37-NH2 peptide mixed with an intact insulin 
molecule in equal molar, and the molecular ion of 30TNVGSNTY37-NH2 peptide 
mixed with equal molar of (B) 3-APS and (C) EGCG molecules.   
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Figure S3.10.  The dissociation curves of (A) the 5+ 30TNVGSNTY37-NH2 
peptide mixed with equal molar of insulin molecule (purple), and the 
30TNVGSNTY37-NH2 peptide mixed with equal molar of (B) 3-APS (green) and 
(C) EGCG (red) molecules which were generated from the Supplementary 
Information Figure S3.9.  The dissociation curve of 30TNVGSNTY37-NH2 
peptide with insulin is lower than the dissociation curves of 30TNVGSNTY37-NH2 
peptide with 3-APS and EGCG as different charge states of molecular ions were 
isolated and fragmented.73  Figure S3.10A clearly shows that the complex of 
30TNVGSNTY37-NH2 peptide with insulin simply dissociates into the monomer 
unit of 30TNVGSNTY37-NH2 peptide and insulin molecule.  In Figure S3.10B, 
1:1 and 2:2 complexes of 30TNVGSNTY37-NH2 peptide with 3-APS molecule(s) 
were co-isolated (different charge state but same m/z ratio).  Dissociation of the 
2:2 complex of 30TNVGSNTY37-NH2 peptide with 3-APS results in an increase of 
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1:2 complex ion of 30TNVGSNTY37-NH2 peptide with 3-APS which indicates the 
binding between the 2:2 complex is either two 3-APS molecules are attaching to 
one 30TNVGSNTY37-NH2 peptide or the 
30TNVGSNTY37-NH2 peptide and 3-APS 
molecule are in sandwich pattern that a 3-APS molecule is placed in the middle of 
two 30TNVGSNTY37-NH2 peptides.  The relative percentage of the 1:1 complex 
of 30TNVGSNTY37-NH2 peptide with 3-APS decreases while the percentage of the 
30TNVGSNTY37-NH2 peptide increases proportionally to the CAD energy applied.  
In Figure S3.10C, the 1:1, 2:2, and 3:3 complexes of 30TNVGSNTY37-NH2 peptide 
with EGCG molecule(s) were co-isolated; and similar dissociation patterns which 
is described above are also observed in the CAD curve of EGCG mixed with 
30TNVGSNTY37-NH2 peptide.  
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(Figure S3.11. Continue)
 
Figure S3.11.  (A) The summarised ECD fragments of the 5+ charge state 
molecular ion of the synthetic 30TNVGSNTY37-NH2 peptide with an intact insulin 
molecule.  The fragments here show there is an interaction between the synthetic 
peptide and the insulin molecule; however, the interaction site between 
30TNVGSNTY37-NH2 peptide and insulin cannot be further narrowed down using 
ECD MS/MS fragmentation.  (B) The ECD MS/MS spectrum of the 5+ charge 
state molecular ion of the synthetic 30TNVGSNTY37-NH2 peptide with an intact 
insulin molecule.  The assigned fragments are listed in the Supplementary 
Information Table S3.5.   
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Table S3.5.  List of the assigned ECD fragments of the 5+ molecular ion of the 
synthetic peptide 30TNVGSNTY37-NH2 with an insulin molecule. 
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Figure S3.12.  (A) The summarised ECD fragments of the 2+ charge state 
molecular ion of the synthetic dimer 30TNVGSNTY37-NH2 peptide with a 3-APS 
molecule.  The fragments here show there is an interaction between the synthetic 
peptide and 3-APS molecule; however, the interaction site between 
30TNVGSNTY37-NH2 peptide and 3-APS molecule cannot be further narrowed 
down using ECD MS/MS fragmentation.  (B) The ECD MS/MS spectrum of the 
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2+ charge state molecular ion o the synthetic 30TNVGSNTY37-NH2 peptide with a 
3-APS molecule.  The assigned fragments are listed in the Supplementary 
Information Table S3.6.  
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Table S3.6.  List of the assigned ECD fragments of the 2+ molecular ion of the 
synthetic peptide 30TNVGSNTY37-NH2 with a 3-APS molecule.  
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Figure S3.13.  (A) The summarised ECD fragments of the 2+ charge state 
molecular ion of the synthetic dimer 30TNVGSNTY37-NH2 peptide with an EGCG 
molecule.  The fragments here show there is an interaction between the synthetic 
peptide and EGCG molecule; however, the interaction site between 
30TNVGSNTY37-NH2 peptide and EGCG molecule cannot be further narrowed 
down using ECD MS/MS fragmentation.  (B) The ECD MS/MS spectrum of the 
2+ charge state molecular ion o the synthetic 30TNVGSNTY37-NH2 peptide with 
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an EGCG molecule.  The assigned fragments are listed in the Supplementary 
Information Table S3.7.  
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Table S3.7.  List of the assigned ECD fragments of the 2+ molecular ion of the 
synthetic peptide 30TNVGSNTY37-NH2 peptide with an EGCG molecule. 
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Figure S3.14.  (A) The summarised ECD fragments of the 7+ charge state 
molecular ion of the wild-type hIAPP dimer with a 3-APS molecule.  The 
highlight area (coloured in green) indicates the proposed non-interruption binding 
region, which does not interfere with the formation of the early oligomers between 
the wild-type hIAPP and a 3-APS molecule.  (B) The ECD MS/MS spectrum of 
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the 7+ charge state molecular ion of the wild-type hIAPP dimer with a 3-APS 
molecule.  The assigned fragments are listed in the Supplementary Information 
Table S3.8.  
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Table S3.8.  List of the assigned ECD fragments of the 7+ molecular ion of the 
wild-type hIAPP dimer with a 3-APS molecule. 
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Figure S3.15.  (A) The summarised ECD fragments of the 7+ charge state 
molecular ion of the wild-type hIAPP dimer with a BISA molecule.  The 
highlight area (coloured in cyan) indicates the proposed non-interruption binding 
region, which does not interfere with the formation of the early oligomers between 
the wild-type hIAPP and 3-APS molecule.  (B) The ECD MS/MS spectrum of 
the 7+ charge state molecular ion of the wild-type hIAPP dimer with a BISA 
molecule.  The assigned fragments are listed in the Supplementary Information 
Table S3.9.  
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(Table S3.9. Continue) 
 
Table S3.9.  List of the assigned ECD fragments of the 7+ molecular ion of the 
wild-type hIAPP dimer with a BISA molecule. 
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Figure S3.16.  (A) The summarised ECD fragments of the 7+ charge state 
molecular ion of the wild-type hIAPP dimer with an EGCG molecule.  (B) The 
ECD MS/MS spectrum of the 7+ charge state molecular ion of the wild-type hIAPP 
dimer with an EGCG molecule.  The assigned fragments are listed in the 
Supplementary Information Table S3.10. 
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Table S3.10.  List of the assigned ECD fragments of the 7+ molecular ion of the 
wild-type hIAPP dimer with an EGCG molecule. 
Chapter 3 – The Inhibition Pathways of hIAPP 
261 
 
 
Chapter 3 – The Inhibition Pathways of hIAPP 
262 
 
Figure S3.17.  The MS spectra of (A) the 10 µM solution of the mutant (isoD)3hIAPP (grey circle) only, the 10 µM aqueous solutions of the 
mutant (isoD)3hIAPP mixed with the (B) 10 µM insulin (purple star), (C) 10 µM 3-APS (green square), (D) 10 µM BISA (cyan pentagon), and (E) 
10 µM EGCG (yellow triangle). 
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Figure S3.18.  (A) The summarised ECD fragments of the 7+ charge state molecular ion of the mutant (isoD)3hIAPP monomer unit and an intact 
insulin molecule.  The highlighted area (coloured in purple) indicates the proposed interaction region between the monomer unit of the mutant 
(isoD)3hIAPP and an insulin molecule which is between Asn-31 and Ser-34 on the mutant (isoD)3hIAPP molecule.  (B) The ECD MS/MS 
spectrum of the 7+ charge state molecular ion of the mutant (isoD)3hIAPP monomer unit and an intact insulin molecule.  The assigned fragments 
are listed in the Supplementary Information Table S3.11.
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Table S3.11.  List of the assigned ECD fragments of the 7+ molecular ion of the 
mutant (isoD)3hIAPP monomer unit with an intact insulin molecule.  
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Figure S3.19.  (A) The summarised ECD fragments of the 4+ charge state 
molecular ion of the mutant (isoD)3hIAPP monomer unit and a 3-APS molecule.  
The highlighted area (coloured in green) indicates the proposed interaction region 
between the monomer unit of the mutant (isoD)3hIAPP and a 3-APS molecule 
which is between Arg-11 and Gly-33 on the mutant (isoD)3hIAPP molecule.  (B) 
The ECD MS/MS spectrum of the 4+ charge state molecular ion of the mutant 
(isoD)3hIAPP monomer unit and a 3-APS molecule.  The assigned fragments are 
listed in the Supplementary Information Table S3.12.   
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Table S3.12.  List of the assigned ECD fragments of the 4+ molecular ion of the 
mutant (isoD)3hIAPP monomer unit with a 3-APS molecule.  
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Figure S3.20.  (A) The summarised ECD fragments of the 4+ charge state 
molecular ion of the mutant (isoD)3hIAPP monomer unit and a BISA molecule.  
The highlighted area (coloured in pink) indicates the proposed interaction region 
between the monomer unit of the mutant (isoD)3hIAPP and the benzimidazole 
group from BISA molecule which is between Lys-1 and Asn-3, as well as, Thr-36 
and Tyr-37 on the mutant (isoD)3hIAPP molecule, the highlighted area (coloured 
in yellow) indicates the proposed interaction region between the monomer unit of 
the mutant (isoD)3hIAPP and sulfonic acid group from BISA molecule which is 
between Lys-1 and Asn-15 on the mutant (isoD)3hIAPP molecule, and the 
highlighted area (coloured in cyan) indicates the proposed interaction region 
between the monomer unit of the mutant (isoD)3hIAPP and a BISA molecule 
which is between Arg-11 and Asn-15 on the mutant (isoD)3hIAPP molecule.  (B) 
The ECD MS/MS spectrum of the 4+ charge state molecular ion of the monomer 
unit of the mutant (isoD)3hIAPP and a BISA molecule.  The assigned fragments 
are listed in the Supplementary Information Table S3.13. 
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(Table S3.13 Continue)
 
Table S3.13.  List of the assigned ECD fragments of the 4+ molecular ion of the 
mutant (isoD)3hIAPP monomer unit with a BISA molecule.  
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Figure S3.21.  (A) The summarised ECD fragments of the 4+ charge state 
molecular ion of the mutant (isoD)3hIAPP monomer unit and an EGCG molecule.  
The highlighted area (coloured in yellow) indicates the proposed interaction region 
between the monomer unit of the mutant (isoD)3hIAPP and an EGCG molecule 
which is between Arg-11 and Ser-34 residues on the mutant (isoD)3hIAPP 
molecule.  (B) The ECD MS/MS spectrum of the 4+ charge state molecular ion 
of the mutant (isoD)3hIAPP monomer unit and an EGCG molecule.  The assigned 
fragments are listed in the Supplementary Information Table S3.14.   
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Table S3.14.  List of the assigned ECD fragments of the 4+ molecular ion of the 
mutant (isoD)3hIAPP monomer unit with an EGCG molecule. 
  
Chapter 3 – The Inhibition Pathways of hIAPP 
278 
 
 
Chapter 3 – The Inhibition Pathways of hIAPP 
279 
 
Figure S3.22.  (A) The summarised ECD fragments of the 7+ charge state 
molecular ion of the mutant (isoD)3hIAPP dimer with a 3-APS molecule.  The 
highlight area (coloured in green) indicates the proposed non-interruption binding 
region, which does not interfere with the formation of the early oligomers between 
the mutant (isoD)3hIAPP and a 3-APS molecule.  (B) The ECD MS/MS spectrum 
of the 7+ charge state molecular ion of the mutant (isoD)3hIAPP dimer with a 3-
APS molecule.  The assigned fragments are listed in the Supplementary 
Information Table S3.15.  
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Table S3.15.  List of the assigned ECD fragments of the 7+ molecular ion of the 
mutant (isoD)3hIAPP dimer with a 3-APS molecule. 
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(Figure S3.23. Continue) 
 
Figure S3.23.  (A) The normalised ThT fluorescence emission of the 50 µM solution of the mutant (isoD)3hIAPP only (grey circle), and mixtures 
of the 50 µM solutions of mutant (isoD)3hIAPP with the addition of equal molar of insulin (purple star), 3-APS (green rectangle), BISA (cyan 
pentagon), and EGCG (yellow triangle) solutions.  Each emission was fitted with a Boltzmann curve and the lag phase of each solution was 
calculated.68-69  (B) The absolute ThT fluorescence emission of the mutant (isoD)3hIAPP (grey circles), and the mutant (isoD)3hIAPP mixed with 
equal molar of insulin (purple star), 3-APS (green rectangle), BISA (cyan pentagon), and EGCG (yellow triangle) solutions.  (C) The absolute 
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ThT fluorescence emission of the ThT control (black hexagon), insulin, 3-APS, BISA, and EGCG solutions.  (D) The corrected absolute ThT 
fluorescence emission of the mutant (isoD)3hIAPP only, and the mutant (isoD)3hIAPP mixed with equal molar of insulin, 3-APS, BISA, and EGCG 
solutions.  The corrected absolute ThT was calculated by using the absolute ThT fluorescence emission of the mutant (isoD)3hIAPP mixed with 
various binding molecules (see Figure S3.21A) minus the absolute ThT fluorescence emission of the binding molecules alone (see Figure S3.21B).  
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Figure S3.24.  The percentage of the soluble hIAPP (red bar), (isoD)3hIAPP 
(black bar), and insulin (blue bar) present in the 10 µM incubated solutions which 
has been mixed with the binding molecules in equal molar and incubated for one 
week.  The percentage of the soluble mutant (isoD)3hIAPP and insulin in the 
fresh and incubated solutions were tested against two-tailed t-tests and the t-test p 
value less than 0.05 (red font) which indicates there is a significant different the 
fresh and incubated solutions.  The percentage different of the soluble amyloid 
proteins and insulin between the wild-type hIAPP and the mutant (isoD)3hIAPP 
solutions were calculated and labelled in the bar chart.  
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Figure S3.25.  (A) The MS spectrum of the 10 µM aqueous solution of EGCG 
only.  The EGCG solution was diluted to 50 µM and vortexed for half an hour, 
then the solution was further diluted to 10 µM and centrifuged at 14,000 rpm 
before MS analysis.  Early oligomers, from monomer to hexamer, of EGCG were 
observed in the MS spectrum which indicates EGCG can rapidly aggregate in an 
aqueous solution.  The TEM images of one week incubated solutions of (B) 10 
µM EGCG solution only, (C) 500 µM EGCG solution only, and (D) 10 µM 
30TNVGSNTY37-NH2 peptide mixed with equal molar of EGCG solution.  
Circular spots are observed in the TEM images with the addition of EGCG solution, 
the average diameter of the circular spots in the 10 µM EGCG solution is 09 nm, 
the average diameter of the spots in the 500 µM EGCG solution is 12 nm, and the 
average diameter of the circular spots in the TEM image of the mixture of equal 
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molar of 30TNVGSNTY37-NH2 peptide and EGCG solution is 16 nm.  The TEM 
images here demonstrate EGCG aggregates in the aqueous solution.   
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Chapter 4 The Next Dimension in Proteomics 
 
 This chapter demonstrates the application of two dimensional mass spectrometry 
(2DMS) to proteomic studies ranging from standard protein digests to a whole cell 
lysate digest without prior separation using online liquid chromatography (LC).  The 
development of 2DMS aims to provide an alternative method for proteomic studies, 
and hopefully it can further apply to study fragile interaction between biomolecules in 
a complex proteomic sample through eliminating the limitations in online LC system.  
 The results presented herein were predominantly carried out by the thesis Author, 
aside from the in-house software was written by Dr. Christopher A. Wootton, Tomos E. 
Morgan, and Remy Gavard from Prof. Peter O’Connor and Dr. Mark P. Barrow groups.  
 A manuscript entitled “The Next Dimension in Proteomics” by Yuko P. Y. Lam, 
Christopher A. Wootton, Cookson K. C. Chiu, Tomos E. Morgan, Remy Gavard, Maria 
A. van Agthoven, M. Li, Mark P. Barrow, and Peter B. O’Connor has been prepared for 
submission to Nature Methods based on the results presented in this chapter.  
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4.1 Abstract 
 Reversed phase liquid chromatography (RP-LC) is an essential tool for the 
proteomic studies due to its powerful separation of peptides and proteins prior to MS 
analysis; however, LC separation of extremely complex samples with widely varying 
properties suffers from the bias of the chromatography columns applied in LC 
separation and incompatibility with certain separation conditions such as solvent 
compatibility, pH, and column chemistry.  An alternative analytical method which is 
able to handle complex proteomic samples and high flexibility in sample conditions is 
required.  Herein, we apply two dimensional mass spectrometry (2DMS) to study 
proteomic samples ranging from a standard protein digest to a whole cell lysate digest.  
In the 2DMS experiments, we show that it is possible to obtain detailed sequence 
information from peptides without online LC separation.  We then compared the 
results obtained from the 2DMS to the LC tandem MS data and show that 2DMS can 
achieve similar results to LC MS/MS for identified proteins in the proteomic samples 
shown.  Furthermore, our data show that the 2DMS experiments tend to be more adept 
at analysing and identifying particularly hydrophilic, basic, or short peptides, which is 
complementary to those being assigned in LC tandem MS.  These results demonstrate 
that 2DMS provides an alternative technique for future proteomics.  
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4.2 Introduction 
 Proteomic studies focus on analysing the proteins generated by living organisms.  
Mass spectrometry (MS) is the leading analytical technique for large scale proteomic 
studies due to its high sensitivity, throughput, acquisition speed, and wide dynamic 
range.1-3  In proteomic studies, MS is used to measure the masses of proteins and 
peptides, then fragment them using serial tandem mass spectrometry to provide 
sequence information and identify the biomolecules present.2-4  Proteomic studies are 
currently involved in searching for biomarkers of diseases,5 quantifying critical proteins 
and relative PTMs changes,6, 7 observing structural changes of proteins,8, 9 as well as 
monitoring the interactions between potential inhibitors and proteins in living 
organisms.2, 10  These studies contribute to prevention and treatment of the diseases, 
such as cancer,11 neurodegenerative diseases,12 bacterial infected diseases.13  
Currently, the majority of proteomics is conducted under the bottom-up regime where 
proteins are chemically or enzymatically digested from proteins and is the most 
common method applied in MS-based proteomics.2, 14 
 MS can detect many ions simultaneously, but it is challenging to handle tens-of-
thousands of peptides from a digested sample in a single injection.  Thus, peptides are 
normally separated using high performance liquid chromatography (HPLC) or nano-
liquid chromatography (nLC) prior to online MS and MS/MS analysis.2, 3  Yeast from 
Saccharomyces cerevisiae is commonly used as a model system to evaluate the 
capabilities of newly developed proteomic systems.15-20  With early methods, the yeast 
proteome was first separated using two dimensional polyacrylamide gels (2D-PAGE), 
the proteins were then digested into peptides and further separated by a C18 reversed 
phase liquid chromatography (RP-LC) column.16  The separated peptides were 
analysed using tandem MS (MS/MS) and 90 proteins were assigned in the experiment.  
Several years later, Washburn et al. demonstrated the application of a two dimensional 
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liquid chromatography (2D-LC) system to study yeast proteome, which assigned more 
than 1,400 yeast proteins in the experiment.17  With the use of multiple orthogonal LC 
columns, the number of identified proteins, as well as the dynamic range of the 
proteome can be enhanced.20  Recently, Hebert et al. showed over 4,000 proteins were 
assigned in a 70-minute C18 RP-LC MS/MS experiment, showing a significant 
improvement in the rate of protein assignments per minute.18, 21  Rapid development 
of multiple dimensional LC MS/MS has led to faster and deeper analysis of proteomes, 
but LC separation, especially low pH RP-LC, becomes unavoidable in current 
proteomic studies which results in limiting the study of species retained tightly in RP 
columns (very hydrophobic peptides), species unable to be retained (very hydrophilic 
peptides), as well as fragile biomolecules and peptide-ligand species due to the 
conditions of the solvents used in RP-LC systems. 
 Study of non-covalent interactions between biomolecules is a critical research area 
for development of therapeutics.22, 23  Non-covalent interactions between 
biomolecules are generally studied by in vitro experiments using direct MS infusion 
with suitable physiological buffers, such as ammonium acetate.24-26  Previous studies 
showed that hydrogen-deuterium exchange (HDX) experiments could preserve the non-
covalent interactions between biomolecules while using RP-LC separation prior to MS 
analysis.27, 28  The generation of complicated MS spectra, however, limits the 
application of HDX experiments in in vivo studies.  Thus, a new analytical technique 
that can provide a higher flexibility in the choices of LC column and the solvent system 
is required for future proteomics, in which the non-covalent interactions between 
biomolecules can be preserved.  
 Two dimensional mass spectrometry (2DMS) was first introduced by Pfandler et 
al. in 1987 and further developed and applied by Ross et al. in 1993 using an FTICR 
mass analyzer.29, 30  In 2DMS, a modulating excitation or de-excitation pulse is used 
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to alter the positions of ions inside the FTICR cell, ions that are modulated to overlap 
with the position of the fragmentation zone are dissociated with the applied radius-
dependent in-cell MS/MS technique, such as infrared multiphoton dissociation 
(IRMPD) or electron capture dissociation (ECD).31, 32  Since the fragment ions are 
modulated with the same frequency as the precursor ion, the modulation frequency can 
be used to correlate fragments with precursors.  In 2DMS, samples are directly infused 
into the MS which allows a broader selection of sample preparation methods, especially 
the selection of sample buffers.  2DMS is a data-independent acquisition technique in 
that all precursor ions are fragmented during the experiment, and a two dimensional 
mass spectrum, showing all precursor and fragment ions, is obtained (see 
Supplementary Information, Figure S4.1).31  Compared to the traditional MS/MS, 
2DMS does not require isolation of a precursor ion prior to fragmentation and detection, 
instead utilising the frequencies of ions in the second dimension to separate the peaks 
which provides an advantage in the application to complex proteomic samples as 
discussed below. 
 2DMS is newly applied to proteomic studies, including both top-down and 
bottom-up proteomics.33  Previous studies showed that similar top-down and bottom-
up fragments were obtained from both quadrupole precursor isolated MS/MS and 
2DMS.34-36  Peptides from digested collagen showed that 2DMS can differentiate and 
fragment two precursor ions with similar mass-to-charge (m/z) ratios, which, in general, 
cannot be isolated and fragmented individually by quadrupole mass isolation.37  
Peptide assignment from the 2DMS spectra of digested proteins, such as cytochrome c, 
calmodulin, and collagen, also showed that 2DMS has the potential for complex 
proteomic studies without LC separation.33, 34, 37, 38  
 Herein, we have applied a mixture of digested standard proteins and a digested 
yeast lysate sample to evaluate the performance of 2DMS by comparing the data to 
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proteomic results obtained from a standard nano-LC (nLC) MS/MS approach.  
Various sample preparation and 2DMS data acquisition methods were used in the 
mixture of digested standard proteins in order to determine the most suitable workflow 
for a complex proteomic study.  The optimized method was further applied to the 
digested yeast sample to demonstrate the ability of 2DMS in proteomic studies.  From 
the results, we showed that 2DMS could identify a significant number of peptides in a 
digested proteomic sample, in which the number of assigned peptides was comparable 
to the nLC MS/MS data.  Furthermore, the identities of proteins and peptides observed 
in the 2DMS experiments were complementary to the results from nLC MS/MS 
experiments, thus a better coverage in proteome as well as protein sequence can be 
obtained through a combination of methods.  The solvent and column constraints in 
LC systems mentioned in above were also shown to be eliminated in our 2DMS 
experiments without affecting the quality of data.  The peptides that were exclusively 
assigned in the 2DMS experiments suggested this newly developed method is suitable 
for complex proteomic studies and associating the data obtained from 2DMS with nLC 
MS/MS results provides a new capability in future proteomic studies. 
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4.3 Experimental Section 
 Sample Preparation   
Standard proteins digestion.  Standard proteins, including bovine serum albumin 
(BSA; Sigma A7030), chicken lysozyme (CLZ; Sigma L6876), human haemoglobin 
(HHA; Sigma H7379), human lysozyme (HLZ; Sigma L1667), and human serum 
albumin (HSA; A3782), were purchased from Sigma-Aldrich Company Ltd (Dorset, 
UK).  The proteins were individually dissolved in 100 mM ammonium bicarbonate 
(ABC) solution to 1 µg/µL.  Protein disulphide bonds were then reduced using 50 mM 
dithiothreitol (DTT) for 30 minutes at 60oC, followed by alkylation using 100 mM 
iodoacetamide (IAA) in the dark at room temperature for 60 minutes.  Bovine trypsin 
solution was added into the alkylated solutions at 25:1 ratio (protein : trypsin) and the 
mixtures were incubated at 37oC for 16 hours.  500 µL was taken from each digested 
sample and combined to generate the “5 digested proteins” (5CP) solution.   
Yeast cell lysis and digestion.  0.1 g of yeast from Saccharomyces cerevisiae 
(Sigma-Aldrich Company Ltd; Dorset, U.K.) was dissolved in 50 mL sodium dodecyl 
sulfate (SDS) lysis buffer containing 50 mM TRIS, 1% SDS, 2% glycerol, 50 mM DTT, 
and 5 mM ethylenediaminetetraacetic acid (EDTA), the pH of the lysis buffer was then 
adjusted to pH 7.5 using hydrochloric acid (HCl).  The solution was incubated at 95oC 
for 5 minutes and centrifuged at 5,000 rpm, 4oC for 30 minutes.  The supernatant was 
collected, mixed with 5-fold of iced acetone solution, and kept at -20oC in a freezer for 
2 hours to isolate the proteins from the lysate.  The iced solution was then centrifuged 
at 5,000 rpm, 4oC for 30 minutes to separate the supernatant from the precipitated 
proteins (in pellet form), the protein pellet was then isolated.  6 M urea was used to 
dissolve the pellet, the amount of protein (µg/µL) in the solution was quantified by 
Bradford reagent assay and then diluted to 1 µg/µL using 100 mM ABC.  The sample 
was then digested using the same protocol mentioned above for standard proteins.   
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Peptide purification using solid phase extraction (SPE) cartridges.  SPE 
cartridges were used to enrich peptides with various physical properties based on the 
principles of LC separation.39  C18 RP (Thermo Fisher Scientific; Loughborough, 
UK), hydrophilic interaction chromatography (HILIC; Macherey-Nagel GmbH & Co. 
KG; Düren, Germany), and strong anion exchange (SAX; Thermo Fisher Scientific; 
Loughborough, UK) SPE cartridges were used to enrich the digested 5CP and yeast 
samples prior to MS analysis.  1 mg of 5CP and yeast samples were loaded onto each 
SPE cartridge.  The pH conditions for the experiments, as well as the loading and 
elution buffers for each SPE cartridge are summarized in the Supplementary 
Information Table S4.1 and S4.2.  After passing through the SPE cartridges, all 
samples were dried down using a Savant SPD121D SpeedVac concentrator (Thermo 
Fisher Scientific; Loughborough, UK) and then re-dissolved in purified H2O from a 
Milli-Q purification system (Direct-Q® 3 UV System, Millipore Corporation, USA) to 
1 µg/µL.   
Peptide fractionation using solid phase extraction (SPE) cartridges.  2.5 mg of 
5CP was loaded onto a C18 RP and HILIC SPE cartridges at pH 2 and pH 6.8 
respectively.  9 fractions were collected from each SPE cartridge extraction by varying 
the percentage of acetonitrile (ACN) in the elution buffers (see Supplementary 
Information Figure S4.2A and S4.2B).  Similarly, 5 mg of yeast was loaded onto a 
C18 RP SPE cartridge at pH 2 and 16 fractions were collected by increasing the 
percentage of ACN in the elution buffers (see Supplementary Information, Figure 
S4.2C).  All individual fractions of 5CP and yeast were then dried down using a 
Savant SPD121D SpeedVac concentrator and re-dissolved in 300 µL of H2O (~ 1 µg/µL 
with an assumption of peptides were evenly distributed across fractions). 
 
Data Acquisition.  
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Data Acquisition of FTICR MS and 2DMS spectra.  All samples were diluted 4-
fold to 0.25 µg/µL to a final solvent ratio of 75:25:0.1 water:acetonitrile:formic acid 
(H2O:ACN:FA).  The samples were then centrifuged at 13,000 rpm for 10 minutes 
prior to MS and 2DMS analysis.  For FTICR MS and 2DMS experiments, samples 
were acquired using nano-electrospray ionization (nESI) with a capillary voltage of 0.6 
– 1.0 kV and a source temperature of 180oC.  nESI glass capillaries (World Precision 
Instruments, England) were pulled to ~ 1 μm internal diameter (i.d.) using a Sutter P-
97 capillary puller instrument (One Digital Drive, Novato, USA).  Samples were 
loaded onto the glass capillaries and a nickel chromium wire (Jacobs, USA) was 
inserted to provide the electric potential connection for ionization. 
All mass spectra were acquired on a 12 tesla solariX FTICR MS (Bruker Daltonics, 
Bremen, Germany) in positive ionization mode.  Sample ions were first accumulated 
from 0.02 – 0.1 seconds in a hexapole collision cell before being directed to an infinity 
ICR cell for excitation and detection.40 
Standard FTICR MS spectra were acquired with 4 mega-word (M) data-points (32 
bits) over a mass range of m/z 147 – 3,000 to produce 1.67 second transients.  Different 
acquisition parameters were applied to the 2DMS spectra in order to optimize analytical 
performance.  In brief, 2DMS spectra with fragment m/z dimension of 128 k/256 k/1 
M/2 M data-points over a mass range of m/z 147 – 3,000 and precursor m/z dimension 
(increments of t1) of 4 k/ 8 k scan lines over a mass range of m/z 328 – 3,000 were 
acquired; the acquisition details of each 2DMS spectrum are summarized in 
Supplementary Information Table S4.1 and S4.2.  A 25 W continuous-wave CO2 
infrared laser was used for infrared multiphoton dissociation (IRMPD) in the 2DMS 
experiments, the pulse length and the power of the laser was set to 0.45 µs and 12.5 W 
respectively.   
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Figure 4.1.  A summarised workflow of the sample preparation as well as 2DMS data 
acquisition of the offline fractionated yeast samples from S. Cerevisiae. 
 
Data Acquisition of nano-Liquid Chromatography tandem MS (nLC MS/MS).  
An 18 cm in-house packed C18 RP nLC column (75 µm internal diameter) was 
connected to an EASY-nLC II system (Thermo Fisher Scientific; Loughborough, UK) 
to separate the peptides of BSA, 5CP, and yeast samples.  0.06 µg and 0.2 µg of BSA 
and 5CP samples respectively were loaded onto the C18 RP column, and a 30-minute 
effective gradient from 5% to 30% ACN in a 90-minute experiment was used (see 
Supplementary Information, Figure S4.3A).  1.5 µg of yeast sample was loaded onto 
the C18 RP column, and an extended 120-minute effective gradient from 5% to 30% 
ACN in a 180-minute runtime experiment was used (see Supplementary Information, 
Figure S4.3B).   
The MS spectra of nLC MS/MS were acquired with 1 M data-points to 0.42 second 
transients.  The eluted peptides from nLC were sprayed into the FTICR MS, the ions 
were accumulated in the hexapole for 0.3 s and transferred to the infinity cell for 
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detection.  Auto MS/MS functionality was used to fragment the ions which contained 
charge states ranging from 1+ to 5+ as well as peak intensities with threshold higher 
than 1E6.  The energies applied in collisionally activated dissociation (CAD) for 
peptide fragmentation were automatically determined according to the masses and 
charges of the ions (see Supplementary Information, Table S4.3).  Ions that contained 
the same m/z ratio (±10 ppm) were excluded from CAD MS/MS automatically for 1 
minute during the experiment to avoid redundant multiple MS/MS events in a similar 
fashion to AL Rocha et al.41 
 
Data Processing.  
One dimensional (1D) MS spectra.  The 1D FTICR MS spectra collected for 
determination of precursor ions were analysed using Bruker DataAnalysis 4.2 software 
(Bruker Daltonics, Bremen, Germany).  Four peptides with known m/z ratio (for BSA 
and 5CP samples) were used to internal calibrate each spectrum.  The Fourier 
transform mass spectrometry (FTMS) peak picking algorithm provided in DataAnalysis 
4.2 software was applied to generate the precursor ion peak list which included the 
peaks with a signal-to-noise (S/N) ratio higher than 10 as well as the charge state 
determination of each peak.  
2DMS spectra.  The 2DMS spectra were first processed with the Spectrometry 
Processing Innovative Kernel (SPIKE) software on the high performing computers 
cluster, Tinis, at the University of Warwick and the urQRD denoising rank was set at 
15.42  The processed data were then loaded onto an in-house T2D software to visualize 
and process the 2DMS spectra, the entire 2DMS spectrum was then inversely Fourier 
transformed and processed, line-by-line to produce transients for export to binary file 
format for Bruker programs (.ser files).  The transients (for the fragment m/z 
dimension) were reduced by half and zero-filled twice using FTMS Processing software 
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(Bruker Daltonics, Bremen, Germany) in order to improve the peak shape.43  The 
processed 2DMS data were imported into Bruker DataAnalysis 4.2 software and a scan 
with known m/z fragments was internally calibrated, the calibration constants were then 
applied to the other scans in the same 2DMS spectrum.  The peaks with S/N ratio over 
5 in each scan line (precursor m/z dimension) were picked and a calibrated peak list was 
generated. 
Mascot database search.  The peaks generated from 1DMS spectra (precursor 
ions) were combined with the 2DMS peak list (fragment ions) to produce the files 
in .mgf format for mascot database search.  The files were submitted to MS/MS Ions 
Search on MASCOT server with carbamidomethyl (C) set as fixed modification, and 
deamidated (NQ), oxidation (HMW), as well as phospho (STY) set as variable 
modifications.  In the MS/MS search, the missed cleavage was set to 1, the peptide 
tolerance was set to 1 ppm (for 2DMS BSA and 5CP)/ 8 ppm (for 2DMS yeast and nLC 
MS/MS), and the MS/MS tolerance was set to 8 ppm.  The 2DMS spectra were then 
manually matched with the shortlisted peptides assigned by MASCOT as the general 
peptide scoring system used in MASCOT could not be fully applied to 2DMS data (see 
Supplementary Information, Figure S4.4).  The hydrophobicity and isoelectric point 
(pI) of peptides were calculated using the Sequence Specific Retention Calculator44 and 
the Compute pI/MW tool.45  
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4.4 Results and Discussion 
 Comparison of 2DMS and nLC MS/MS using digested BSA.  Digested BSA 
provides a standard proteomic sample to evaluate the performance of different 
systems.46, 47  Herein, digested BSA was used to evaluate 2DMS for proteomic 
applications by comparing with the results obtained from a standard nLC MS/MS 
obtained on the same instrument.  A 2DMS spectrum, with 256 k * 4 k data-points 
(fragment m/z dimension * precursor m/z dimension), was obtained (see Figure 4.2A) 
and displayed as a contour plot of all peaks with an absolute intensity greater than 1E7 
which is ~ 300 S/N ratio at m/z 600.  The resolving power (full width half maximum) 
of the fragment m/z and the precursor m/z dimensions were ~ 25 k and ~ 1 k at m/z 
449.8 respectively (see Figure 4.2B).  The 1 k resolving power of the precursor m/z 
dimension was not sufficient to baseline-resolve the 2+ charge state ion at m/z 449.8 in 
a single dimension; however, with an additional fragment m/z dimension the contour 
peaks in Figure 4.2B were completely resolved.  The results indicate that the total 
resolving power in 2DMS is higher than a 1DMS dimension, demonstrating the 
capability of 2DMS to resolve peaks with a small m/z ratio difference in a complex 
proteomic sample which can’t be isolated in a single MS dimension.   
 In the 2DMS spectrum, the auto-correlation line (m/z precursor = m/z fragment) 
represents all the precursor ions fragmented in the 2DMS experiment (see Figure 4.2C).  
The precursor ions (on the auto-correlation line) of digested BSA in the 2DMS spectrum 
were similar to its 4 M data-points 1DMS spectrum (see Supplementary Information, 
Figure S4.5).  Thus, the peaks in the 1DMS spectrum could be used for the precursor 
ion masses in database searches to improve calibration and 1D resolving power. 
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Figure 4.2.  2DMS spectrum of BSA tryptic digest.  (A) The 2DMS spectrum of 
digested BSA acquired with 256 k * 4 k data-points (fragment m/z dimension * 
precursor m/z dimension).  (B) Zoom-in of the 2DMS spectrum at m/z 449.8 region.  
Extractions of the (C) auto-correlation line (red arrow) and (D) 5 consecutive 
fragmentation scans (blue arrow) from the 2DMS spectrum in Figure 4.2A.   
 
2DMS is a truly data independent acquisition method in which all detectable ions 
are fragmented simultaneously.  Figure 4.2D shows the five consecutive 
fragmentation scans (from line number 2,758 to 2,762) in the 2DMS spectrum of the 
digested BSA which involved the fragmentation of two peptides with an m/z difference 
of ~ 2.  In the 2,758th scan, the peptide ATEEQLK with an m/z of 818.4268 was 
assigned with the presence of the y4 and y5 fragments.  The intensity of the precursor 
ion decreased ~ 2.4-fold with the scan number increased from 2,758 to 2,760.  In the 
2,760th scan, the 2DMS spectrum contained two precursor ions which represented the 
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peptides of ATEEQLK and KVPQVSTPTLVEVSR were co-fragmenting, the key 
fragments from both peptides, therefore, were observed in the same 2DMS spectrum.  
From the scans of 2,760 to 2,762, the intensity of the precursor ion increased again as 
the scanning precursor ion mass was approaching m/z 820.4771 which was the m/z ratio 
of the KVPQVSTPTLVEVSR peptide.  In the 2,762th scan, y6, y11, y12, as well as y13 
fragments from KVPQVSTPTLVEVSR were observed while the fragments from 
ATEEQLK peptide were not detected.  Thus, we can baseline-differentiate the 
fragments of a peptide at m/z 818.43 from another of m/z 820.48, which demonstrated 
the advantage of using 2DMS over quadrupole isolation to separate ions with close m/z 
ratios as the ions were entirely isolated in two 2DMS spectra using an automatic pulse 
program without prior separation in a true data independent fashion, and the same effect 
is observed automatically throughout the 2DMS, demonstrating the potential of 
applying 2DMS to the study of complex proteomic samples with minimal or no LC 
separation. 
 Using the nLC FTICR CAD MS/MS, 42 peptides of the digested BSA were 
assigned, the sequence and cleavage coverages of BSA were 62% and 49% respectively 
(see Supplementary Information, Figure S4.6).  The 2DMS of digested BSA with 
IRMPD fragmentation assigned 31 peptides which covered 51% of the sequence as well 
as 34% of the cleavage sites (see Supplementary Information, Figure S4.7).  
Combining the results of 2DMS with nLC MS/MS, 47 peptides in total were identified 
which covered 68% and 57% of the sequence and the potential cleavage sites (see 
Figure 4.3A).  26 out of 47 peptides (55%) were commonly identified in the 2DMS 
and nLC MS/MS experiments (see Figure 4.3B) and the fragments obtained from the 
2DMS were comparable with the nLC MS/MS results (see Figure 4.3D).  
Complementary fragments were observed in 2DMS compared to nLC CAD MS/MS.  
The data showed the capability of 2DMS to analysis proteomic samples as nLC MS/MS.
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Figure 4.3.  Proteomic results of BSA tryptic digest using 2DMS and nLC MS/MS.  
(A) Fragmentation map of digested BSA using 2DMS and nLC MS/MS.  (B) Venn 
diagram showing the overlapping of the identified peptides from 2DMS and nLC 
MS/MS experiments.  (C) Box chart showing the range of hydrophobicity, pI, and 
length covered by 2DMS only (yellow), 2DMS and nLC MS/MS (purple), and nLC 
MS/Ms only (green).  (D) Spectra showing example peptides assigned by 2DMS (left) 
and nLC MS/MS (right) experiments.  (E) Spectra showing peptides exclusively 
assigned by the 2DMS experiment.  
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Five peptides (11%) were exclusively detected by the 2DMS experiment with 
good sequence coverage that could not be assigned in the nLC MS/MS experiment (see 
Figure 4.3B & Figure 4.3E).  The average hydrophobicity and the length of the 
peptides that were exclusively assigned by 2DMS were lower than those being assigned 
by the nLC MS/MS experiment, suggesting 2DMS has the advantage in detecting 
hydrophilic and/or short peptides over nLC MS/MS (see Figure 4.3C).  The exclusive 
peptides being identified by 2DMS also contained higher pI value which implied those 
peptides were composed of more basic amino acid residues.  The results herein 
showed peptides that were hydrophilic, short, and basic could be exclusively assigned 
by a 2DMS experiment, while these peptides were likely not retained on the column of 
RP-LC.  These data suggested the results obtained from the 2DMS and nLC MS/MS 
experiments were partially complementary and the sequence as well as cleavage 
coverages were significantly enhanced when both methods were applied.   
 
Comparison of 2DMS and nLC MS/MS using a mixture of standard digested 
proteins.  A mixture of 5 digested proteins (5CP) was used to further evaluate the 
performance of 2DMS compared to nLC MS/MS.  75 peptides of 5CP were assigned 
in a nLC MS/MS experiment and the average sequence as well as cleavage coverages 
per protein were 60% and 47% respectively (see Supplementary Information, Figure 
S4.8).  Using the same sample in the 2DMS experiment (256 k * 4 k data-points), only 
30 peptides were assigned without prior separation, the average sequence and cleavage 
coverages per protein were 35% and 19% respectively (see Supplementary Information, 
Figure S4.9).  This result showed that the performance of 2DMS was limited 
compared to nLC MS/MS for a more complex proteomic sample, suggesting either 
prior sample preparation or higher resolution of 2DMS experiment is required, so 
partial fractionation using SPE cartridge was explored in the first instance.  
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Three different SPE cartridges, including RP, HILIC, and SAX, were used to 
enrich peptides with various physical properties,39 to vary the types of peptides 
observable in the 2DMS experiments.  A 2DMS spectrum (256 k * 4 k data-points) 
was acquired for each of the SPE enriched sample (see Supplementary Information, 
Figure S4.10 – S4.14), the numbers of peptide assigned from each experiment were 51 
(RP pH 2), 35 (HILIC pH 6.8), 37 (RP pH 10), and 33 (SAX pH 10) (see Figure 4.4A).  
The Venn diagram of the peptides identified by various SPE cartridges showed that 
most of the peptides were able to be observed in the conditions of C18 RP at pH 2 and 
HILIC at pH 6.8, suggesting further experiments could focus on these two enrichment 
samples as they could provide the highest sequence coverage of the digested 5CP 
sample.   
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Figure 4.4.  Proteomic results of 5CP tryptic digest using 2DMS with SPEs 
enrichment and nLC MS/MS.  (A) The number and Venn diagram of peptides from 
5CP identified by C18 RP at pH 2 (purple), HILIC at pH 6.8 (cyan), C18 RP at pH 10 
(pink), and SAX at pH 10 (green).  (B) Venn diagram of peptides being identified by 
2DMS via SPE cartridge enrichment and nLC MS/MS.  (C) Box chart diagram to 
show the hydrophobicity, pI, and length of peptides being detected in 2DMS and nLC 
MS/MS. (D) Spectra showing the exclusive peptides being assigned by 2DMS 
experiments.  (E) Fragmentation maps of the digested 5CP showing the 
complementary results of 2DMS and nLC MS/MS experiments. 
 
From the 5CP sample, 69 peptides in total were assigned from the 2DMS spectra 
of the SPE enriched samples and the average sequence as well as cleavage coverages 
per protein were 45% and 29% respectively (see Supplementary Information, Figure 
S4.15).  Compared to the non-enriched 2DMS result, 10% additional coverage was 
observed in both average sequence as well as cleavage coverages.  26 out of 101 
peptides (26%) were exclusively detected in the 2DMS spectra with good sequence 
coverage while 43% of the peptides were mutually observed in both 2DMS and nLC 
MS/MS spectra (see Figure 4.4B & 4.4D).  The average sequence and cleavage 
coverages per protein were enhanced by 8% and 6% respectively (see Figure 4.4E) by 
combining the results to the nLC MS/MS data (see Supplementary Information, Figure 
S4.8).  As seen previously, the more hydrophilic, basic, and short peptides were 
exclusively identified in the 2DMS experiment; the range of physical properties, 
however, were enhanced after the SPE cartridges enrichment (see Figure 4.4C).  The 
results here demonstrated the peptides’ properties were diversified through SPE 
enrichment, more exclusive peptides were detected in the experiments of 2DMS which 
resulted in enhancing the sequence and cleavage coverages of the proteins when the 
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data of 2DMS and nLC MS/MS were combined.  More importantly, the solvents used 
in each 2DMS experiment could be varied due to the different buffers required for SPE 
cartridge enrichment; but the variations in solvents did not affect the performance of 
the 2DMS experiments, suggesting this method could remove some solvent limitations 
and retention bias.  
 
Figure 4.5.  High resolution 2DMS spectrum of 5CP tryptic digest.  (A) 2DMS 
spectrum with resolution 1 M * 8 k data-points (fragment m/z * precursor m/z) of 
digested 5CP which was enriched by C18 RP SPE cartridge at pH 2.  (B) Zoom-in of 
the 2DMS spectrum at the m/z 437.8 region.  (C) The 14 consecutive fragmentation 
scans (from scan number 2,306 to 2,319) extracted from the 2DMS spectrum which 
correspond to the HGLDYR peptide.   
 
Optimisation of acquisition parameters was also explored to improve 2DMS 
proteomic using 5CP (see Supplementary Information, Figure S4.16 – S4.21).  
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Unsurprisingly using a higher resolution in both fragment and precursor m/z dimensions 
(1 M * 8 k data-points) increased detectable fragment intensity, allowing more 
fragments to be observed and assigned in the 2DMS spectrum of the digested 5CP with 
SPE enrichment (see Figure 4.5A), and the 2DMS experiment time expanded from ~ 
55 minutes to ~ 167 minutes (see Supplementary Information, Table S4.1).  The peak 
resolutions (at m/z 437.8) in the fragment and precursor m/z dimension were ~ 96 k and 
~ 2 k respectively (see Figure 4.5B), additionally these resolutions improved peak 
shapes in the 2DMS spectrum through resolving closely spaced peaks and enhanced 
peak S/N ratios which assisted in peptide assignment (see Supplementary Information, 
Figure S4.22).   
Increasing the resolution in the fragment and precursor m/z dimensions did not 
only enhance the number of peptides identified, but also improved separation in the 
mass of precursor ion.  In Figure 4.5C, 14 consecutive fragmentation scans were 
extracted from the 2DMS spectrum (1 M * 8 k data-points) of the digested 5CP (see 
Figure 4.5A), these 14 scans all show the HGLDNYR peptide at m/z 437.7119 (2+).  
The intensity of the precursor ion (green region) increased twice within these spectra 
which were between the 2,306th and 2,309th scans and the 2,313th and 2,316th scans, 
similar intensity variation was observed in the key fragment (y6) ion (pink region).  
Zooming-in the m/z region of the precursor ion clearly shows the first increment in 
intensity was due to the rise of the 1st isotope of the precursor ion (between the 2,306th 
and 2,309th scans) and the second increment in the intensity was caused by the rise of 
the 2nd isotope of the precursor ion (between the 2,313th and 2,316th scans); as a result, 
a similar observation was also obtained for the y6 fragment.  Thus, 2DMS has baseline 
separated precursor and fragments at the individual isotope level which is difficult to 
achieve using quadrupole or even in-cell isolations in a data independent fashion.  
This capability will be particularly useful for separation of fragments from nearby 
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precursors such as the peaks between deamidated and non-deamidated species (Δ mass 
= 0.984 Da).48, 49 
 Mass range fractionation using several wide mass isolation windows in the 
quadrupole (see Supplementary Information, Figure S4.23 – S4.24) as well as SPE 
offline fractionation (see Supplementary Information, Figure S4.25 – 4.26) were 
applied in combination to reduce the number of ions in the FTICR cell and minimize 
ion suppression effects, so that the number of peptides being identified by 2DMS could 
be enhanced further.  The results of the mass range fractionation showed that the 
number of peptides could be significantly enhanced (RP identified: 64 and HILIC 
identified: 85), as a result, a better sequence and cleavage coverages were achieved (see 
Supplementary Figure S4.27 – S4.28).  The data showed that the number of peptides 
being identified by 2DMS could reach a similar, or even better than that of standard 
nLC MS/MS without online LC separation and extra sample preparation, suggesting 
this method is suitable for the study of complex proteomic samples as limited sample 
preparation and separation was required; while still able to achieve similar results as 
standard nLC MS/MS.  
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Figure 4.6.  Proteomic results of 5CP tryptic digest using 2DMS with SPE offline 
fractionation and nLC MS/MS.  (A) Peptides identified in each offline fraction using 
RP (pink) and HILIC (cyan) SPE technique.  (B) Venn diagram showing the 
overlapping of peptides that identified in 2DMS (fractionated) and nLC MS/MS.  (C) 
Box chart showing the physical properties of the peptides that identified in 2DMS 
(fractioned) and nLC MS/MS.  (D) Spectra of the exclusive peptides identified using 
2DMS.  (E) Fragmentation maps of digested 5CP using offline fractionation 2DMS 
and nLC MS/MS. 
 
The offline SPE fractionation using RP and HILIC cartridges provided the highest 
sequence and cleavage coverages for the 5CP among all the methods tested (see 
Supplementary Information, Figure S4.29 and S4.30).  92 and 85 peptides in total 
were assigned by the RP and HILIC fractionation 2DMS, respectively (see Figure 4.6A), 
and more peptides were assigned using either one of these methods compared to nLC 
MS/MS.  Thus, the offline SPE fractionation provided a similar or better analytical 
ability than nLC MS/MS in proteomic study.   
121 peptides were assigned using the offline fractionation 2DMS and nLC MS/MS 
results (see Figure 4.6B).  47 out of 121 peptides (39%) were exclusively identified 
using 2DMS.  The average sequence and cleavage coverages per protein were 76% 
and 61%, respectively, (see Figure 4.6E) which has been increased by 27% and 30% 
compared to purely nLC MS/MS (see Supplementary Information, Figure S4.8).  
These results, once again, showed that the data obtained from 2DMS and nLC MS/MS 
were complementary, thus applying both 2DMS and nLC MS/MS could provide the 
highest sequence and cleavage coverages of proteins.  The box chart diagram in Figure 
4.6C shows the peptides exclusively assigned by 2DMS were more hydrophilic, basic, 
as well as shorter in general than nLC MS/MS as previously noted.  However, the 
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ranges of the physical properties were the widest compared to the previous 2DMS 
results, suggesting the offline SPE fractionation was a better method to diversify the 
types of peptides observable in 2DMS.  The most significant improvement in using 
offline fractionation was relatively long peptides with good sequence coverage were 
able to be detected and assigned in the 2DMS spectra (see Figure 4.6D).   
 
Comparison of 2DMS and nLC MS/MS using digested yeast.  From the 
2DMS results of the digested 5CP, the high resolution (1 M * 8 k data-points) and C18 
RP SPE cartridge offline fractionation 2DMS experiments yielded the highest number 
of identified peptides per sample.  Thus, these two acquisition methods were 
combined and applied to the digested yeast sample to evaluate the performance of 
2DMS in complex proteomic studies.  The digested yeast sample was first analysed 
using nLC MS/MS (see Supplementary Information, Figure S4.31), 153 proteins and 
332 peptides were identified at 1% false discovery rate (FDR).  The number of 
proteins and peptides being identified in this nLC MS/MS experiment was not as high 
as the previous literature,21 mainly because the scan rate in FTICR MS limited the 
number of tandem MS/MS spectra acquired per injection.  
The digested yeast sample was then analysed using 2DMS with 1 M * 8 k data-
points (see Supplementary Information, Figure S4.32A).  28 peptides corresponding 
to 20 yeast proteins were manually assigned in the 2DMS spectra, and 16 peptides (57%) 
were exclusively observed in the 2DMS (see Supplementary Information, Figure 
S4.32B – S4.32D).  The number of peptides being identified in the 2DMS without 
fractionation was lower than expected, the main reason was due to the complexity of 
the digested yeast sample (see Supplementary Information, Figure S4.33).  In the 5CP 
and the yeast 2DMS experiments, samples were both diluted into 0.25 µg/µL and 
sprayed into the MS.  In the 5CP sample, there were ~ 400 peptides (including 1 
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missed cleavage) and the dynamic range of the sample was around an order of 
magnitude; however in the digested yeast, it contained more than 577,000 tryptic 
digested peptides (no missed cleavage included) and the dynamic range of the proteins 
was at least 6 orders of magnitude.50  The concentration per peptide in the yeast 
solution, therefore, was much lower than the peptide concentration in the 5CP sample.  
Since the initial intensity as well as the fragmentation efficiency were the two factors 
that influenced the intensities of fragments, thus the fragments obtained in the 2DMS 
spectrum of yeast were extremely low that the fragment peaks could not picked by the 
software used.  Further optimisation of the loading of sample for yeast 2D MS analysis 
is ongoing.
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Figure 4.7.  Comparison of SPE fractionated 2DMS and nLC MS/MS results for yeast tryptic digest.  (A) Graph showing the accumulated 
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number of proteins and peptides being identified in each offline fraction using 2DMS as well as nLC MS/MS.  (B) Venn diagram showing the 
complementary proteins and peptides assigned in 2DMS and nLC MS/MS experiments.  (C) Box chart showing the physical properties of the 
peptides identified in 2DMS only (yellow), 2D and nLC (purple), and nLC only (green).  (D) 2DMS spectra showing peptides exclusively 
assigned by 2DMS.
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The yeast sample was then separated into 16 fractions using a C18 RP SPE 
cartridge, shown above to achieve a higher number of peptide assignments (see Figure 
4.6).  16 2DMS spectra in total with 256 k * 4 k data-points each were then acquired 
(see Supplementary Information, Figure S4.34 – S4.35).  147 proteins and 243 
peptides in total were manually assigned in the experiment (see Figure 4.7A).  The 
results here show that the number of proteins being identified in 2DMS was similar to 
the result obtained from nLC MS/MS (147 vs 153), but the assigned peptides in the 
2DMS experiment were ~ 25% fewer than the nLC MS/MS experiment (243 vs 332).  
Combining the results of 2DMS with nLC MS/MS, 258 proteins and 505 peptides in 
total were identified; however, only 42 proteins (16%) and 70 peptides (14%) were 
commonly assigned in both experiments (see Figure 4.7B).  The numbers of protein 
and peptides were doubled compared to purely 2DMS or nLC MS/MS result, indicating 
the data provided by 2DMS and nLC MS/MS experiments were largely complementary, 
which is useful to enhance the analysis coverage of proteomes.  The 243 yeast peptides 
which were assigned in the 2DMS experiment were further compared with the previous 
literature that has been recognized as the benchmark of protein and peptide assignments, 
for yeast, being assigned in a single experiment (see Supplementary Information, 
Figure S4.36).18  126 out of 243 peptides (52%) from 2DMS experiment were 
commonly assigned in both experiments, which indicated 48% of the peptides were not 
detected previously, showing certain areas of the proteome may be more easily accessed 
or studied using 2DMS than standard nLC MS/MS.  
The average value in the box chart of assignments (see Figure 4.7C) also showed 
the peptides that were exclusively assigned by 2DMS tends to be more hydrophilic, 
basic, and short as shown previously.  Example peptides that represented different 
physical properties and those exclusively assigned by 2DMS are shown in Figure 4.7D.  
The results of the yeast analysis effectively demonstrated the capability of 2DMS in 
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proteomic studies of complex systems as the number of proteins and peptides being 
assigned in the experiments were similar to that of nLC MS/MS experiment.  However, 
the peptides assigned in 2DMS were also frequently complementary to nLC MS/MS 
results.  Combining the results of 2DMS with nLC MS/MS enhanced the coverage of 
the yeast proteome.   
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4.5 Conclusion 
 The results presented demonstrate that 2DMS is a viable alternative technique for 
proteomic studies, showing online LC MS/MS is no long an unavoidable tool in 
proteomics. Therefore, many proteomic analyses, such as biomolecular non-covalent 
interactions, which are usually very limited by available LC solvent systems and the 
column chemistry of chromatography, are able to be performed using 2DMS.  
Furthermore, complementary protein and peptide assignments from the results of 
2DMS and nLC MS/MS suggests a deeper proteome coverage can be achieved by 
combing the data obtained from 2DMS and nLC MS/MS, which also indicates the 
proteomes that exclusively covered by 2DMS are currently under-studied by standard 
nLC MS/MS techniques. Thus 2DMS is not only an alternative but may be considered 
as a required complementary technique for deeper proteome analysis.  2DMS also 
shows to have a higher efficiency in observing hydrophilic, basic, or short peptides, 
suggesting 2DMS is also suitable for the application in PTMs analysis as most of the 
important PTMs in disease-related issue, such as phosphopeptides and glycopeptides, 
are extremely hydrophilic which is challenging to analysis using standard nLC MS/MS 
technique. 
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4.7 Supplementary Information 
 
Figure S4.1.  Four key 2DMS lines; autocorrelation (purple), neutral loss (cyan), 
vertical precursor ion scan (green), and horizontal fragment ion scan (red) lines, in a 
standard two dimensional mass spectrometry (2DMS) spectrum.  The auto-correlation 
line contains the same mass-to-charge (m/z) ratio in the x-axis (fragment m/z dimension) 
and the y-axis (precursor m/z dimension), representing the fragmented precursor ions 
in the spectrum.  The neutral loss line is produced by precursor ions (autocorrelation 
line) losing the same side chain group or molecule, such as water (mass difference of 
18 Da in the x-axis from the autocorrelation line).  The horizontal fragment ion scan 
line contains fragments from different precursor ions (represented by the number on the 
y-axis). 
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Table S4.1 to summarising experimental parameters of 5 combined proteins (5CP) analysis in 2DMS experiments 
  
File Name 
Buffer for  
loading & Elution 
Final Solvent Composition  
for nESI 
Acquisition File size 
(Fragment * Precursor) 
Acquisition Length File size 
Tinis 
Process  
Time 
non-desalted samples (BSA & 5 CP) 
2D_BSA (non-desalt) 
N/A 
H2O:ACN:FA 
75%:25%:0.1%  
256 k * 4 k 
55 - 59 minutes  
(depending on ion 
accumulation time) 
11.7 GB ~ 30 minutes 
2D_5CP (non-desalt) 
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(Table S4.1. Continue)       
File Name 
Buffer for  
loading & Elution 
Final Solvent Composition  
for nESI 
Acquisition File size 
(Fragment * Precursor) 
Acquisition Length File size 
Tinis 
Process  
Time 
Pass through SPE column - one step elution (5 CPs) 
2D_5CP 
C18 RP pH 2 
Load: H2O/0.1% FA 
Elute:80%ACN/0.1%FA 
H2O:ACN:FA 75%:25%:0.1%  
256 k * 4 k 
55 - 59 minutes  
(based on ion 
accumulation time) 
11.7 GB ~ 30 minutes 
2D_5CP 
C18 RP  pH 10 
Load: H2O/NH4OAc 
Elute:80%ACN/NH4OAc 
H2O:ACN:FA 75%:25%:0.1% 
2D_5CP 
HILIC pH 6.8 
Load: ACN/HCOONH4 
Elute:80%H2O/HCOONH4 
H2O:ACN:FA 75%:25%:0.1% 
2D_5CP 
SAX pH 10 
Load: 
H2O/ACN/NH4OH(pH10) 
Elute: H2O/ACN/FA(pH 2) 
H2O:ACN:FA 75%:25%:0.1%  
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File Name 
Buffer for  
loading & Elution 
Final Solvent Composition  
for nESI 
Acquisition File size 
(Fragment * 
Precursor) 
Acquisition 
Length 
File size 
Tinis 
Process  
Time 
Low Resolution and High Resolution (5 CPs) 
2D_5CP 
C18 RP pH 2_8192*128k 
Load: H2O/0.1% FA 
 
Elute: 80%ACN/0.1%FA 
H2O:ACN:FA 
75%:25%:0.1%  
128 k * 8 k 106 minutes 11.7 GB ~ 30 minutes 
2D_5CP 
C18 RP pH 2_8192*1M 
1 M * 8 k 167 minutes 93.1 GB ~ 5 hours 
2D_5CP 
C18 RP pH 2_4096*2M 
2 M * 4 k 110 minutes 92.9 GB ~ 5 hours 
2D_5CP 
HILIC pH 6.8_8192*128k 
Load: ACN/HCOONH4 
 
Elute: 80%H2O/HCOONH4 
H2O:ACN:FA 
75%:25%:0.1% 
128 k * 8 k 106 minutes 11.7 GB ~ 30 minutes 
2D_5CP 
HILIC pH 6.8_8192*1M 
1 M * 8 k 167 minutes 93.1 GB ~ 5 hours 
2D_5CP 
HILIC pH 6.8_4096*2M 
2 M * 4 k 110 minutes 92.9 GB ~ 5 hours 
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(Table S4.1 Continue) 
File Name 
Buffer for  
loading & Elution 
Final Solvent Composition  
for nESI 
Acquisition File size 
(Fragment * 
Precursor) 
Acquisition 
Length 
File size 
Process  
Time 
m/z Range Fractionation (5 CPs) 
2D_5CP 
C18 RP pH 2_m/z fraction 
 
- m/z 400/600/800 ± 200 
- m/z 1200 ± 600 
Load: H2O/0.1% FA 
Elute: 
80%ACN/0.1%FA 
H2O:ACN:FA 
75%:25%:0.1%  
256 k * 4 k 
55 - 59 minutes * 4  
(based on ion 
accumulation time) 
= ~ 228 minutes 
11.7 GB * 4 
=46.8 GB 
~ 30 
minutes  
(processed 
in parallel) 
2D_5CP 
HILIC pH 6.8_m/z fraction 
 
- m/z 400/600/800 ± 200 
- m/z 1200 ± 600 
Load: ACN/HCOONH4 
 
Elute: 
80%H2O/HCOONH4 
H2O:ACN:FA 
75%:25%:0.1% 
55 - 59 minutes * 4  
 
= ~ 228 minutes 
11.7 GB * 4 
=46.8 GB 
~ 30 
minutes  
(processed 
in parallel) 
 
  
Chapter 4 – The Next Dimension in Proteomics 
334 
 
(Table S4.1 Continue) 
File Name 
Buffer for  
loading & Elution 
Final Solvent 
Composition  
for nESI 
Acquisition File size 
(Fragment * Precursor) 
Acquisition 
Length 
File size 
Process  
Time 
Offline Fractionation (5 CPs) 
2D_5CP C18 RP pH 2_offline 
fractionation (9 fractions) 
Gradient:  
see RP gradient 
(see Figure S4.2) 
H2O:ACN:FA 
75%:25%:0.1%  
256 k * 4 k 
55 - 59 minutes * 9  
(based on ion 
accumulation time) 
= ~ 513 minutes 
11.7 GB * 9 
=105.3 GB 
~ 30 
minutes  
(processed 
in parallel) 
2D_5CP  
HILIC pH 6.8_offline 
fractionation 
(9 fractions) 
Gradient:  
see HILIC gradient  
(see Figure S4.2) 
H2O:ACN:FA 
75%:25%:0.1% 
55 - 59 minutes * 9  
 
= ~ 513 minutes 
11.7 GB * 9 
=105.3 GB 
~ 30 
minutes  
(processed 
in parallel) 
Table S4.1.  Summary of the experimental details of 5 combined proteins (5CP) in the 2DMS experiments. The offline fractionation gradients 
applied in C18 reserved phase (RP) and hydrophilic interaction chromatography (HILIC) solid phase extraction (SPE) cartridges are shown in the 
Supplementary Information Figure S4.2A and S4.2B. 
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Table to summarise all experimental parameters of yeast in 2DMS experiments 
Table S4.2.  Summary of the experimental details of tryptic digested yeast in the 2DMS experiments.  The offline fraction gradient applied in 
C18 RP SPE cartridge is shown in Supplementary Figure S4.2C.
File Name 
Buffer for  
loading & Elution 
Final Solvent 
Composition  
for nESI 
Acquisition File size 
(Fragment * 
Precursor) 
Acquisition Length File size 
Tinis Process  
Time 
Pass through SPE column - one step elution (Yeast) 
2D_Yeast 
C18 RP pH 2 
Load: H2O/0.1% FA 
 
Elute: 80%ACN/0.1%FA 
H2O:ACN:FA 
75%:25%:0.1%  
1 M * 8 k 167 minutes 93.1 GB ~ 5 hours 
       
Offline Fractionation (Yeast) 
2D_Yeast  
C18 RP pH 2_ 
offline 
fractionation 
(16 fractions) 
Gradient:  
see RP gradient 
H2O:ACN:FA 
75%:25%:0.1%  
256 k * 4 k 
55 - 59 minutes * 16  
(based on ion 
accumulation time) 
= ~ 912 minutes 
11.7 GB * 16 
=187.2 GB 
~ 30 minutes  
(processed in 
parallel) 
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Rolling Energy Equations Applied by the 12 T solariX 
 
 
Table S4.3.  Online CAD automatic MS/MS rolling energy parameters applied 
by 12 T Bruker solariX for nLC MS/MS analysis.  Using the values in Table S4.3, 
the collision energy for 1+ charge state peptides with m/z 300 – 1,500 are ranging 
from 25.1 eV to 57.5 eV, the collision energy for 2+ charge state peptides with m/z 
300 – 1,500 are ranging from 8.1 eV to 54.9 eV, and the collision energy for the 
3+/4+/5+ charge state peptides with m/z 300 – 1,500 are ranging from 7.6 eV to 
42.5 eV. 
  
Charge state Slope Intercept 
1+ 0.027 17.044 
2+ 0.039 -3.558 
3+/4+/5+ 0.029 -1.045 
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Figure S4.2.  Offline fractionation gradients of 5CP using (A) C18 RP SPE 
cartridge at pH 2 and (B) HILIC SPE cartridge at pH 6.8.  The ACN (H2O) 
percentages used for 5CP peptides elution in the C18 RP SPE cartridge are 18% 
(82%), 22% (78%), 26% (74%), 30% (70%), 34% (66%), 45% (55%), 55% (45%), 
70% (30%), and 80% (20%); and 9 offline fractions in total were collected.  The 
ACN (H2O) percentages used for peptides elution of 5CP in the HILIC SPE 
cartridge are 72% (28%), 70% (30%), 68% (32%), 66% (34%), 60% (40%), 55% 
(45%), 45% (55%), 30% (70%), and 20% (80%); and 9 offline fractions in total 
were collected.  (C) The offline fractionation gradient graph of yeast using C18 
RP SPE cartridge at pH 2.  The ACN (H2O) percentages used for yeast peptides 
separation are 16% (84%), 18% (82%), 20% (80%), 22% (78%), 24% (76%), 26% 
(74%), 28% (72%), 30% (70%), 32% (68%), 34% (66%), 40% (60%), 45% (55%), 
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50% (50%), 55% (45%), 60% (40%), and 80% (20%); and 16 offline fractions in 
total were collected.  
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Figure S4.3.  The nLC gradient of the tryptic digested (A) BSA and 5CP, as well 
as (B) yeast.  The solvents used for C18 RP nLC columns are H2O and ACN with 
0.1% formic acid.  The effective gradients for peptide separation are between 5% 
and 30% ACN in 30 and 120 minutes for standard proteins and yeast samples 
respectively, including the time of sample loading and nLC column re-
equilibration, the total runtimes are 90 and 120 minutes for the samples 
respectively.   
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Figure S4.4.  2DMS spectra of (A) DVFLGMFLYEYAR from HSA and (B) 
KVLGAFSDGLAHLDNLK from HHB, which were classified as unassigned 
peptides in the MASCOT search.  In MASCOT database search, the intensity of 
fragment ion is one of the key factors which affects the score of peptide assignment, 
and a minimum of score ~ 13 is required for a confident peptide assignment.  In 
collisionally activated dissociation tandem MS (CAD MS/MS), the intensity of 
precursor ion decreases while the intensities of fragment ions increase.  Thus, the 
intensities of the fragment ions are similar or even higher than the intensity of 
precursor ion.  In 2DMS spectrum, the intensities of peaks (both precursor and 
fragment ions) depend on the original intensity as well as the change of magnitude 
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during fragmentation.29  Thus, the intensity of precursor ion is much higher than 
the intensities of fragment ions in the 2DMS spectrum.  Furthermore, the 
presence of the strong harmonics in both precursor m/z and fragment m/z 
dimension, which are treated as noise peaks in MASCOT searching engine and 
further reduces the scores of peptides.  Even though the average mass accuracies 
of precursor and fragment ions are below 1 ppm, the scores for peptides are still 
quite low.  
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Figure S4.5.  Spectra of digested BSA in (A) an 1DMS spectrum and (B) an 
extraction of auto-correlation line in the 2DMS spectrum.  The auto-correlation 
line is the most closely compacted scan in the 2DMS spectrum, a high resolution 
scan, therefore, is required.  For the 1DMS spectrum, the data were acquired with 
4 M data-points, 10 spectra accumulation; and the acquisition time was ~ 1 minute.  
The resolution of m/z 449.8 in the 1DMS spectrum is ~ 351 K, which is 14 times 
higher than the resolution of the 2DMS with 256 k data-points on the fragment m/z 
dimension (see Figure 4.2B).  In order to obtain a similar resolution (4 M) in the 
fragment m/z dimension, a 3-hour 2DMS experiment would be required.  The 
precursor ions (on the auto-correlation line) of digested BSA in the 2DMS 
spectrum are similar to the 1DMS spectrum of the digested BSA, thus the peaks in 
1DMS can be used as the accurate masses of precursor ions for database searches 
for 2DMS.  
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Figure S4.6.  Fragmentation map of the digested BSA with 62% sequence 
coverage and 49% cleavage coverage using nLC FTICR CAD MS/MS.  The 
peptides assigned by nLC MS/MS are highlighted in green.  
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Figure S4.7.  Fragmentation map of the digested BSA with 51% sequence 
coverage and 34% cleavage coverage using IRMPD 2DMS.  The peptides 
assigned by 2DMS are highlighted in yellow.  
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Figure S4.8.  Fragmentation maps of the digested 5CP using nLC FTICR CAD 
MS/MS.  The peptides assigned by nLC MS/MS are highlighted in green.   
Chapter 4 – The Next Dimension in Proteomics 
346 
 
 
 
Chapter 4 – The Next Dimension in Proteomics 
347 
 
(Figure S4.9. Continue) 
 
Figure S4.9.  2DMS results of 5CP without prior purification and separation. 
(A) Fragmentation maps of the digested 5CP using IRMPD 2DMS.  The 
peptides assigned by 2DMS are highlighted in yellow.  (B) Venn diagram 
showing the difference of peptides identified by 2DMS and nLC MS/MS.  (C) 
Box chart showing the physical properties range of hydrophobicity, pI, and 
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length of the peptides identified by 2DMS and nLC MS/MS.  The number of 
peptides being identified by 2DMS is less than nLC MS/MS; however, 11 out of 
86 peptides (13%) are exclusively detected by 2DMS.  The box chart further 
shows the peptides identified by 2DMS are more hydrophilic, basic, and shorter 
than those in nLC MS/MS.  
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Figure S4.10.  2DMS spectra (256 k * 4 k) of digested 5CP enriched using SPE 
cartridges of C18 RP at pH 2, HILIC at pH 6.8, C18 RP at pH 10, and SAX at pH 
10. 
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(Figure S4.11. Continue) 
 
Figure S4.11.  2DMS results of 5CP with C18 RP pH 2 SPE cartridge 
purification.  (A) Fragmentation maps of digested 5CP with peptide enrichment 
using 2DMS with C18 RP SPE cartridge enrichment.  The peptides assigned by 
2DMS are highlighted in yellow.  (B) Venn diagram showing the difference of 
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peptides identified by 2DMS and nLC MS/MS.  (C) Box chart showing the 
physical properties range of hydrophobicity, pI, and length of the peptides 
identified by 2DMS and nLC MS/MS.  Compared to the non-enriched 2DMS 
experiment (see Supplementary Information, Figure S4.9), the number of unique 
peptide detected by 2DMS increases by 2 only; while the number of common 
peptide detected by commonly between 2DMS and nLC MS/MS has been 
doubled.  Furthermore, the hydrophobicity range of the exclusive peptides 
detected by 2DMS contains similar average hydrophobicity the peptides being 
detected by nLC MS/MS.  This result suggests more peptides can be observed 
by applying C18 RP pH 2 SPE cartridge enrichment as it helps to remove non-
peptide peaks in the spectrum and enhance the intensities of peptides.  
However, the peptides that can be observed in the 2DMS after RP enrichment 
containing similar physical properties to those peptides being detected in nLC 
MS/MS as RP-LC has been applied in both methods, in which the hydrophilic 
peptides are less likely to retain on the SPE RP cartridge. 
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(Figure S4.12. Continue) 
 
Figure S4.12.  2DMS results of 5CP with HILIC SPE cartridge purification. (A) 
Fragmentation maps of digested 5CP with peptide enrichment using HILIC SPE 
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cartridge at pH 6.8 and then analysed by IRMPD 2DMS.  The peptides assigned 
by 2DMS are highlighted in yellow.  (B) Venn diagram showing the difference of 
peptides being identified by 2DMS and nLC MS/MS.  (C) Box chart showing the 
physical properties range of hydrophobicity, pI, and length of the peptides 
identified by 2DMS and nLC MS/MS.  The number of peptides identified in the 
HILIC enriched 2DMS is similar to the number of peptides that has been identified 
in non-enriched 5CP sample (see Supplementary Information, Figure S4.9).  The 
hydrophobicity of the peptides being exclusively identified in the HILIC enriched 
2DMS is much lower than the peptides that identified in nLC MS/MS.  Despite 
the number of peptides being identified in the 2DMS (HILIC enrichment) does not 
increase sharply, the physical properties of the identified peptides are significantly 
different from those being detected in nLC MS/MS which suggests combining the 
HILIC enrichment 2DMS with nLC MS/MS can enhance the sequence and 
cleavage coverage of the proteomics sample.   
  
Chapter 4 – The Next Dimension in Proteomics 
356 
 
 
 
Chapter 4 – The Next Dimension in Proteomics 
357 
 
(Figure S4.13. Continue) 
 
Figure S4.13.  2DMS results of 5CP with C18 RP pH 10 SPE cartridge 
purification.  (A) Fragmentation maps of digested 5CP with peptide enrichment 
using 2DMS with C18 RP SPE cartridge enrichment at pH 10.  The peptides 
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assigned by 2DMS are highlighted in yellow.  (B) Venn diagram showing the 
difference of peptides being identified by 2DMS and nLC MS/MS.  (C) Box chart 
to show the physical properties range of hydrophobicity, pI, and length of the 
peptides that were identified by 2DMS and nLC MS/MS.  Similar observations 
in the physical properties of the peptides being identified using RP SPE cartridge 
at pH 2 and pH 10, but the number of peptides identified by RP SPE cartridge after 
pH 10 is less than the number of identified peptides at pH 2 (see Supplementary 
Information, Figure S4.11).    
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(Figure S4.14. Continue) 
 
Figure S4.14.  2DMS results of 5CP with SAX SPE cartridge purification.  (A) 
Fragmentation maps of digested 5CP with peptide enrichment using 2DMS with 
SAX SPE cartridge enrichment.  The peptides assigned by 2DMS are highlighted 
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in yellow.  (B) Venn diagram showing the difference of peptides being identified 
by 2DMS and nLC MS/MS.  (C) Box chart diagram showing the physical 
properties range of hydrophobicity, pI, and length of the peptides that were 
identified by 2DMS and nLC MS/MS.  The enrichment with SAX cartridge 
shows the highest number of exclusive peptides being detected by 2DMS which 
suggests complementary data can be obtained when sample is analysed by SAX 
enriched 2DMS as well as nLC MS/MS.   
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Figure S4.15.  The combined fragmentation maps of 5CP using 4 different SPE 
cartridges enrichment and then analysed by 2DMS.   
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Figure S4.16.  2DMS spectra of the digested 5CP with C18 RP pH 2 
enrichment conducting in various resolutions of fragment and precursor m/z 
dimensions.  The 2DMS contour plots are displayed in same intensity. 
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(Figure S4.17. Continue) 
 
Figure S4.17.  The fragmentation maps of the digested 5CP with C18 RP 
Chapter 4 – The Next Dimension in Proteomics 
367 
 
enrichment at pH 2 using 2DMS with resolutions at 128 k * 8 k (left) and 256 k * 
4 k (right).  The peptides assigned by 2DMS are highlighted in yellow.  The 
average sequence and cleavage coverage per protein in the 128 k * 8 k spectrum 
are 28% and 13% respectively, while the coverages in the 256 k * 4 k spectrum are 
37% and 19% correspondingly.  The data show that in the low resolution 2DMS, 
the resolution increment in the fragment m/z dimension is more important than the 
resolution increment in the precursor m/z dimension.  
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(Figure S4.18. Continue) 
 
Figure S4.18.  The fragmentation maps of the digested 5CP with C18 RP 
enrichment at pH 2 using 2DMS with resolutions at 1 M * 8 k (left) and 2 M * 4 k 
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(right).  The peptides assigned by 2DMS are highlighted in yellow.  The average 
sequence and cleavage coverage per protein in the 1 M * 8 k spectrum are 43% 
and 24%, respectively, while the coverages in the 2 M * 4 k spectrum are 32% and 
17% correspondingly.  The data show that in the high resolution 2DMS, the 
resolution increment in the precursor m/z dimension is more critical than the 
resolution increment in the fragment m/z dimension.  
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Figure S4.19.  2DMS spectra of the digested 5CP with HILIC enrichment 
conducting in various resolutions of fragment and precursor m/z dimensions.  The 
2DMS contour plots are displayed with the same intensity. 
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(Figure S4.20. Continue) 
 
Figure S4.20.  The fragmentation maps of the digested 5CP with HILIC 
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enrichment using 2DMS with resolutions at 128 k * 8 k (left) and 256 k * 4 k 
(right).  The peptides assigned by 2DMS are highlighted in yellow.  The average 
sequence and cleavage coverage per protein in the 128 k * 8 k spectrum are 22% 
and 11% respectively, while the coverages in the 256 k * 4 k spectrum are 24% 
and 14% correspondingly.  The data show that in the low resolution 2DMS, the 
resolution increment in the fragment m/z dimension is more important than the 
resolution increment in the precursor m/z dimension, similar to as shown above 
(see Supplementary Information, Figure S4.17) 
  
Chapter 4 – The Next Dimension in Proteomics 
375 
 
 
 
Chapter 4 – The Next Dimension in Proteomics 
376 
 
(Figure S4.21. Continue) 
 
Figure S4.21.  The fragmentation maps of the digested 5CP with HILIC 
enrichment using 2DMS with resolutions at 1 M * 8 k (left) and 2 M * 4 k (right).  
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The peptides assigned by 2DMS are highlighted in yellow.  The average sequence 
and cleavage coverage per protein in the 1 M * 8 k spectrum are 41% and 25% 
respectively, while the coverages in the 2 M * 4 k spectrum are 41% and 24% 
correspondingly.  The data show in the high resolution 2DMS, the resolution 
increment in the precursor m/z dimension is more important than the fragment m/z 
dimension.  
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Figure S4.22.  Proteomic results of 5CP using high resolution 2DMS with RP 
and HILIC enrichment.  (A) Fragmentation maps of the digested 5CP analysed 
using 2DMS with resolution at 1 M * 8 k (fragment m/z * precursor m/z) with RP 
and HILIC SPE cartridges enrichment.  The average sequence and cleavage 
coverages per protein are 52% and 33% respectively, which are better than the 
results obtained from the 2DMS spectra of 256 k * 4 k (Figure 4E).  (B) Venn 
diagram of peptides identified from 2DMS, including RP and HILIC SPE 
cartridges enrichment, and nLC MS/MS.  (C) Box chart showing the physical 
properties of the identified peptides from 2DMS and nLC MS/MS.  The ranges 
of physical properties being covered by 2DMS are similar to the observations in 
the results of 2DMS with resolution at 256 k * 4 k (Figure 4C), suggesting that 
increasing the resolving power of the fragment and precursor m/z dimension 
doesn’t greatly enhance the coverage of different types of peptide but it can help 
to improve the assignment of peptides that originally contain a relative low S/N 
ratio. 
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Figure S4.23.  2DMS spectra (256 k * 4 k) of the digested 5CP samples with C18 
RP enrichment at pH 2.  The sample was then separated into 4 different m/z range 
using the quadrupole before the acquisition of 2DMS.  The 2DMS contour plots 
are displayed with the same intensity.  
  
Chapter 4 – The Next Dimension in Proteomics 
382 
 
 
Figure S4.24.  2DMS spectra (256 k * 4 k) of the digested 5CP samples with 
HILIC enrichment at pH 6.8.  The sample was then separated into 4 different m/z 
range using the quadrupole before the acquisition of 2DMS.  The 2DMS contour 
plots are displayed with the same intensity.  
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Figure S4.25.  2DMS spectra (256 k * 4 k) of the digested 5CP samples with 
offline fractionation using C18 RP SPE cartridge at pH 2.  The 2DMS contour 
plots are displayed with the same intensity.  
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Figure S4.26.  2DMS spectra (256 k * 4 k) of the digested 5CP samples with 
offline fractionation using HILIC SPE cartridge at pH 6.8.  The 2DMS contour 
plots are displayed with the same intensity.  
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Figure S4.27.  (A) Fragmentation maps of the digested 5CP with RP enrichment 
which was then isolated using the quadrupole and 4 m/z fractions were acquired 
using 2DMS.  The peptides assigned by 2DMS are highlighted in yellow.  The 
average sequence and cleavage coverage per protein are 46% and 28%, which are 
higher than the result obtained previously using the same sample but without m/z 
fractionation (see Supplementary Information, Figure S4.11).  (B) The graph to 
show the accumulation number of peptides being identified in each m/z fraction.  
(C) Venn diagram to show the overlapping of peptides between 2DMS using m/z 
fractionation and nLC MS/MS.  (D)  The box chart diagram to show the 
physical properties of the identified in the 2DMS and nLC MS/MS.  Compared 
to the previous results without m/z fractionation (see Supplementary Information, 
Figure S4.11C), the ranges of hydrophobicity and length that can be covered by 
2DMS are slightly enhanced, suggesting reduced number of ions in the FTICR cell 
during 2DMS can improve the identification of the hydrophobic, long peptides. 
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Figure S4.28.  (A) Fragmentation maps of the tryptic digested 5CP with HILIC 
enrichment which was mass range isolated using quadrupole and each mass range 
was acquired with 2DMS.  The peptides assigned by 2DMS are highlighted in 
yellow.  The average sequence and cleavage coverage per protein are 48% and 
31% respectively, which are higher than the previous result using the same sample 
but without any fractionation (see Supplementary Information, Figure S4.12).  (B) 
Cumulative number of identified peptides in each mass range fraction.  (C) Venn 
diagram showing the overlapping of peptides between 2DMS with mass range 
fractionation and nLC MS/MS.  (D)  Box chart showing the physical properties 
of the identified in the 2DMS and nLC MS/MS.  Compared to the previous results 
without mass range fractionation (see Supplementary Information, Figure S4.12C), 
the ranges of hydrophobicity and length that can be covered by 2DMS are 
enhanced, suggesting reduced the number of ions in the FTICR cell during 2DMS 
can improve the identification of the hydrophobic, long peptides.  The results of 
the digested 5CP enriched by RP and HILIC SPE cartridges which were then 
further isolated using quadrupole show that m/z range fractionation can effectively 
enhance the number of peptides being identified in 2DMS, the hydrophobicity 
range as well as the length of the peptides are also extended. 
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Figure S4.29.  Fragmentation maps of the digested 5CP with offline C18 RP SPE 
cartridge fractionation using IRMPD 2DMS.  The peptides assigned by 2DMS 
are highlighted in yellow.  The sample was fractionated into 9 fractions and 9 
2DMS spectra were obtained (see Supplementary Information, Figure S4.25).  
The average sequence and cleavage coverages are 60% and 42% respectively, 
which provides the highest coverages among all the methods employed.  
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Figure S4.30.  Fragmentation maps of the digested 5CP with offline HILIC SPE 
cartridge fractionation using IRMPD 2DMS.  The peptides assigned by 2DMS 
are highlighted in yellow.  The sample was fractionated into 9 fractions and 9 
2DMS spectra were obtained (see Supplementary Information, Figure S4.26).  
The average sequence and cleavage coverages are 55% and 36% respectively.  
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Figure S4.31.  The total ion chromatogram (TIC) of the digested yeast analysed 
using a C18 RP nLC MS/MS with a 120-minute effective gradient, 160-minute 
total acquisition time.  
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Figure S4.32.  Proteomic results of yeast tryptic digest using 2DMS and nLC 
MS/MS.  (A) 2DMS spectrum of yeast with resolution of 1 M * 8 k (fragment 
m/z * precursor m/z).  (B) Venn diagram showing the overlapping of peptides 
between 2DMS and nLC MS/MS.  28 peptides were identified using 2DMS, and 
16 out of these (57%) are not assigned using nLC MS/MS.  (C) Spectra showing 
the peptide assigned using 2DMS (left) and nLC MS/MS (right).  (D) Spectra 
showing the peptides exclusively assigned using 2DMS.  (E) Box chart showing 
the physical properties of the identified peptides in the 2DMS and nLC MS/MS.  
The physical properties of the peptides being identified using 2DMS are similar to 
the observations in 2DMS of 5CP sample, in which more hydrophilic, basic, and 
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short peptides are assigned by 2DMS.  
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Figure S4.33.  1DMS spectrum of the tryptic digested yeast with 100 
accumulation spectra. 
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Figure S4.34.  2DMS spectra of digested yeast with 256 k * 4 k resolution of the 
fraction 1-9 using C18 RP SPE cartridge at pH 2.  The 2DMS contours plots are 
displayed with the same intensity.  
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Figure S4.35.  2DMS spectra of digested yeast with 256 k * 4 k resolution of the 
fraction 10-16 using C18 RP SPE cartridge at pH 2.  The 2DMS contours plots 
are displayed with the same intensity.  
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Figure S4.36.  Venn diagram showing the overlapping of the yeast peptides 
identified in the offline fractionated 2DMS experiment and the best set of yeast 
data obtained from the previous literature.18   
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Chapter 5 Conclusion and Future Work 
The work presented within this thesis has demonstrated the application of mass 
spectrometry (MS) together with various advanced fragmentation techniques for 
the study of amyloid proteins as well as complex proteomic studies.  This chapter 
aims at summarising and outlining the achievements for each of the previous 
chapters, future plans are also included which may help to improve the 
experiments or enhance the data quality in the near future. 
 
Chapter 2: Exploring the Aggregation and Deamidation Mechanisms of Human 
Islet Amyloid Polypeptide Using Fourier Transform Ion Cyclotron Resonance 
Mass Spectrometry 
 
 Chapter 2 focused on the study of aggregation mechanisms as well as the 
deamidation rate and sites of human islet amyloid polypeptide (hIAPP) using ultra-
high resolution Fourier transform ion cyclotron resonance mass spectrometry 
(FTICR MS) together with fluorescence spectrometry and transmission electron 
microscopy (TEM).   
From the MS results, hIAPP aggregates rapidly to form early oligomers, 
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ranging from dimer to pentamer, which were detected in the MS spectrum.  The 
electron capture dissociation tandem MS (ECD MS/MS) results showed the region 
around Gly-33 and Ser-34 is the most critical region for the formation of dimerized 
hIAPPs as it is the minimal interaction region between two hIAPP units, this 
observation was further supported by the ECD MS/MS results from the trimer of 
hIAPP.  Furthermore, the aggregation of individual hIAPP units into oligomers 
was shown to occur much faster than deamidation. 
The collisionally activated dissociation (CAD) MS/MS results of deamidated 
hIAPP show that Asn-21, Asn-22, and Asn-35 residues are significantly 
deamidated within one month.  The extent of deamidation was higher in the 
fibrillary pellets than in the solutions, which indicates that the deamidated hIAPP 
tends to form fibrils faster than wild-type hIAPP.  This hypothesis is further 
supported by accelerated aggregation rate observed for ((D)3hIAPP) and 
((isoD)3hIAPP) and a higher percentage of mutant hIAPPs identified in the fibrils 
of hIAPP solutions spiked with mutants ((D)3hIAPP) or ((isoD)3hIAPP) in wild-
type hIAPP solutions. 
The TEM images showed the difference in morphology of (isoD)3hIAPP 
fibrils compared to wild-type hIAPP and ((D)3hIAPP) fibrils, which helps explain 
the acceleration of aggregation caused by the deamidated hIAPP.  Moreover, the 
amount of amyloid fibril formed is directly proportional to the spiking percentage 
of mutant hIAPPs; and the effect of seeding ((isoD)3hIAPP) is twice that of seeding 
the same amount of ((D)3hIAPP) into non-deamidated hIAPP solutions. 
The results herein demonstrate FTICR MS with electron capture dissociation 
is a suitable analytical tool to understand the aggregation mechanism of amyloid 
proteins, indicating these techniques can be further applied to other amyloid 
proteins to investigate the aggregation mechanisms.  The deamidation sites as 
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well as the effects of deamidation are shown using MS; however, the individual 
effect of each of the proposed deamidation sites is still unknown.  Synthesising 
deamidated peptides with various combinations of deamidation site at Asn-21, 
Asn-22, and Asn-35 will help to narrow down the deamidation effect contributed 
by each site.  
 In future, research can focus on studying the effects of each individual 
deamidation site (Asn-21, Asn-22, and Asn-35) and combinations thereof towards 
the rate and morphology of hIAPP aggregation via different synthetic deamidated 
hIAPP configurations. This approach would allow the most critical deamidation 
site towards hIAPP aggregation to be determined.  Results obtained could be 
particularly useful in further therapeutic development for identifying the most 
critical protein transformations.  
 
Chapter 3: The Inhibition Pathways of Human Islet Amyloid Polypeptide 
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Chapter 3 focused on the study of inhibition pathways of hIAPP using FTICR 
MS together with fluorescence spectrometry and TEM, in which the potential 
pathways shown herein may help for accelerating therapeutic development in the 
coming future.   
The experimental results here demonstrated two potential inhibition pathways 
are occurring to prevent the formation of toxic hIAPP aggregates.  Inhibitors like 
insulin adopt a direct pathway through interaction with hIAPP between Ser-29 and 
Asn-35 residues which were proposed to be the most critical aggregation region 
for the formation of hIAPP early oligomers.  These inhibitors are not only 
effective in preventing the formation of toxic hIAPP aggregates, but are also able 
to dissociate the hetero-complexes back into the monomer units of hIAPP and 
inhibitor, which is a possible key feature for potential drug development.  These 
inhibitors, however, are only effective to limited amyloid protein sequences and 
structures, as a result, they are not viable to prevent the aggregation of mutant 
hIAPPs or other amyloid proteins. 
 On the other hand, other inhibitors, such as EGCG, can self-aggregate and 
trigger the formation of non-toxic, amorphous hIAPP aggregates faster than 
forming the toxic hIAPP aggregates.  These inhibitors interact non-specifically to 
the amyloid proteins, thus they are effective to prevent the formation of toxic 
aggregates regardless of the sequences and structures of amyloid proteins.  
Despite the inhibition effect, the formation of amorphous aggregates seems to 
indicate the hIAPP units are continuously consumed once mixed with these 
inhibitors, in a long term, very low or even no free hIAPP unit is available for the 
normal physiological function inside the human body. 
 The results herein demonstrate MS together with fluorescence spectrometry 
and TEM help to determine the inhibition pathways of amyloid protein which can 
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be used to improve therapeutic development.  In the future, the scale of this 
experiment should be expanded so that at least three different potential inhibitors 
are used in each measurement of a particular inhibition pathway to determine the 
variations of inhibition effects.  Furthermore, the mixing ratio between hIAPP 
and potential inhibitors was set to 1:1 in all the experiments, however, this value 
has not been particularly optimised for a potential inhibitor.  The lowest effective 
inhibition ratio should also be determined for each potential inhibitor as the 
concentration effect of the inhibitor may affect the performance in preventing 
amyloid fibril formation.  
 In future, more compounds could be explored for their inhibitory potential 
both to evaluate possible new inhibitors for potency, but also potentially discover 
even more new inhibition mechanisms of amyloid protein aggregation. 
Furthermore, targeted inhibitors with similar features to insulin (specific 
interaction with hIAPP) and EGCG (self-aggregation) could be synthesised and 
studied for their effectiveness on preventing the aggregation of hIAPP.   
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Chapter 4: The Next Dimension in Proteomics 
 
 Chapter 4 focuses on studying proteomics using an alternative method – two 
dimensional mass spectrometry (2DMS) which allows the study of complex 
samples via direct infusion into the MS without prior online LC separation.  
 The results presented demonstrate that 2DMS is a viable alternative technique 
for proteomic studies, showing online LC MS/MS is no longer an essential tool in 
proteomics. Therefore, many proteomic analyses, such as biomolecular non-
covalent interactions, which are usually very limited by available LCMS-
compatible solvent systems and the available column chemistry of liquid 
chromatography, are able to be performed using 2DMS.   
 Furthermore, complementary protein and peptide assignments from the 
results of 2DMS and nLC MS/MS suggests a deeper proteome coverage can be 
achieved by combing the data obtained from 2DMS and nLC MS/MS, which also 
indicates the proteomes that are exclusively covered by 2DMS are currently under-
Chapter 5 – Conclusion and Future Work 
 
408 
 
studied using purely standard nLC MS/MS techniques, thus 2DMS is not only an 
alternative but may soon be considered as a required complementary technique for 
deeper proteome analysis. 
 2DMS is also shown to have a higher efficiency in observing hydrophilic, 
basic, or short peptides, suggesting 2DMS is also suitable for application in PTM 
analysis as most of the important PTMs in disease-related issue, such as 
phosphopeptides and glycopeptides, are extremely hydrophilic which is 
challenging to analysis using standard nLC MS/MS technique. 
 2DMS is an advanced technique that has only recently been applied to 
proteomic studies, in which there are still lots of unexplored, potential areas for 
application of 2DMS.  Native proteomics is a key priority experiment in the 
coming future since it is difficult to perform using traditional LC MS/MS which 
has been mentioned above.  Analysis of native proteins is still challenging to 
perform using 2DMS as the current cell lysate and digestion methods are not well-
optimised for native proteomics, thus increased optimisation for the workflow of 
native proteomics is required.  Furthermore, top-down proteomics using 2DMS 
can also be performed.  In top-down proteomics, proteins can be effectively 
separated by size exclusion chromatography, ion-exchange chromatography, 
and/or affinity chromatography, in which all the buffers used in these 
chromatography separations are incompatible with MS in an online LC mode.  
Thus, 2DMS is an obvious high-performance alternative method for analysing the 
fractioned proteins directly from these columns without applying the standard RP 
online chromatography columns.   
